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1 Introduction 
 
1.1 The immune system 
The human immune system constantly works to recognize agents perceived to be foreign, 
such as bacteria, virus, fungi, internal parasites or cancerous cells, preventing their spread and 
ultimately clearing them from the body. Outer barriers against foreign material are formed by 
the skin and mucosal surfaces lining the respiratory, gastrointestinal and urogenital tracts, but 
when these are broken, the innate immune system is called into action. If the cells and soluble 
mediators of the innate immune system do not defeat the infection, the adaptive immune 
system adds to the ongoing immune responses. Whereas the innate immune system mediates 
fast, unspecific responses (i.e. it utilizes general recognition mechanisms to detect the 
presence of potentially harmful material) with no long-term memory, the adaptive immune 
system has the ability to acquire specific responses and develop long-term memory towards 
foreign antigens. Adaptive immune responses consist of antibody and cell-mediated responses 
that are carried out by B and T lymphocytes. T cells are central regulators in adaptive 
immunity and support both humoral and cell-mediated immune responses through the 
production of cytokines that support antibody maturation and B cell growth as well as 
cytolytic activity of effector T cells. Different aspects of T cell activation and function have 
been studied in this Thesis and will therefore be the focus of this introduction. 
 
1.2 T cell development and function 
T cell progenitors originate from hematopoietic stem cells in the bone marrow and 
differentiate, undergo selection and mature into functional T cells in the thymus. The thymus 
provides the microenvironment essential for development towards the T cell lineage, and 
thymocyte subpopulations can be identified by tracing the gradual alterations in co-receptor 
expression on the cell surface (Koch and Radtke, 2011). Double negative cells, which express 
neither CD4 nor CD8, differentiate into double positive thymocytes, which are the first cells 
to express a functional T cell receptor (TCR). The majority of T cells express the TCR as an 
Įȕ heterodimer. An enormous clonal diversity of TCRs is formed by rearrangements within 
the Į and ȕ chain encoding genes and by combining different Į and ȕ chains, ultimately 
generating a highly specific antigen-binding site. The double positive thymocytes that express 
potentially useful TCR specificities are triggered through the TCR to undergo positive 
selection and differentiate into either CD4 or CD8 single positive cells. A proportion of the 

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single positive cells carry TCRs that recognize self-antigens and these autoreactive T cell 
clones undergo negative selection or are rendered non-responsive (i.e. anergic) in the thymus 
by central tolerance mechanisms (Wing and Sakaguchi, 2011). Finally, naïve CD4+ and CD8+ 
cells with specificity for non-self exit the thymus and perform their immunosurveillance 
activities by migrating between the blood, lymphatic system and peripheral lymphoid organs 
in response to chemokines, constantly looking for antigens. CD4 and CD8 serve as co-
receptors for interaction with antigens presented as peptides on major histocompatibility 
complex (MHC)-II and MHC-I, respectively. All nucleated cells can present peptides derived 
from antigens of intracellular origen on MHC-I, whereas professional antigen-presenting cells 
(APCs) (i.e. dendritic cells, macrophages and B cells) present antigens from endocytosed 
molecules as peptides on MHC-II. 
Naïve CD4+ T cells respond to antigen stimulation by APCs in lymphoid organs by 
developing into distinct effector cell lineages such as T helper type 1 (TH1) cells, TH2 cells, 
TH17 cells and regulatory T cells. The affinity of the antigen, the strength of TCR signaling 
and the cytokine environment are pivotal in the fate decisions towards distinct effector 
phenotypes (Constant and Bottomly, 1997; Zhu et al., 2010). Polarization of naïve TH cells 
into TH1 or TH2 effector cells occurs within a few days of direct contact with APCs 
(Nakamura et al., 1997) and as the differentiation proceeds, TH1 and TH2 effector cells can be 
distinguished by their cytokine expression profiles. TH1 cells produce interferon (IFN) Ȗ as 
their signature cytokine in addition to lymphotoxin, interleukin (IL)-12 and tumor necrosis 
factor (TNF) Į. By contrast, TH2 fail to produce IFNȖ or lymphotoxin and their signature 
cytokines are IL-4, IL-5 and IL-13. They also produce TNFĮ and some produce IL-9 and 
modest amounts of IL-12 (Zhu et al., 2010). Through the secretion of cytokines, TH2 cells 
support high-affinity antibody production and B cell growth, whereas TH1 cells support 
activation of macrophages and the cytolytic activity of CD8+ T cells. CD8+ T cells exert their 
effector function by production of the cytotoxic enzymes perforin and granzyme B employed 
in direct killing of infected cells. Furthermore, CD8+ T cells secrete IFNȖ and thus contribute 
to macrophage activation in host defense and in hypersensitivity reactions (reviewed in Zhang 
and Bevan, 2011).  
In the naïve T cell repertoire, antigen-specific T cells are very rare, but in response to 
activation, the antigen-specific T cells undergo massive expansion, followed by contraction to 
a stable number of memory cells. The type of pathogen and extent of infection are thought to 
determine both the magnitude of T cell expansion and the ensuing contraction to a stable 
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number of memory T cells (Schumacher et al., 2010). A marked increase in the proportion of 
memory T cells occurs in the first decade of life whereas the overall size of the memory T cell 
pool remains relatively stable during adulthood (Farber et al., 2014). The longevity of 
memory T cells were thought to require intermittent stimulation with non-cognate TCR 
interactions (Gray and Matzinger, 1991), but have later been shown to be largely independent 
of both antigen and MHC molecules (Lau et al., 1994; Murali-Krishna et al., 1999) and rather 
maintained through contact with IL-7 and IL-15 (Kondrack et al., 2003; Berard et al., 2003). 
With ageing, memory T cells alter function in a process termed immunosenescence, marked 
by increased susceptibility to pathogens, partly caused by age-associated immune 
dysregulation (Farber et al., 2014).  
The activation and differential status of human T cell subsets have classically been 
distinguished by expression of different CD45 isoforms, generated by alternate exon splicing  
 
 
 
Figure 1. Differentiation of naïve CD4+ and CD8+ T cells into effector and memory cells. During the 
primary immune response, naïve CD4+ and CD8+ T cells recognize antigenic peptides bound to MHC complexes 
on APCs in the spleen and lymph nodes and undergo clonal expansion. Depending on the nature of antigen and 
the inflammatory milieu, antigen-specific CD4+ T cells are induced to differentiate into TH1 or TH2 cells, 
whereas CD8+ T cells differentiate into antigen-specific cytotoxic T cells. Both CD4+ and CD8+ effector T cells 
then migrate to peripheral tissues to exert their function. After eliminating the pathogen, most effector cells 
undergo apoptosis, but some (10–20%) survive to form long-lived memory cells. As CD4+ and CD8+ T cells 
transition from naïve to effector to memory cells, the overall gene expression profile changes, resulting in 
secretion of distinct cytokines. Adapted from Salek-Ardakani and Croft, 2006 and Zhang and Bevan, 2011. 
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(Barclay and McCall, 1992). After upregulation of both the high-molecular weight CD45RA 
and the low-molecular weight CD45RO isoforms shortly after activation, T cells gradually 
(within 3-6 days) lose CD45RA expression and maintain CD45RO expression (Akbar et al., 
1988; Deans et al., 1992). However, the reciprocal division of T cells into CD45RA+ naïve 
and CD45RO+ memory T cells seems to be an oversimplification. CD45RO+CD45RA- T cells 
have been shown to comprise heterogeneous populations of memory T cells, among these 
central memory T cells expressing the chemokine receptor CCR7, which traffic to lymphoid 
tissues and CCR7 effector memory T cells, not expressing CCR7, which can migrate to 
multiple peripheral tissue sites (Sallusto et al., 1999). In addition, human memory T cells can 
also revert from the CD45RO+ to the CD45RA+ phenotype in vivo (Michie et al., 1992; Wills 
et al., 1999), but still retain their capacity to mediate multiple recall effector functions  (Appay 
et al., 2002). The generation of distinct populations of effector T cells and their conversion to 
memory cells during an immune response are illustrated in Figure 1. 
 
1.3 The role of plasma membrane organization in T cell signaling 
The plasma membrane consists of a bilayer of glycerolphospholipids, sphingolipids and 
cholesterol embedded with proteins where all components are associated through non-
covalent interactions. Following activation of T cells, the plasma membrane components 
reorganize and signals are passed on from the membrane to cytoplasmic and nuclear activities 
essential to regulation of T cell immune responses. The plasma membrane of T cells thus 
forms relay points where proteins, lipids and other signaling molecules are structurally and 
kinetically organized. In the following sections, specialized membrane structures of T cells 
central to this Thesis will be presented. 
 
1.3.1 The lipid raft model 
Current models on plasma membrane organization have evolved from the fluid mosaic model 
proposed by Singer and Nicolson which described a homogeneous distribution of lipids in the 
two-dimensional surface of the plasma membrane with randomly distributed proteins 
diffusing freely (Singer and Nicolson, 1972). In contrast, van Meer and Simons discovered an 
asymmetric distribution of lipids over the exoplasmic and cytoplasmic leaflets in the 
membrane (van Meer and Simons, 1988). These findings subsequently led to formulation of 
the lipid raft hypothesis by Simons and Ikonen, referring to the concept of lateral organization 
of cholesterol- and sphingolipid-enriched domains within the exoplasmic cell membrane 

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(Simons and Ikonen, 1997). According to this model, phase separation of the lipids in the 
plasma membrane is facilitated by distinct biophysical properties and large differences in 
saturation of acyl chains. Glycerolphospholipids tend to adopt to a fluid phase, whereas 
sphingolipids show a more tightly packed organization, favor interaction with cholesterol and 
can be segregated from the more disordered surrounding bulk membrane (Brown and London, 
1998). The specific targeting of proteins into these lipid microdomains also affects the 
functionality of the cell membrane and the residing proteins. By revising the lipid raft 
hypothesis, protein-protein and protein-lipid interactions in addition to the lipid-lipid 
interactions were increasingly recognized as important factors in the molecular dynamics of 
raft domains (reviewed in Simons and Gerl, 2010). Throughout this Thesis, the term 
membrane raft will therefore be used when referring to the concept of nanoscale, 
heterogeneous, highly dynamic cholesterol- and sphingolipid-enriched domains that can be 
stabilized by clustering to engage in membrane functions (Pike, 2006). The propensity of 
lateral assembly of plasma membrane components has been demonstrated to be critical for 
cellular processes such as vesicular trafficking, immune receptor signaling, cell migration and 
polarization of epithelial cells (Brown and Rose, 1992; Simons and Ikonen, 1997). 
Furthermore, changes in the composition or structure of membrane domains could play a role 
in human pathogenesis as non-constitutive protein components of membrane rafts have been 
shown to fluctuate in cancer (Staubach and Hanisch, 2011), in T lymphocytes isolated from 
patients with autoimmune disease (Krishnan et al., 2004) and as certain viruses may utilize 
membrane domains to enter the target cell (Manes et al., 2000; Isa et al., 2004). 
Some of the initial observations of the role of membrane rafts in T cell signaling 
include the findings that antibody-crosslinking at the T cell surface causes membrane raft 
proteins and lipids to co-patch and exclude non-raft proteins (Harder et al., 1998), and that raft 
integrity is a prerequisite for the assembly of activated TCRs and associated signaling 
molecules in large macromolecular complexes (Xavier et al., 1998; Montixi et al., 1998). The 
importance of membrane rafts in T cell signaling was consolidated with experiments showing 
that displaced membrane raft anchoring of proteins such as the lymphocyte-specific protein 
tyrosine kinase (Lck) (Kabouridis et al., 1997; Hawash et al., 2002) and linker for activation 
of T cells (LAT) (Zhang et al., 1998a; Lin et al., 1999; Zeyda et al., 2002) or disrupted 
membrane raft integrity by cholesterol depletion (Kabouridis et al., 2000) impaired T cell 
signaling. Similarly, co-patching experiments mediated by cholera toxin crosslinking resulted 
in domains containing essential T cell activation proteins as observed by fluorescence 
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microscopy (Janes et al., 1999). Since then, accumulated research has demonstrated that 
compartmentalized membrane structures with particular protein compositions confer 
specialized signaling functions in T cell activation (reviewed in He and Marguet, 2008; 
Horejsi and Hrdinka, 2014). In addition to the TCR, other multichain immune recognition 
receptors such as the B cell antigen receptor (BCR) (Cheng et al., 1999) and the 
immunoglobulin (Ig) E receptor of mast cells (Sheets et al., 1999), appear to use membrane 
rafts for signaling. Despite extensive studies, significance of membrane raft-based 
mechanisms in immunoreceptor signaling and even their existence remain disputed 
(Kenworthy, 2008; Leslie, 2011), mainly due to methodological limitations in assessing 
membrane rafts in situ, as will be further discussed in section 4.1.  
 
1.3.2 Targeting of T cell signaling proteins to membrane rafts 
Raft affinity of membrane proteins is commonly inferred from analysis of detergent-resistant 
membranes (DRMs) that are found in non-ionic detergent lysates of cells. The tightly packed 
structure of membrane rafts mediated by concentration of saturated fatty acid chains and 
cholesterol stabilization cause resistance to certain non-ionic detergents. This can be exploited 
in separation of membrane rafts components from the bulk membrane by density gradient 
centrifugation media at low temperatures (Brown and Rose, 1992; Macdonald and Pike, 2005). 
After centrifugation, the detergent-resistant membrane fractions will float to the low density 
fractions due to their high lipid:protein ratio while other solubilized membrane constituents 
will be present in the lower, denser fractions. Cholesterol-induced membrane thickening have 
been postulated to selectively exclude most transmembrane proteins (e.g. the highly abundant 
phosphatase CD45) in accordance with the lenghts of their transmembrane domain (Sharpe et 
al., 2010). Proteins such as CD4, the adhesion receptor CD44, phosphoprotein associated with 
glycosphingolipid-enriched microdomains (PAG)/Csk-binding protein (Cbp) (hereafter 
referred to as PAG), LAT and several members of the TNF receptor family possess longer 
transmembrane domains that allow segregation into membrane rafts (Horejsi, 2003). 
Furthermore, specific post-translational lipid modifications are important determinants of 
protein partitioning in membrane rafts. Sterols and long-chain saturated fatty acids (e.g. dual 
acylations, either with myristate and palmitate, or with two palmitates) promote raft 
association for transmembrane proteins and intracellular proteins such as the Src family 
kinases and Ras. In contrast, the presence of short, branched and/or unsaturated fatty acids 
(e.g. prenyl) mediates membrane exclusion. Palmitoylation is essentially the only lipid 
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modification that is reversibly regulated and thereby serves as a dynamic membrane raft 
targeting mechanism (Levental et al., 2010). The addition of a glycosyl-inositolphosphatidyl 
(GPI)-moiety targets proteins to the outer leaflet of the cell membrane. Extracellular proteins 
containing a GPI-anchor, such as CD14 and CD59, are often used as membrane raft markers 
(Veit and Thaa, 2011). Other important constituents in the cytoplasmic leaflet of membrane 
rafts are phosphorylated phosphatidylinositols, in particular phosphatidylinositol 4,5-
bisphosphate (PIP2) (Hope and Pike, 1996), and more proteins might be targeted to membrane 
rafts indirectly by binding to more tightly associated proteins or lipids (Melkonian et al., 
1999). 
 
1.3.3 Membrane rafts as a membrane organization principle in T cell signaling 
Membrane rafts are considered to have a particular important role as coordinators of the initial 
T cell activiation events. This is achieved by segregating distinct signaling molecules in the 
resting state to diminish the probability of spontaneous activation and by reorganizing and 
concentrating signaling molecules in the stimulated state to allow optimal exposure and 
enhanced association rates. Analyses show that constraining proteins to two dimensions at the 
cell surface greatly enhances their reaction rates (Gureasko et al., 2008). Indeed, pre-
allocating purified Lck and CD3ȗ to liposomes at physiological densities resulted in 
phosphorylation rates several hundred-fold faster than in solution (Hui and Vale, 2014) (see 
following sections for more details on Lck and CD3ȗ).  
The composition of membrane raft-associated proteins changes after TCR triggering. 
Upon crosslinking with antibodies, the TCR itself has been shown to partly translocate to 
membrane rafts where it becomes phosphorylated by resident Src family kinases (Xavier et al., 
1998; Janes et al., 1999; Pizzo et al., 2004) followed by rapid raft-accumulation of CD3ȗ, 
zeta-chain-associated protein kinase of 70 kDa (ZAP-70), phospholipase CȖ1 (PLCȖ1), 
phosphoinositide 3-kinase (PI3K), protein kinase C ș (PKCș), IL-2 inducible T cell kinase 
(Itk), and the adaptors PAG and SH2 domain containing leukocyte protein of 76 kDa (SLP-76) 
(Montixi et al., 1998; Xavier et al., 1998; Kosugi et al., 1999; Bunnell et al., 2000; Brdicka et 
al., 2000; Boerth et al., 2000; Bi et al., 2001). Palmitoylation of the TCR co-receptors, CD4 
and CD8, is required for membrane raft affinity and efficient co-receptor function, and their 
association with TCR upon antigen encounter may contribute to co-aggregation of the 
receptor complex with membrane rafts (Arcaro et al., 2000; Fragoso et al., 2003). 
Alternatively, TCR and other immunoreceptors may be pre-associated with membrane rafts 
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(Drevot et al., 2002) and ligation of TCR may induce reorganizations that facilitates optimal 
exposure of the CD3ȗ chains to the Src family kinases. The co-stimulatory receptors studied 
in this Thesis, CD2 and CD28, have also been shown to associate with membrane rafts upon 
antibody-crosslinking (Yang and Reinherz, 2001; Sadra et al., 2004).  
In addition to playing an important role in initiation of proximal signaling responses, 
membrane rafts also contribute to stabilization and amplification of signaling events. This is 
enabled by aggregation of small and dynamic rafts into larger complexes, as illustrated in 
Figure 2. Most likely, protein-lipid interactions support nanoscale membrane rafts in resting T 
cells, but once the T cell is triggered and protein phosphorylation drives the formation of the 
signalosome, protein-protein interactions become predominant (Zeyda and Stulnig, 2006).  
 
 
  
Figure 2. The dynamics of membrane raft organization. Resting membrane rafts are dynamic, nanoscale 
assemblies of raft lipids and proteins. Most membrane raft proteins are either solely lipid-anchored (GPI-
anchored in the exoplasmic leaflet (1) or doubly acylated (2) in the cytoplasmic leaflet), or they contain acyl 
chains in addition to their transmembrane domain (3). Some proteins can undergo a conformational change when 
partitioning into membrane rafts (4). Transmembrane non-raft proteins are excluded from these assemblies (5). 
Following oligomerization of membrane raft proteins by multivalent ligands (6) or scaffolding elements such as 
cortical actin (7), the small raft domains fuse and become more stable. Large raft clusters are probably only 
assembled when protein modifications such as phosphorylation (8) increase the number of protein-protein 
interactions, leading to the coalescence of small clusters into larger domains. Membrane rafts in this activated 
state constitute a more ordered assembly. Adapted from Lingwood and Simons, 2010 and Simons and Sampaio, 
2011. 
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1.3.4 Studies of the T cell membrane raft proteome 
The first reported proteomic study on DRM fractions isolated from human T cells identified 
70 proteins, the majority of which constituted cytoskeletal proteins and proteins involved in 
signal transduction (von Haller et al., 2001). In contrast, the first comprehensive analysis of a 
T cell raft proteome identified 685 proteins in DRMs from the Jurkat T cell line, but this study 
focused mostly on the bioinformatics handling of the data (von Haller et al., 2003). Another 
study using two-dimensional gel electrophoresis, revealed that DRMs of Jurkat T cells rapidly 
reorganize upon TCR/CD28 co-stimulation, resulting in recruitment of about 30 proteins, 
including heat shock proteins, calmodulin, vimentin and a Rho-GDP dissociation inhibitor 
(RhoGDI) (Tu et al., 2004). However, the authors could not predict any functional role for 
these proteins in signaling through TCR/CD28. Proteomic profiling of Jurkat T cell DRMs 
upon activation of the chemokine receptor CCR6 identified 852 proteins, of which 85 were 
dynamically recruited and likely to be involved in the control of actin assembly and 
disassembly regulating CCR6 activation-induced cell migration (Lin et al., 2010). However, 
the abundance of cytoskeletal proteins and comparably few transmembrane or membrane 
embedded proteins identified in this study, indicated methodological issues when analyzing 
the DRM proteome by mass spectrometry. Notably, it has been challenging to obtain a 
comprehensive profile of the membrane raft proteome in human primary T cells. We therefore 
set out to provide an unbiased qualitative mass spectrometric characterization of the DRM 
proteome in human primary T cells under both resting and activated conditions, and tested 
different methods to make membrane proteins available for the analysis (Paper I). 
 
1.3.5 The immunological synapse 
Upon recognition of a peptide-MHC (pMHC) ligand by the TCR, polarized reorganization of 
TCRs is initiated towards the T cell-APC interface together with migration of additional cell 
surface receptors, adhesion molecules and intracellular signaling molecules. These stable 
junctions are referred to as an immunological synapse (IS) (reviewed in Fooksman et al., 
2010). The IS structure may be maintained for hours and has been shown necessary for the 
sustained signals required to obtain full T cell activation (Grakoui et al., 1999; Huppa et al., 
2003). Furthermore, the IS permits efficient delivery of effector molecules and intercellular 
signals across the synaptic cleft (Stinchcombe et al., 2006). The prototypical IS of a T cell is 
organized into distinct regions, including a central zone of TCR/MHC complexes called the 
central supra-molecular activation cluster (cSMAC). Adhesion molecules such as leukocyte 
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function-associated antigen (LFA)-1 and CD2 that structurally support the IS surround the 
cSMAC in a peripheral supra-molecular activation cluster (pSMAC), whereas the distal supra-
molecular activation cluster (dSMAC) is enriched in actin and CD45 (Monks et al., 1998; 
Grakoui et al., 1999; Freiberg et al., 2002). Receptors and adhesion molecules at the interface 
segregate passively and are considered to be spatially ordered by the size of their ectodomains. 
Larger proteins such as LFA-1 and the tyrosine phosphatases CD45 and CD148 are therefore 
excluded from the TCR contact area (Davis and van der Merwe, 2006). Prior to the mature IS 
formation much smaller TCR micro-clusters continuously form at the contact site of the T 
cell-APC. These subsequently move to the cSMAC region in an actin-dependent process to 
converge with the cSMAC of the conventional IS (Yokosuka et al., 2005; Campi et al., 2005). 
Many of the proteins and lipids enriched in membrane rafts also occur at the interface between 
the APC and the T cell, particularly in the cSMAC (Burack et al., 2002; Zech et al., 2009), 
suggesting that membrane rafts coalesce into the IS. Of note, a CD28 co-stimulation- 
dependent interaction with filamin A (FlnA), a large actin-crosslinking protein, has been 
shown to amplify TCR signaling by recruiting membrane rafts into the IS (Viola et al., 1999; 
Tavano et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. T cell-APC interaction induces the formation of two protein complexes at opposing poles. The 
highly ordered immunological synapse, containing the central, distal and peripheral SMAC regions, resides at the 
T cell-APC contact site. Distal to the site of TCR engagement, the distal pole complex forms, in which 
localization of PKA type I, CD43, ezrin, EBP50, PAG and Csk is shown. TCR-dependent reorganization of the 
actin cytoskeleton is necessary for the formation of both complexes. MTOC; microtubule organizing center. 

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1.3.6 The distal pole complex 
As the immunological synapse forms, there is concomitant migration of selected signaling 
proteins to the opposite pole of the T cell (Figure 3). Phosphatases and inhibitors of T cell 
activation such as Src homology (SH) 2 domain-containing tyrosine phosphatase 1 (SHP-1), 
CD148, protein tyrosine phosphatase-BL (PTP-BL), CD43, RhoGDI and discs-large 
homologue-1 (DGL1) accumulate in a distal pole complex (DPC) (Burkhardt et al., 2008), 
suggesting that the DPC may sequester proteins inhibitory to full T cell activation away from 
the immunological synapse (Allenspach et al., 2001; Cullinan et al., 2002). At the time of 
initiation of the project culminating in Paper II, proteins of the ezrin, radixin and moesin 
(ERM) family, of which ezrin and moesin are expressed in T cells (Shcherbina et al., 1999), 
were known as central regulators of DPC formation (Shaffer et al., 2009). Disruption of the 
DPC by inhibition of ERM function had been shown to impair T cell secretion of IL-2 and 
IFNȖ (Allenspach et al., 2001; Tong et al., 2004). The adaptor protein ERM binding 
phosphoprotein of 50 kDa (EBP50) and PAG had also been localized to the DPC (Shaffer et 
al., 2009). Furthermore, most of the work concerning the DPC had been performed in the 
Jurkat T cell line or in primary mouse T cells. In Paper II we therefore set out to confirm the 
localization of ezrin, phosphorylated ERM proteins in general, EBP50, PAG and CD43 to the 
DPC upon sustained activation of primary human T cells. In addition, we investigated the 
translocation of the negative regulators protein kinase A (PKA) type I and C-terminal Src 
kinase (Csk) to the DPC upon T cell activation. 
 
1.3.7 Proteins regulating the formation and functionality of the distal pole complex 
In addition to function as key regulators of the DPC composition, ERM proteins also regulate 
signaling pathways by acting as scaffolds for transmembrane receptors such as the highly 
abundant transmembrane glycoprotein CD43 (Sperling et al., 1998) and cytoplasmic proteins 
such as EBP50 (Reczek et al., 1997). In resting T cells, intramolecular interactions between 
the N- and C-terminal keep the ERM proteins in a folded confirmation in the cytoplasm and 
mask protein-protein and filamentous actin (F-actin) interaction sites (Pearson et al., 2000). 
Upon TCR ligation, ERM proteins are strongly phosphorylated and associated with the 
plasma membrane. Activation of ERM and the maintenance of an open and active 
confirmation require binding of PIP2 to the N-terminal domain and phosphorylation of a 
threonine residue within the C-terminal actin binding domain (Simons et al., 1998; Fievet et 
al., 2004). When activated, the N-terminal domain can bind to the cytoplasmic portion of 
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transmembrane proteins such as CD43, CD44 and intercellular adhesion molecules (ICAMs) 
(Yonemura et al., 1998) as well as EBP50 (Reczek et al., 1997). Furthermore, in the open 
configuration, the central region can associate with PKA (Dransfield et al., 1997) and the C-
terminal domain with F-actin (Turunen et al., 1994), thus connecting the cortical actin 
network to the plasma membrane. Within seconds after contact with the APC, ERM proteins 
undergo transient dephosphorylation of Thr567 leading to release of these proteins from actin 
filaments and plasma membrane binding proteins (Delon et al., 2001). The resulting 
dissociation of ERM proteins from the plasma membrane is thought to facilitate a more 
efficient T cell-APC conjugate formation by allowing enhanced lateral mobility of cell surface 
proteins (Faure et al., 2004). About three minutes after TCR engagement, ERM proteins 
undergo re-phosphorylation at the activating threonine, making the ERM proteins and their 
binding partners move toward the distal pole (Huang and Burkhardt, 2007).  
 
1.3.8 The actin cytoskeleton in membrane organization 
At the inner leaflet of the plasma membrane, the cortical actin cytoskeleton provides the 
structural matrix to control the distribution of both lipids and proteins in the membrane during 
T cell activation. Dynamic rearrangements of the actin cytoskeleton following TCR 
engagement maintain cell-cell adhesion, stabilize and nucleate membrane compartments and 
regulate processes such as cell polarization and motility (reviewed in Billadeau et al., 2007; 
Chichili and Rodgers, 2009). The actin cytoskeleton consists of branched actin filaments held 
together by actin binding proteins and is tethered to the plasma membrane through the 
interaction of ERM proteins with transmembrane proteins (Neisch and Fehon, 2011). In 
resting T cells, the actin cytoskeleton constrains the lateral movement of plasma membrane 
proteins with their cytoplasmic domains extending into the cortical actin network. However, 
in response to binding of an antigen, the lateral mobility increases concurrent with the 
detachment of the underlying cortical actin from the plasma membrane and a transient actin 
disassembly. Signals that emanate from T cell-APC interaction lead to the synchronized 
activation of actin-regulatory proteins like PLCȖ1, Itk, Vav1 and non-catalytic region of 
tyrosine kinase (Nck) (Koretzky et al., 2006) which control the reassembly and disassembly of 
the actin cytoskeleton in T cells. Downstream of Vav1 are the Rho GTPases cell division 
cycle (Cdc) 42 and Rac1 which upon binding of GTP activate the Wiskott-Aldrich syndrome 
protein (WASP)-interacting protein (WIP) and WASP-family verprolin-homologous protein-2 
(WAVE2) complexes, respectively. These in turn regulate the actin-related protein 2/3 
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(ARP2/3) complex which binds actin filaments and drives the subsequent actin 
polymerization (Billadeau et al., 2007; Chichili and Rodgers, 2009). Proteins activating the 
ARP2/3 complex direct the formation of an actin scaffold at the immunological synapse, 
whereas ezrin and moesin seem to direct binding of signaling molecules to actin filaments 
within the DPC (Huang and Burkhardt, 2007). Disruption of actin filaments or depletion of 
actin cytoskeleton regulators have been shown to regulate the accumulation of TCR and 
phosphotyrosine-containing proteins to the IS (Wulfing et al., 2000; Campi et al., 2005) and 
impair the organization of the DPC (Huang and Burkhardt, 2007). Thus, the actin 
cytoskeleton is a dynamic structure that changes in response to extracellular signals, and may 
therefore also influence the size and distribution of membrane rafts. Proteomic studies show 
that DRMs are particularly enriched with cytoskeletal proteins (von Haller et al., 2001; Bini et 
al., 2003) and clustering of DRM markers in the plasma membrane often correlates with the 
content of actin filaments in the cell (Rodgers and Zavzavadjian, 2001; Gomez-Mouton et al., 
2001), suggesting a dependency on actin cytoskeleton reorganization to induce and maintain 
membrane raft clustering. Cytoskeletal components seem to be pre-associated with membrane 
rafts or become increasingly associated with them following crosslinking of the TCR (Montixi 
et al., 1998; Xavier et al., 1998; Drevot et al., 2002). However, the degree to which the actin 
cytoskeleton contributes toward protein clustering relative to that of the cholesterol-dependent 
lipid ordering, is not established. 
 
1.4 T cell activation 
Naïve T cells are in constant motion, scanning the lymph nodes at high rates in search of 
antigen (Miller et al., 2002), and T cell activation is initiated when the T cell receptor (TCR) 
encounters and binds composite surfaces of antigenic peptides embedded in MHC molecules. 
The TCR represents the chief molecular checkpoint for T cell development, homeostasis and 
immune responses. Threshold of T cell activation must therefore be precisely tuned to ensure 
that the cells only detect foreign pMHC ligands (signal) in the presence of high levels of self-
pMHC molecules (noise) (Kuhns and Davis, 2012). To achieve this, the TCR antigen 
recognition needs to be extremely sensitive, and indeed, TCRs can be triggered when a single 
or only a few antigenic pMHC ligands are present within the contact area (Irvine et al., 2002). 
Specificity is another unique feature of the TCR, a requirement for maintaining the potential 
for self-reactivity in order to undergo positive selection in the thymus, but keep reactivity 
under control by mechanisms of peripheral tolerance. The observation that autoimmune 
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pathology is fairly rare demonstrates that this self-reactive potential is rigorously controlled in 
normal individuals (Brownlie and Zamoyska, 2013). Lastly, it is necessary for the same TCR 
to recognize multiple ligands with a range of affinities and to produce distinct signaling 
responses depending on the binding affinity (van der Merwe and Dushek, 2011). Signaling 
responses after TCR engagement occurs on a timescale of seconds (Huse et al., 2007), but 
TCR signaling must be sustained for several hours in order for T cells to secrete cytokines and 
proliferate (Huppa et al, 2003). The focus of this Thesis has been on the early defining events 
necessary for T cell activation to occur. 
The TCR is composed of a variable, ligand-binding TCRĮȕ heterodimer which forms 
a multi-subunit receptor complex with the non-variable CD3 protein consisting of İȖ, İį and 
ȗȗ dimers. All CD3 subunits contain immunoreceptor tyrosine-based activation motifs 
(ITAMs) in their cytoplasmic domains that are essential for TCR-mediated activation (van der 
Merwe and Dushek, 2011). How antigen engagement links to T cell activation remains elusive 
despite decades of research in the field, but most likely it involves both TCR clustering and 
conformational changes within the cytoplasmic part of the CD3 components (Smith-Garvin et 
al., 2009). The TCR has no intrinsic enzymatic activity and instead depends on the kinase 
activity of Src family kinases, particularly Lck, to initiate signaling. Lck activity is largely 
controlled by the dynamic action of phosphorylation and dephosphorylation events at a C-
terminal inhibitory tyrosine (Tyr505) and an activating tyrosine (Tyr394) in the catalytic 
domain (Veillette and Fournel, 1990; Yamaguchi and Hendrickson, 1996). A large proportion 
of Lck in primary human T cells seems to localize to membrane rafts through interaction with 
CD4 molecules (Irles et al., 2010), and regulation of the C-terminal inhibitory tyrosine in 
resting cells is partly achieved by exclusion of the activator CD45 from membrane rafts 
(Rodgers and Rose, 1996), in addition to association of the negative regulator Csk with PAG 
residing in membrane rafts (Davidson et al., 2003). However, a fraction of active Lck is also 
constitutively present in unstimulated cells, suggesting a model in which regulated amounts of 
pre-activated Lck in membrane rafts are necessary to confer rapid and efficient TCR-induced 
ITAM phosphorylation (Nika et al., 2010). Lck-dependent phosphorylation of the ITAMs 
allows the subsequent recruitment and activation of ZAP-70. This Lck-dependent 
phosphorylation results in conformational changes in ZAP-70, which promotes its kinase 
activity (Deindl et al., 2007), leading to phosphorylation of its target molecules, including the 
transmembrane protein LAT (Zhang et al., 1998b) and SLP-76 (Bubeck et al., 1996). 
Phosphorylated LAT recruits SLP-76 to the cell membrane where these two adaptors function 
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as docking sites for multiple downstream effector proteins, including PLCȖ1, growth factor 
receptor-bound protein 2 (Grb2) and associated son of sevenless (Sos), Grb2-related adaptor 
protein 2 (Gads), Vav1, Nck, the p85 subunit of PI3K and Itk (Tuosto et al., 1996; Trub et al., 
1997; Liu et al., 1999; Wunderlich et al., 1999; Zhang et al., 2000; Shim et al., 2004; Bogin et 
al., 2007). The coordinated binding of members of the LAT/SLP-76 adaptor complex seems 
to be necessary in order to form a particularly stable supramolecular signaling complex that 
organizes downstream signaling in a spatiotemporal manner. See Figure 4 for an illustrative 
overview of T cell signaling. 
 
 
 
Figure 4. Overview of TCR/CD28-mediated signaling pathways that lead to T cell activation. Engagement 
of the TCR and CD28 during antigen presentation mediates the formation of a complex interaction network 
comprising central kinases and adaptors leading to downstream signaling events. These signaling cascades 
culminate in activation of transcription factors which altogether regulate T cell proliferation, differentiation, 
function and survival (see text for further details). Adapted from Acuto et al., 2008 and Riha and Rudd, 2010. 

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Phosphorylated LAT binds the SH2 domain of PLCȖ1 and places the enzyme in close 
proximity of its substrate PIP2 (Zhang et al., 2000). Activation of PLCȖ1 is dependent on the 
Gads-mediated recruitment of SLP-76 to LAT (Yablonski et al., 1998; Liu et al., 1999) and 
the binding of Itk to SLP-76 (Schaeffer et al., 1999). Recruited Itk phosphorylates and 
activates PLCȖ1 and activated PLCȖ1 subsequently hydrolyzes PIP2, leading to an increase in 
cytoplasmic calcium by inositol trisphosphate (IP3) and activation of PKCș and Ras guanyl 
nucleotide-releasing protein (RasGRP) by diacylglycerol (DAG) production (Huang and 
Sauer, 2010). Ras is a guanine nucleotide binding protein, only active in the GTP-bound state, 
and activation of Ras involves two guanosine nucleotide exchange factors (GEFs), Sos1 and 
RasGRP in a positive feedback loop which is required for the activation of the kinase Raf-1. 
Raf-1 initiates the mitogen-associated protein kinase (MAPK) phosphorylation and activation 
cascade, involving MAPK kinase (Mek) and extracellular signal-regulated kinase (Erk), 
which contributes to the activation of the activator protein-1 (AP-1) (consisting of Fos/Jun) 
transcription complex (Smith-Garvin et al., 2009). Another major signaling pathway initiated 
by DAG production is mediated by PKCș which regulates the activation of the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-țB) family of transcription factors. NF-
țB activation depends on phosphorylation-induced degradation of the inhibitor of NF-țB (IțB) 
proteins, allowing NF-țB to translocate to the nucleus (Oeckinghaus and Ghosh, 2009). The 
IP3 generated by TCR-stimulated PLCȖ1 activity stimulates calcium permeable ion channel 
receptors on the endoplasmic reticulum (ER) membrane, leading to the release of ER calcium 
stores into the cytoplasm. Depletion of ER calcium stores triggers a sustained influx of 
extracellular calcium through the activation of plasma membrane calcium release-activated 
channels (CRACs), and the intracellular concentration of Ca2+ increases from 50 nM to 
around 1 μM upon stimulation (Robert et al., 2011). Sustained, increased concentration of 
calcium is required for motility and immunological synapse formation in T cells and is 
involved in the regulation of members of the nuclear factor of activated T cells (NFAT) 
family (Oh-hora, 2009). Thus, signaling from the TCR results in changes in gene expression 
by controlling the activation of the transcription factors NF-țB, NFAT and AP-1 that mediate 
T cell developmental and effector programs. The numerous signaling elements mentioned 
above serve to indicate that initial T cell signaling is a complex process and in need of tight 
regulatory control. In the present Thesis, we have investigated the role of co-stimulatory 
receptors, which contribute to regulation of the T cell activation process. Ligation of the TCR 
alone generates only short-lasting and incomplete activation events that are insufficient to 
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cause cell proliferation and differentiation, more likely it will render the T cell anergic to 
further antigenic stimulation (Quill and Schwartz, 1987; Jenkins et al., 1990). In addition to 
signals from the TCR, optimal T cell activation therefore requires a second, antigen-
independent signal mediated by accessory co-stimulatory receptors such as CD28 and CD2, 
which will be further elaborated in the next sections. 
 
1.4.1 Co-signaling receptors 
The requirement for accessory molecules for full lymphocyte activation to occur forms the 
basis of the two-signal model proposed by Bretscher and Cohn in 1970 as a mechanism for 
discrimination of self and non-self in B cells (Bretscher and Cohn, 1970). Later on, the model 
was expanded to also comprise T cell activation (Lafferty and Cunningham, 1975). According 
to this model, recognition of cognate pMHC complexes on APCs by the TCR delivers the first 
signal, whereas co-signaling receptors on the cell surface trigger the second signal (Figure 5). 
An emerging group of both co-stimulatory and co-inhibitory receptors have been identified, 
displaying great diversity in expression, structure and ability to control immune responses 
(reviewed in Chen and Flies, 2013). The function of these receptors is largely context- 
dependent and at the present time, T cell co-signaling is therefore recognized as an integrating 
process of positive and negative signals that dictates the outcome of a T cell response (Beier 
et al., 2007). Two major groups of co-signaling receptors have been described, the 
immunoglobulin and the TNF receptor superfamily. Co-signaling receptors can be further 
subdivided into specific families based on primary amino acid sequences, protein structure 
and function (Chen and Flies, 2013). Members of the Ig superfamily include CD28 and CD2, 
studied in this Thesis, as well as inducible T cell co-stimulator (ICOS), cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). 
 
1.4.2 The CD28 co-receptor 
CD28 is the founding receptor of the Ig superfamily and was first identified in the 1980s as a 
co-receptor that enhanced TCR-induced proliferation and promoted the differentiation of 
naïve CD4+ T cells (Hansen et al., 1980; Lesslauer et al., 1986), thus providing evidence for 
the two-signal model of T cell activation. Ligation of CD28 has been shown to increase the 
IL-2 production, both by augmented transcriptional activity of NFAT, NF-țB and AP-1 and 
by messenger RNA stabilization (Fraser et al., 1991; Granelli-Piperno and Nolan, 1991; 
Shapiro et al., 1997), to preferentially promote TH2 differentiation (King et al., 1995; Rulifson 
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Figure 5. The T cell co-signaling paradigm.
The two-signal hypothesis states that 
engagement of the TCR in the absence of a 
co-stimulatory signal is insufficient to 
activate the T cell and may render it 
unresponsive to further stimulation (upper T 
cell). Illustrated on the figure is the CD28/B7 
receptor/ligand complex, the most well 
characterized co-stimulatory interaction. 
CD28 is constitutively expressed on the cell 
surface of naïve CD4+ and CD8+ T cells and 
provides an essential co-stimulatory signal 
for T cell activation upon ligation by B7 on 
APCs. Expression of B7 is modulated by the 
activation state of the APC. CTLA-4 is 
induced following T cell activation and 
suppresses T cell responses. When CTLA-4 
is upregulated, CD28 expression is 
subsequently downregulated by endocytosis. 
Adapted from Chen and Flies, 2013. 
 
et al., 1997) and to promote cell survival by increasing glucose metabolism and inducing the 
expression of anti-apoptotic proteins such as B cell lymphoma (Bcl)-XL and Bcl-2 (Boise et 
al., 1995; Mueller et al., 1996).  
Approximately 90% of human CD4+ T cells and 50% of human CD8+ T cells express 
CD28 (Hansen et al., 1980), and the co-receptor has been shown to bind to either of the 
structurally homologous B7-1 (CD80) or B7-2 (CD86) ligand pair (Azuma et al., 1993; 
Freeman et al., 1993) expressed by professional APCs. Both ligands are upregulated by 
activating stimuli and display largely overlapping functions (Schweitzer et al., 1997). In 
contrast to the TCR complex that binds to a range of different peptides with varying affinity, 
CD28 binds to the B7 molecules with constant affinity, but the on and off-rates for CD28-B7 
interactions are much faster than TCR-pMHC interactions (van der Merwe and Davis, 2003). 
CD28 shares its ligands with the inhibitory receptor CTLA-4 that opposes the CD28-mediated 
co-stimulation (Krummel and Allison, 1995). CD28 and CTL4-A both bind to B7 molecules 
by recognizing a MYPPPY motif within the Ig-like domain (Peach et al., 1994), but in 
contrast to CD28, CTLA-4 expression is induced upon activation and has higher affinities for 
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B7 ligands than CD28 (Walunas et al., 1994). CTLA-4 may therefore exclude CD28 from the 
immunological synapse and outcompete it for the shared ligands. More recently, CTLA-4-
expressing cells were shown to downregulate the surface expression of B7 on APCs through 
trans-endocytosis, resulting in impaired co-stimulation via CD28 (Qureshi et al., 2011).  
The intracellular domain of CD28 comprises 41 amino acid residues that possess no 
intrinsic enzymatic activity. However, regions within the short cytoplasmic tail interact with 
intracellular adaptor proteins and enzymes, as illustrated in Figure 6, that interact with 
multiple downstream pathways (reviewed in Rudd et al., 2009). Mutagenesis studies have 
identified two regions of particular importance for recruitment of intracellular signaling 
proteins to CD28, the YMNM and PYAP motifs that bind to SH2 and SH3 domains, 
respectively. The YMNM motif in the membrane proximal region of the cytoplasmic domain 
is phosphorylated by Lck and Fyn within seconds after CD28 crosslinking (Raab et al., 1995), 
and the phosphorylated tyrosine residue binds to the p85 subunit of PI3K (Pages et al., 1994), 
Grb2 (Schneider et al., 1995) and Gads (Ellis et al., 2000). The p110 catalytic subunit of PI3K 
catalyzes the conversion of PIP2 to PIP3 at the plasma membrane, and localized PIP3 
generation recruits pleckstrin homology (PH) domain containing proteins, including 
phosphoinositide-dependent kinase-1 (PDK1) and its target Akt (also known as protein kinase 
B) (Parry et al., 1997). Akt is a particularly important PI3K-dependent effector protein in 
CD28 signaling. The downstream targets of Akt are diverse and include glycogen synthase 
kinases (Gsk) 3 Į and ȕ, a serine-threonine kinase involved in the nuclear localization of 
NFAT (Beals et al., 1997), mammalian target of rapamycin (mTOR), involved in increased 
cell cycle activity and glucose metabolism, cAMP responsive element binding protein 
(CREB), FOXO family of transcription factors and IțB (Vanhaesebroeck and Alessi, 2000). 
Following Akt activation, phosphorylation of the IțB complex results in NF-țB translocation 
to the nucleus and subsequent transcription of NF-țB target genes (Jones et al., 2000; Park et 
al., 2009). While most antigen-induced T cell signaling events are under tight control by the 
TCR, activation of the NF-țB pathway and NF-țB regulated genes seem to be a unique 
feature of CD28 (Takeda et al., 2008; Annibaldi et al., 2008) as will be further discussed in 
section 4.3.  
Signaling by the more distal PYAP motif is initiated by recruitment and activation of 
Lck (Holdorf et al., 1999) and Grb2 (Okkenhaug and Rottapel, 1998). In particular, CD28 co- 
stimulation has been shown to sustain Lck activity in the immune synapse of CD4+ T cells
(Holdorf et al., 2002). Grb2 in turn constitutively binds Sos1, which activates p21ras and 
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downstream MAPK signaling (Schneider et al., 1995). CD28-Grb2 interaction is required to 
phosphorylate and activate Vav1 and then cooperates with Vav1 to activate NFAT and AP-1-
dependent transcription (Schneider and Rudd, 2008). The PYAP motif has also been shown to 
bind Itk (Marengere et al., 1997) and the actin-binding scaffold protein FlnA (Tavano et al., 
2006). The roles of the two binding regions in CD28 signaling have been examined in several 
experiments using transgenic mice with contradictory results. Genetic disruption of the 
YMNM motif prevented PI3K binding and phosphorylation of Akt, but had no effect on IL-2 
production or T cell proliferation (Okkenhaug et al., 2001; Dodson et al., 2009). On the other 
hand, mutation of the distal proline PYAP motif resulted in impaired CD28-dependent 
functions, including proliferation and secretion of IL-2 and other cytokines (Friend et al., 
2006; Dodson et al., 2009). A subsequent study in mice found that neither the YMNM nor the 
PYAP domain enhanced the proliferation of the effector cell population after bacterial 
infection (Pagan et al., 2012). This in vivo discrepancy in mice is surprising and may be due to 
variations in the response of T cells from different mouse strains and to the use of non-
physiological stimuli and different antigens.  
           Just downstream of the YMNM motif, CD28 has a PRRPGP docking site that has been 
reported to interact with the SH3 domains of the kinases Itk and Tec, but the physiological 
role of this binding is still unclear. CD28 co-ligation enhances Itk-dependent phosphorylation 
 
 
 
Figure 6. Motif specific protein-protein interactions with the cytoplasmic tail of CD28 and CD2. The 
proximal YMNM motif in CD28, when phosphorylated by Lck and Fyn, binds the p85 subunit of PI3K, Grb2 
and Gads via their SH2 domains. The distal proline-rich motifs bind the SH3 containing proteins Itk at the 
sequence PRRP and Grb2, FlnA and Lck at the sequence PYAP. Mechanisms by which CD2 couples to signal 
transduction molecules are more uncertain, butCD2 may interact with SH3 domains of cytoplasmic proteins via 
poly-proline rich sequences. Both Lck, PI3K, CD2AP and CD2BP1 have been reported to interact with the distal 
proline-rich region. Adapted from Boomer and Green, 2010 and cited literature in the Thesis. 
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of PLCȖ1, but surprisingly, T cells deficient in Itk have been reported to be hyperresponsive 
to CD28 co-stimulation (Liao and Littman, 1995), suggesting that the kinase also affects co-
stimulation negatively. 
 
1.4.3 The CD2 co-receptor  
CD2 is a transmembrane glycoprotein expressed on the surface of T lymphocytes as well as 
on a majority of thymocytes and natural killer (NK) cells (Davis and van der Merwe, 1996). 
Structurally, the molecule consists of two Ig-like domains followed by a single 
transmembrane sequence and a cytoplasmic region of 116-117 amino acid residues (Chang et 
al., 1989). CD2 acts to enhance T cell-APC adhesion by binding to its ligand CD58 (LFA-3) 
on APCs (Selvaraj et al., 1987). The weak affinity of the interaction between CD2 and CD58 
is associated with remarkably fast on and off rates that foster exchange between CD2 and 
CD58 partners on opposing cell surfaces (Dustin et al., 1997), allowing CD2 to facilitate 
motility of T cells along APCs. CD2-CD58 interactions also promote the formation of optimal 
intercellular membrane spacing suitable for TCR recognition of pMHC (Wang et al., 1999) 
and thus promote T cell activation at lower antigen concentrations (Bachmann et al., 1999). It 
has been shown that stimulation of human CD2 induces T cell proliferation and can reverse T 
cell anergy induced by B7 blockage (Boussiotis et al., 1994). Concomitant with its role as an 
adhesion molecule, CD2 has therefore been considered to be a co-stimulatory signaling 
molecule. The cytoplasmic domain of CD2 has no intrinsic enzymatic activity and strikingly 
lacks any tyrosine residues serving as docking sites for SH2 domains upon phosphorylation 
(Fukai et al., 2000). However, proline-rich sequences in the cytoplasmic domain can serve as 
docking sites for SH3 (Bell et al., 1996) or glycine-tyrosine-phenylalanine (GYF) (Nishizawa 
et al., 1998) domain interactions. CD2 binds to the PI3 kinase (Kivens et al., 1998), the 
adaptor protein CD2 associated protein (CD2AP), connecting CD2 to the cytoskeleton (Dustin 
et al., 1998), and with the CD2 binding protein 1 (CD2BP1), resulting in downregulation of 
activation-dependent CD2 adhesion (Li et al., 1998). The proline-rich stretches interact with 
the SH3 domains of Src family kinases, mediating a coupling to downstream signal 
transduction pathways (Carmo et al., 1993) (Figure 6). By using soluble anti-CD2 antibodies 
to elicit signaling it has been shown that Lck, Fyn, LAT, ZAP-70 and PLCȖ as well as a rise 
in intracellular calcium levels are involved in CD2 downstream signaling events (Siliciano et 
al., 1985; Martelli et al., 2000; Fukai et al., 2000). When using the native GPI-anchored form 
of CD58 as a ligand, CD2-CD58 interactions were found to be followed by an actin-
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dependent reorganization of CD2 and downstream signaling molecules into membrane rafts 
(Kaizuka et al., 2009). The CD2-induced assembly of the plasma membrane components 
resembled those induced by the TCR. It is therefore plausible that these receptors act 
synergistically at the T cell-APC interface to enhance T cell activation. A study from our 
group recently showed that co-stimulation through CD28 and CD2 trigger overlapping, but 
distinct signaling pathways. CD28 co-stimulation specifically induced signaling necessary for 
proper NF-țB activation, whereas CD2 signaled more strongly to S6 ribosomal protein 
(Kalland et al., 2011). In Paper III, we follow up on this study by investigating whether 
different signaling patterns induced by CD28 versus CD2 co-stimulation are linked to distinct 
functional outcomes. 
 
1.5 The cAMP-PKA type I-Csk signaling pathway in T cells 
The versatile intracellular second messenger cyclic adenosine 3’, 5’ monophosphate (cAMP) 
is recognized as a potent inhibitor of T cell function and proliferation (Skålhegg et al., 1992; 
Aandahl et al., 2002). Pre-treatment of T cells with a cAMP elevating agent prior to TCR 
stimulation inhibits tyrosine phosphorylation of proteins involved in proximal T cell signaling 
(Klausner et al., 1987). Effects of cAMP on proximal T cell signaling have attracted 
considerable interest in work from our laboratory and a negative pathway for regulation of the 
T cell activation process by a cAMP-PKA-Csk signaling cascade has been unraveled. 
In the immune system, cAMP mediates the effect of extracellular ligands such as 
eicosanoids, peptide hormones and ȕ-adrenergic agonists (Mosenden and Taskén, 2011). 
When these agents bind to transmembrane G protein-coupled receptors (GPCRs) interacting 
with heterotrimeric G proteins, conformational changes are induced that lead to release of 
activated stimulatory G protein Į subunits from G protein ȕ/Ȗ dimers and the subsequent 
activation of adenylyl cyclases (ACs), which hydrolyse adenosine triphosphate (ATP) to 
cAMP (Willoughby and Cooper, 2007). Although other effectors of cAMP have been 
identified, such as cyclic nucleotide-gated ion channels (Kaupp and Seifert, 2002) and 
exchange proteins activated by cAMP (EPACs), most of the immunoregulatory effects of 
cAMP appear to be mediated through PKA (also known as cAMP-dependent protein kinase) 
(Kawasaki et al., 1998; Fuld et al., 2005). The PKA holoenzyme is composed of two catalytic 
(C) subunits held in an inactive conformation by association with a regulatory (R) subunit 
dimer (Soderling et al., 1973; Potter and Taylor, 1979). Cooperative binding of two cAMP 
molecules to each of the R subunits induces a conformational change and leads to release of 
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active C subunit monomers (Kopperud et al., 2002), now able to phosphorylate a broad range 
of nearby substrates. Four R subunit (RIĮ, RIȕ, RIIĮ and RIIȕ) and three C subunit (CĮ, Cȕ 
and PRKX) genes are transcribed into functional subunits in humans (Skålhegg and Taskén, 
2000). Protein kinase A enzymes containing RI and RII subunits are designated PKA type I 
and II, respectively (Corbin et al., 1975) and they possess distinct activation thresholds and 
subcellular localizations (Dostmann and Taylor, 1991). In T cells, 80% of the total PKA 
activity is associated with the PKA type I isoform (RIĮ2C2) (Skålhegg et al., 1992). Analyses 
of membrane raft purifications from normal resting T cells for the presence of different 
subunits of PKA reveal that both the catalytic subunits CĮ and Cȕ2 (Orstavik et al., 2005) and 
the regulatory subunit RIĮ, but no RII subunits, are constitutively associated with membrane 
rafts (Vang et al., 2001). Furthermore, in contrast to PKA type II, specific activation of PKA 
type I is sufficient for cAMP-mediated inhibition of T cell proliferation (Skålhegg et al., 
1992), providing further evidence for a dominant role of PKA type I in T cell responses. 
Despite the broad substrate specificity of PKA, a high degree of subcellular specificity 
is achieved by opposing roles on cAMP generation by nine membrane-bound ACs and 
isoforms from 11 families of cyclic nucleotide phosphodiesterases (PDEs) (Lugnier, 2006). 
Isoforms from the PDE4 subfamily seem to represent the majority of cAMP hydrolyzing 
activity in T cells (Erdogan and Houslay, 1997). Orientation of PKA towards substrates is
attained by interactions with A-kinase anchoring proteins (AKAPs) and their role as 
scaffolding proteins provide further spatiotemporal regulation in cAMP-PKA-mediated 
signaling. The AKAP that specifically targets PKA type I to membrane rafts in T cells has 
been identified as ezrin (Ruppelt et al., 2007), which belongs to the ERM family of proteins. 
By localizing to membrane rafts, PKA type I harbors the ability to directly modulate 
the events that take place after engagement of the TCR. The most proximal target for PKA 
phosphorylation in T cell membrane rafts is the non-receptor tyrosine kinase Csk (Vang et al., 
2001), and observed inhibitory effects of cAMP on TCR-induced CD3ȗ chain phosphorylation 
point towards an important role of Csk in negative regulation of T cell responses. Ezrin has 
been shown to co-localize PKA type I and Csk in membrane rafts by forming a 
supramolecular signaling complex consisting of PKA type I, ezrin, EBP50 and PAG. The 
transmembrane adaptor protein PAG recruits Csk to membrane rafts through interaction with 
phosphorylated Tyr317 on PAG (Brdicka et al., 2000; Kawabuchi et al., 2000) and the 
interaction increases Csk activity (Takeuchi et al., 2000). In resting T cells, PAG is kept in a 
hyperphoshorylated state, most probably by the constitutive activity of Fyn (Yasuda et al., 
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2002), thereby targeting Csk to membrane rafts. Phosphorylation of Csk on Ser364 by PKA 
type I further increases the kinase activity of membrane raft recruited Csk two- to four-fold 
(Vang et al., 2001) so that interaction with phosphorylated PAG and phosphorylation by PKA 
type I act together in a positive spatiotemporal regulation of Csk activity (Vang et al., 2003). 
Additionally, Csk has been shown to negatively regulate Lck activity by phosphorylating the 
conserved Tyr505 on Lck (Bergman et al., 1992; Chow et al., 1993), which provides a 
powerful mechanism for reducing Lck phosphorylation of CD3ȗ chains and thereby terminate 
proximal TCR signaling (Figure 7). However, upon TCR engagement, PAG is rapidly 
dephosphorylated by a mechanism that appears to involve the activity of the transmembrane 
phosphatase CD45 (Davidson et al., 2003) and Csk is transiently released from its membrane 
raft anchoring (Brdicka et al., 2000; Kawabuchi et al., 2000), which is a necessary event to 
allow T cell activation to proceed. 
In Paper I we confirmed membrane rafts to be complex signalosomes and that PKA 
type I is a central node in proximal TCR signaling, while in Paper II we investigated the effect 
of sequestration of PKA type I and Csk from the immunological synapse. Thus, in this Thesis, 
a key focus is on the cAMP-PKA-Csk inhibitory pathway as a central mechanism contributing 
to regulation of T cell activation. Furthermore, since the cAMP-PKA pathway is strongly 
involved in the regulation and modulation of immune responses, it is not surprising that  
 
 
 
Figure 7. The inhibitory cAMP-PKA type I-Csk pathway in membrane rafts. Generation of local pools of 
cAMP through G protein-coupled receptors (e.g. EP2/4) and adenylyl cyclase activity is able to attenuate 
proximal TCR signaling by activating a PKA type I-Csk-Lck inhibitory pathway. Ezrin targets PKA type I to 
membrane rafts in the proximity of its downstream substrate Csk by forming a supramolecular signaling complex 
consisting of PKA type I, ezrin, EBP50, PAG and Csk. PKA-mediated phosphorylation of Csk and targeting to 
the transmembrane adaptor PAG both contribute to increased Csk activity. As a consequence, Src kinase activity 
is dampened and proximal T cell signaling is inhibited. 
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numerous diseases and conditions involving T cells are associated with dysregulations in the 
cAMP system (Aandahl et al., 1998; Aukrust et al., 1999; Kammer et al., 2004). Against this 
background, we set out to investigate proximal signaling mechanisms underlying diseased T 
cell functions in a colorectal cancer setting, in which the production of the cAMP elevating 
agent prostaglandin E2 (PGE2) is increased (Paper IV). 
  
1.6 Colorectal cancer 
Cancer of the colon and rectum is the third most commonly diagnosed cancer throughout the 
world, and constitutes about 10% of the estimated 14 million new cancer cases per year. The 
highest incidences are found in industrialized regions such as Australia/New Zealand, Europe 
and Northern America while the lowest incidences are found in Middle/Western Africa and 
South-Central Asia (WHO, 2012). The majority of colorectal cancer (CRC) deaths are due to 
the sporadic origin, slow progression and hence diagnosis at an advanced stage. Five-year 
survival rates for patients diagnosed with localized disease is 90%, whereas the survival rate 
drops to nearly 10% for patients that present with distant metastases at diagnosis (National 
Cancer Institute, 2014). The liver is the dominant metastatic site and hepatic metastases are 
estimated to account for two thirds of CRC patient deaths (Van den Eynde and Hendlisz, 
2009). 15-25% of CRC patients present with liver metastasis at the time of diagnosis of their 
primary cancer and an additional 15-40% develop liver metastasis during the course of their 
cancer (Mayo et al., 2011).  
The incidence of CRC can be separated into 72% for cancer in the colon and 28% in 
the rectum (Centelles, 2012). Aside from hypermutated cancers, colon and rectal cancers are 
not distinguishable at the genomic level (The Cancer Genome Atlas Network, 2012), but the 
anatomical distinction might have both surgical and radiotherapeutic management 
implications as well as an impact on prognosis. 
 
1.6.1 Risk factors and pathophysiology of colorectal cancer 
The pathogenic mechanisms underlying CRC development are multifactorial and 
heterogeneous, and the majority of cases are sporadic in origin where both genetic and 
environmental factors contribute to carcinogenesis. Epidemiological studies have implicated 
diets high in unsaturated fats, processed and red meat (Alexander et al., 2011), excessive 
alcohol consumption (Ferrari et al., 2007) and smoking (Hannan et al., 2009) combined with a 
sedentary lifestyle and excess bodyweight (Ning et al., 2010) to be among the most influential 
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dietary and lifestyle risk factors for developing CRC. Inverse associations include exercise, 
non-steroidal anti-inflammatory drugs, estrogen, calcium (Fearon, 2011) and possibly high 
intake of dietary fiber (Aune et al., 2011). Individuals with chronic inflammatory disorders are 
at increased risk of developing CRC compared with the general population (Andersen and 
Jess, 2013). Lastly, as for most cancers, age is by far the highest risk factor as more than 90% 
of new CRC cases occur in individuals aged 50 or older (National Cancer Institute, 2014). 
Most CRCs arise from altered differentiation of glandular colonic epithelium into 
adenocarcinomas. The multistep accumulation of genetic and epigenetic alterations that drive 
the progression of benign adenomas to malignant adenocarcinomas led to the linear 
“adenoma-carcinoma sequence” model (Vogelstein et al., 1988). Adenomas approximately 10 
mm in size have an estimated 25-40% cumulative chance of progressing to carcinomas over a 
10-year period (Brenner et al., 2007), and removal of colonic adenomas has been shown to 
reduce the incidence of CRC by over 70% (Winawer et al., 1993).  
The initial step of tumorigenesis is associated with loss of the adenomatous polyposis 
coli (APC) gene. More than 90% of CRC patients have alterations that affect APC which acts 
to promote degradation of ȕ-catenin and so limit the transcription of Wnt target genes 
involved in regulation of the cell cycle (Thorstensen et al., 2005). Larger adenomas and early 
carcinomas might acquire mutations in the K-Ras oncogenes, although they are present in less 
than 40% of CRCs (Andreyev et al., 1998), followed by loss of SMAD4 (member of the 
transforming growth factor (TGF) ȕ signaling pathway) and the inactivation of the tumor 
suppressor gene TP53 late in colorectal carcinogenesis (Walther et al., 2009). 
Two major types of genomic instability are recognized as alternative mechanisms of 
colorectal carcinogenesis, chromosome instability (CIN) and microsatellite instability (MSI) 
which is present in approximately 65-70% and 15% of the cases, respectively (Walther et al., 
2009).  
Approximately 15-30% of CRCs have a major hereditary component, given the 
occurrence of CRC in first- or second-degree relatives. Most inherited cases are attributable to 
the autosomal dominant syndrome hereditary nonpolyposis CRC (HNPCC), also known as 
Lynch syndrome, and familial adenomatous polyposis (FAP). FAP is associated with an 
inactivating mutation in the APC gene and presents with multiple adenomatous polyps and 
carcinomas of the colon and rectum, while HNPCC is a CRC without extensive polyposis and 
is associated with a high frequency of the MSI phenotype and mutations in DNA mismatch 
repair genes (Fearon, 2011). 
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1.6.2 The role of prostaglandin E2 in homeostasis and colorectal cancer pathophysiology 
Prostaglandins (PGs) are biologically potent lipids generated by hydrolysis of arachidonic 
acid through the action of cytosolic phospholipase A2. Phospholipase A2 releases arachidonic 
acid from membrane phospholipids, before cyclooxygenase (COX) enzymes convert the 
arachidonic acid to the common precursor of all prostaglandins, PGH2. Lastly, specific 
prostaglandin synthases convert PGH2 to various prostaglandins, of which PGE2 is the most 
abundant prostaglandin found in the human body (Dey et al., 2006). Prostaglandin E2 is 
relatively stable in vitro, but has a fast turnover in vivo and is rapidly eliminated from tissues 
and circulation (Forstermann and Neufang, 1983). Cyclooxygenase-1 is expressed 
constitutively in most cells and is the predominant enzyme that generates prostaglandins that 
serve normal homeostasis functions in the reproductive, gastrointestinal, immune, 
cardiovascular and nervous systems (Smyth et al., 2009). In contrast, COX-2 is induced by 
inflammatory stimuli, hormones and growth factors and is the rate-limiting step in PGE2 
synthesis during pathophysiological responses like inflammation, chronic infections and in 
proliferative diseases such as cancer. All cells in the body can produce PGE2, with epithelia, 
fibroblasts and infiltrating inflammatory cells representing the major sources of PGE2 in the 
course of an immune response (Kalinski, 2012).  
Prostaglandin E2 binds to four GPCRs termed EP receptors (EP1-EP4) that are 
distinguished by the signal transduction pathway activated upon ligand binding. Studies have 
confirmed that EP2 and EP4 are the main receptors to mediate the actions of PGE2 in human 
naïve CD4+ T cells and that they are upregulated in response to activation (Boniface et al., 
2009). Prostaglandin receptors EP2 and EP4 activate ACs via stimulatory GPCRs, thus 
increasing intracellular cAMP levels, as well as the Gsk/ȕ-catenin pathway (Fujino et al., 
2002). Activation of EP1 leads to mobilization of free intracellular calcium, whereas EP3 
isoforms couple to inhibitory GPCRs to elevate intracellular calcium and inhibit cAMP 
generation (Dey et al., 2006). Depicted in Figure 8 are PGE2 synthesis, the various EP 
receptors and initial events induced by PGE2. Drug targets exploited in regulation of PGE2 
activity are also illustrated. 
Cyclooxygenase-2 is known to be upregulated in a subset of colorectal adenomas and 
in a majority of carcinomas (Eberhart et al., 1994; Elder et al., 2002), and the tumorigenic 
effects of COX-2 in CRC neoplasia have largely been attributed to its role in producing PGE2. 
Levels of PGE2 increase in a size-dependent manner in adenomas of FAP patients (Yang et al., 
1998),  suggesting  a  correlation  between  tumor  growth  and  prostaglandin  biosynthesis.  
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Figure 8. Regulation of PGE2 synthesis, degradation and responsiveness. Synthesis of PGE2 is initiated by 
the phospholipase A2-driven release of arachidonic acid from the cell membrane. The arachidonic acid becomes 
the substrate for COX-1 (constitutively active) and COX-2 (inducible) that convert the arachidonic acid to PGH2, 
which is then converted to biologically active PGE2 by PGE synthases. Prostaglandin E2 signals via four known 
receptors (EP1-EP4) and engagement of EP2 and EP4 leads to increased intracellular cAMP levels. Local PGE2 
degradation is regulated by 15-PGDH. Currently applied drugs, inhibitory to the action of PGE2, are indicated 
with black arrows, grey dotted arrows indicate potential targets for prospective drugs. Adapted from Kalinski, 
2011. 
 
Furthermore, administration of a PGE2 monoclonal antibody in mice to sequester PGE2 has 
been demonstrated sufficient to retard the growth of transplantable tumors in vivo (Stolina et 
al., 2000). Overexpression of COX-2, leading to increased PGE2 levels, is associated with 
poor prognosis, a high tumor grade and metastatic dissemination (Rigas et al., 1993; Tsujii et 
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al., 1997). Prostaglandin E2 has been implicated in tumor progression through stimulation of 
angiogenesis, cell invasion and metastasis, and by inhibiting apoptosis via numerous signaling 
pathways, thereby promoting cell survival (reviewed in Wang and DuBois, 2010). 
Furthermore, PGE2 mediates tumor-promoting effects in colorectal cancer cells by acting on 
immune cells, which will be the focus of the next section. 
 
1.6.3 Regulation of T cell immune function by prostaglandin E2
Generally, PGE2 has been recognized as a pro-inflammatory mediator of active inflammation 
that also harbors the ability to directly suppress immune responses associated with chronic 
inflammation and cancer. Effector functions of NK cells, dendritic cells, B and T cells have 
all been shown to be suppressed by PGE2 (Goto et al., 1983; Simkin et al., 1987; Harizi et al., 
2002). Apart from inhibiting T cell proliferation in both CD4+ and CD8+ cells (Goodwin et al., 
1977; Hendricks et al., 2000), PGE2 can also suppress the ability of fully developed CD8+ to 
interact with their targets and eliminate tumor cells (Valitutti et al., 1993; Specht et al., 2001). 
By altering the cytokine expression profile of DCs, PGE2 suppresses antitumor cytotoxic T 
cells (Ahmadi et al., 2008) and contributes to tumor evasion of immunosurveillance. 
Prostaglandin E2 can also influence the polarization of TH cells. In particular, it has been 
proposed that PGE2 signaling promotes a TH2 cell fate. In line with this, PGE2 has been 
shown to inhibit the TH production of IFNȖ (Betz and Fox, 1991) and suppress the 
responsiveness to IL-12 (Wu et al., 1998). Furthermore, PGE2 has been observed to 
upregulate production of the TH2-derived cytokines IL-4, IL-5, IL-10 and IL-13 (Snijdewint et 
al., 1993; Demeure et al., 1997). Models of infection and autoimmunity propose PGE2 to also 
play a role in the differentiation of TH17 cells and the TH17 promoting activity of PGE2 seems 
to be related to its ability to enhance TH17 supporting IL-23 production in a dose-dependent 
manner (Khayrullina et al., 2008; Boniface et al., 2009). Prostaglandin E2 also supports 
development of regulatory T cells (Tregs) and increases their suppressive activity on effector 
T cell stimulation pathways (Baratelli et al., 2005; Mahic et al., 2006). However, in a context-
dependent manner, PGE2-regulated infiltration of effector cells into affected tissue and 
induction of immune responses in lymphoid and peripheral tissue seem to mediate both pro- 
and anti-inflammatory effects. For instance, it has been demonstrated that PGE2 can favor DC 
migration (Legler et al., 2006) and induce the expression of the co-stimulatory molecules on 
DCs (Krause et al., 2009) and thus enhance their ability to augment T cell activation. To 
summarize, PGE2 induces prolonged T cell immune suppression by a net inhibitory activity 
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Figure 9. Regulation of the anti-tumor immune responses by PGE2. Prostaglandin E2 produced by tumor 
epithelial cells and/or their surrounding stromal cells induces immunosuppression through several ways, 
including downregulation of anti-tumor T helper 1 (TH1) cytokines and upregulation of immunosuppressive TH2 
cytokines, inhibition of CD8+ T cell proliferation and effector functions, suppression of the anti-tumor activity of 
natural killer (NK) cells, stimulation of the expansion of regulatory T (Treg) cells, inhibition of CD8+ T cell anti-
tumor functions by impairing the ability of tumor cells to directly present tumor antigen, inhibition of dendritic 
cell (DC) differentiation and by switching the function of dendritic cells from induction of immunity to T cell 
tolerance. Adapted from Wang and DuBois, 2010. 
 
on proliferation and apoptosis of antigen-specific T cells and by shifting the pattern of T cell 
cytokine responses towards TH2, TH17 and Treg activity (Figure 9). 
The suppressive mechanisms of PGE2 on activation, expansion and differentiation of 
antigen-specific naïve T cells include a direct inhibitory effect on IL-2 production (Walker et 
al., 1983; Mary et al., 1987), expression of the IL-2 receptor (Rincon et al., 1988; Anastassiou 
et al., 1992) and Janus kinase (JAK) 3 protein levels (Kolenko et al., 1999), which mediate the 
responsiveness of T cells to IL-2. Previously, inhibition of secondary messenger generation 
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including cytosolic calcium, DAG and IP (Lerner et al., 1988; Liang et al., 1989; Choudhry et 
al., 1995) have been implicated as mechanisms of PGE2-induced anti-proliferative effects in 
response to T cell activation. Furthermore, PGE2-mediated attenuation of Fyn (Choudhry et al., 
1998) and Lck (Chemnitz et al., 2006) kinase activity have been reported as TCR-proximal 
signaling events in suppressed T cell responses. Besides the above mentioned research, 
signaling studies in T cells under PGE2 stimulation are sparse and further investigations of 
downstream PGE2 signaling pathways in primary human T cells have been warranted. A study 
in our laboratory more recently mapped PGE2-dependent signaling networks in human 
lymphocytes from healthy individuals and found PKA to be the strongest signaling node 
downstream of the EP receptors (Oberprieler et al., 2010). Furthermore, a detailed analysis of 
naïve and effector/memory CD4+ and CD8+ T cell populations revealed constitutively 
augmented PKA activity in effector/memory cells, especially in CD8+ T cells. The higher 
activation status of PKA in these cells correlated with suppressed TCR-proximal signaling, 
providing evidence that PKA plays a role in setting the threshold for T cell activation. 
Moreover, earlier studies in our group observed elevated circulating levels of PGE2 in a 
majority of CRC patients (Yaqub et al., 2008; Brudvik et al., 2012). Combined, these findings 
led to an interest in assessing whether T cell signaling responses in T lymphocytes obtained 
from peripheral blood of CRC patients were affected by the sustained exposure to increased 
levels of PGE2. To enable identification of PGE2 sensitive signaling elements in T 
lymphocytes from CRC patients we evaluated the phosphorylation status of an extended panel 
of proteins involved in downstream signaling cascades in T cells at a single cell level, both in 
naïve and antigen-experienced cells (Paper IV). 
 
1.6.4 Treatment for colorectal cancer 
Surgical resection is the only curative treatment for patients with locally confined CRC, 
although a large proportion of patients are unresectable at the time of diagnosis. Patients with 
untreated liver CRC metastases have a median survival of 6-12 months (Bengtsson et al., 
1981), whereas five-year survival rates following curative intent surgery for CRC liver 
metastasis now approaches 50% (de Jong et al., 2009). However, risk of recurrence remains 
high and patients with advanced and aggressive CRC disease need adjuvant therapies. 
Adjuvant treatment in CRC has evolved greatly over the last decade and patients can currently 
benefit from alternatives such as radiation therapy and chemotherapy, as mono- or 
combination therapy, in addition to the more recent incorporation of molecular-targeted 
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therapies. Three chemotherapy drugs, 5-fluorouracil (administered with folinic acid), 
oxaliplatin and irinotecan, and five targeted drugs, bevacizumab, aflibercept (vascular 
endothelial growth factor (VEGF) inhibitors), cetuximab, panitumumab (epidermal growth 
factor receptor (EGFR) antibodies) and regorafenib (multikinase inhibitor), are approved for 
the treatment of metastatic CRC (Schmoll and Stein, 2014). Addition of targeted therapies has 
the potential to extend survival and improve clinical outcome in metastatic CRC, and might 
improve the resection rate of liver metastases in some circumstances (Price et al., 2013). 
Proper selection of patients, precise combinations and the timing of administration are of great 
importance regarding toxicity, efficacy, risk of resistance, patient benefit and costs of these 
targeted drugs. Currently, the only robust molecular predictive marker is that of K-Ras status. 
K-Ras mutation in exons 2-4 predicts for lack of response to anti-EGFR agents, and these 
patients derive no benefit, but potential harm from EGFR inhibitors (Karapetis et al., 2008). 
The long premalignant and preclinical course in combination with effective surgical 
treatment of localized malignancy makes CRC screening feasible, although the downsides 
such as costs, hazard of invasive diagnostic tests, the risk of false test results and 
overdiagnosis should also be taken into consideration. Current invasive screening tests such as 
colonoscopy and flexible sigmoidoscopy detect precancerous polyps (Davies et al., 2005), and 
in a large multicenter randomized controlled trial flexible sigmoidoscopy was shown to 
reduce CRC incidence and mortality by 18% and 28%, respectively (Atkin et al., 2010). 
Repetitive fecal occult blood testing detects early invasive cancer and has also been shown to 
reduce CRC mortality, but not CRC incidence (Hardcastle et al., 1996; Lindholm et al., 2008). 
Carcinoembryonic antigen (CEA) was the first blood-based marker associated with CRC 
(Thomson et al., 1969), and appears to be mostly absent from healthy adult colon (Gold and 
Freedman, 1965). Levels increase with advancing tumor stage, but CEA is of less value in 
screening as fewer than 25% of patients with cancer confined to the colon have elevated CEA 
levels (Perkins et al., 2003). Still, expression levels of CEA are often monitored pre- and post-
treatment in CRC patients as it has been found to be indicative of prognosis and cancer 
relapse (Lin et al., 2011). Fecal and blood-based screening of biomarkers associated with 
adenomas and related cancers is a rapidly emerging field, but large-scale evidence to support 
their use is required. 
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2 Aims of the studies 
 
Upon encounter with antigen, receptors localized to defined areas in the T cell plasma 
membrane integrate and couple to components of intracellular signaling pathways, thereby 
translating external cues into specific effector responses. The ability of T cell surface 
receptors to discriminate between different contexts of immune activation and modulation of 
downstream signaling events are crucial both for effective activation and in order to avoid 
exaggerated immune responses. Two concepts in T cell activation are central to this Thesis, 
the reorganization of compartmentalized proteins in the plasma membrane and receptor-
proximal phosphorylation cascades in healthy and diseased settings. 
 
The present Thesis has aimed to:  
1. Investigate the protein composition of detergent-resistant membranes from resting and 
activated human primary T cells by qualitative proteomics as a model system for 
profiling of proteins in membrane rafts. 
2.  Elucidate whether PKA type I and thus the negative mediator of T cell receptor 
signaling, cyclic AMP, is sequestered away from the immunological synapse upon 
sustained T cell activation. 
3.  Provide a detailed investigation of the relative contribution of CD28 and CD2 co-
stimulation on signaling responses and functional outcomes in activated naïve and 
effector/memory T cells. 
4.  Reveal how proximal signaling cascades in T cells obtained from colorectal cancer 
patients are affected by the systemic exposure to the immunomodulatory agent 
prostaglandin E2, building on previous work in our laboratory (Oberprieler et al., 
2010). 


34 

3 Synopsis of the publications 
 
Paper I: A proteomic approach to screening of dynamic changes in detergent-resistant 
membranes from activated human primary T cells 
To engage in receptor signaling and guide external stimuli to the intracellular compartment, 
the cell membrane segregates its constituents laterally in membrane domains commonly 
referred to as lipid rafts. Upon stimulation of the T cell receptor (TCR), membrane rafts 
ensure a rapid and efficient signal transduction by clustering and reorganizing proteins 
involved in proximal T cell signaling. Membrane rafts can be biochemically separated from 
the bulk plasma membrane as detergent-resistant membrane (DRM) fractions and to assess 
membrane raft protein composition, we here provide a qualitative mass spectrometric 
characterization of the DRM proteome in human primary T cells. We identified a total of 425 
proteins and went on to address which proteins that were exclusively observed in resting or 
activated T cells. Despite the many dramatic events following TCR engagement we found the 
protein composition of DRMs to remain remarkably stable. Classification of all proteins 
identified in DRMs into functional categories by bioinformatics tools, revealed a prominent 
fraction of cytoskeletal proteins, indicating that DRMs remain attached to the underlying 
cortical actin cytoskeleton upon stimulation of T cells. Advances in proteomic approaches 
have permitted interesting studies on protein dynamics, however, to our knowledge this is the 
first proteomic study on the recruitment of proteins to DRMs obtained from resting and 
activated human primary T cells.  
Paper II: Effects of type I protein kinase A modulation on the T cell distal pole complex 
The distal pole complex (DPC) assembles signaling proteins at the T cell pole opposite the 
immunological synapse (IS) and is thought to facilitate T cell activation by sequestering 
negative regulatory molecules away from the T cell receptor-proximal signaling machinery. 
Here, we report the translocation of type I protein kinase A (PKA) to the DPC in a fraction of 
T cells following activation and the localization of type I PKA with known components of the 
DPC. We propose that sequestration of type I PKA and concomitant loss of cAMP-mediated 
negative regulation at the IS may be necessary to allow full T cell activation. Moreover, 
composition of the DPC appears to be modulated by type I PKA activity, as the type I PKA 
antagonist Rp-8-Br-cAMPS inhibited translocation of type I PKA and other DPC proteins. 
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Paper III: T cell co-stimulation through the CD2 and CD28 co-receptors induces distinct 
signaling responses 
Full T cell activation critically depends on the engagement of the T cell receptor (TCR) in 
conjunction with a second signal by co-stimulatory receptors. Here, we have compared 
signaling patterns induced by the two co-receptors CD2 and CD28 in human peripheral T 
cells by a combination of multi-parameter phospho-specific flow cytometry, phospho-kinase 
arrays and western blotting techniques. The CD2 and CD28 co-receptors were previously 
suggested to be redundant in function, but we demonstrate that engagement of the CD2 co-
receptor more profoundly enhances phosphorylation of the TCR-proximal signaling complex, 
whereas CD28 produces unique signals essential for activation of distal signaling molecules 
including the transcription factors NF-țB, ATF-2, STAT3/5, p53 and c-Jun. These signaling 
patterns were conserved in both naïve and effector/memory T cell subsets. We show that free 
intracellular calcium and signaling through the PI3K/AKT pathway are required for proper 
CD28-induced NF-țB activation. Moreover, the specific signaling patterns elicited by CD2 
and CD28 co-stimulation are reflected in cytokine secretion and cell proliferation. In 
conclusion, co-stimulation through the CD2 and CD28 co-receptors induce distinct signaling 
responses and functional outcomes in T cells. 
Paper IV: Proximal signaling responses in peripheral T cells from colorectal cancer 
patients are affected by high concentrations of circulating prostaglandin E2 
Patients with colorectal cancer (CRC) have been shown to have elevated levels of circulating 
prostaglandin E2 (PGE2), and PGE2 promotes tumor growth and suppresses T cell responses. 
In this paper we aimed to evaluate whether T cells obtained from peripheral blood of CRC 
patients were affected by the sustained exposure to increased levels of PGE2. Indeed, T cells 
from CRC patients with elevated plasma concentrations of PGE2 displayed aberrant T cell 
signaling responses when compared to T cells from CRC patients with lower levels of PGE2 
and to T cells from healthy blood donors. More specifically, we found reduced 
phosphorylation levels downstream of the T cell receptor (phospho-CD3ȗ and SLP-76), 
downstream in the PGE2 pathway (phospho-VASP and Gsk3Į), and after triggering the IL-2 
receptor (phospho-STAT5). Although limited by a small sample size, this signal profiling 
study of circulating T cells from CRC patients consolidate the role of PGE2 in inhibiting T 
cell function and confirm phospho-specific flow cytometry to be a valuable tool for revealing 
specific signaling signatures in immunological disorders. 
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4 Discussion 
 
4.1 Methodological considerations for analyzing membrane raft proteomes 
Studying the dynamic distribution of membrane components in the intact cell is 
methodologically challenging. Many of the structural and functional properties of membrane 
microdomains have therefore been derived from biochemical and biophysical parameters 
which have generated multiple plausible modes of lateral membrane organization (reviewed in 
Klammt and Lillemeier, 2012). The heterogeneity of membrane raft domain models appears 
to be a result of artefacts of isolation and detection techniques, lack of direct visualization, 
ambiguous nomenclature and use of various cell types and translation of results obtained with 
less complex model-membrane systems to prove domain formation in living cells (Horejsi and 
Hrdinka, 2014). As an example, estimates of membrane raft dimensions range from 4-5 nm 
(Sharma et al., 2004) to 10-450 nm (Goswami et al., 2008) using fluorescence resonance 
energy transfer (FRET) and from 30-300 nm in murine T cells using electron microscopy 
(Lillemeier et al., 2006) to less than 20 nm in living cells of an epithelial cell line by 
stimulated emission depletion (STED) microscopy (Eggeling et al., 2009). Most recently, 
atomic force microscopy on native membranes has proved the presence of membrane rafts in 
erythrocytes with a size of 100-300 nm (Cai et al., 2012) and in human breast cancer cells 
with sizes of 100-500 nm (Orsini et al., 2012). Thus, membrane raft size estimates span a 
range from the accommodations of a few proteins to large-scale complex assemblies. The 
same variability has been observed for estimates of the life-time of membrane rafts, and the 
broad range of dimensions and life-times suggests that membrane rafts with distinctly 
different protein and/or lipid components co-exist within cells with each raft being specialized 
for participation in one or more membrane associated processes. 
Although detergent-resistant membranes (DRMs) and in vivo membrane rafts may not 
be identical, the analysis of DRM composition has traditionally been the first step in the 
identification of putative membrane raft components. Given that the solubilization-dependent 
co-fractionation method is the only available biochemical approach to evaluate the protein 
distribution to DRM, and thus its membrane raft function, the choice of an appropriate 
detergent is of critical importance. Detergent resistant membrane fractions have mainly been 
prepared with Triton X-100 (Brown and Rose, 1992), but other detergents such as the non-
ionic Brij-series and Lubrol or the zwitterionic CHAPS have also been used (Schuck et al., 
2003; Macdonald and Pike, 2005). Studies reveal that the nature of the detergent, 
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concentration, time of exposure and temperature influence the composition of lipids and 
proteins of the isolated DRMs (Schuck et al., 2003; Babiychuk and Draeger, 2006; Lingwood 
and Simons, 2007). For example, the addition of Triton X-100 was shown to create ordered 
clusters of lipids and proteins in membranes resembling the outer leaflet of the plasma 
membrane (Heerklotz, 2002), whereas more recent research shows that Triton X-100 does not 
induce domain formation, although it does increase domain size by coalescing preexisting 
domains (Pathak and London, 2011). Brij-based membrane solubilization has been shown to 
promote extraction of distinct subpopulations of DRMs (Otahal et al., 2010; Ballek et al., 
2012). These subtypes of DRMs gave explanations to an unresolved problem regarding the 
membrane raft protein LAT. Signaling mediated by LAT was initially demonstrated to require 
membrane raft association (see section 1.3.1), whereas subsequent research showed that a 
fusion protein targeting LAT to non-raft membrane fractions was fully capable of replacing 
LAT in T cell development and function (Zhu et al., 2005). This observation suggested that 
membrane rafts are not essential to T cell signaling. In a follow-up study, the mutant LAT was 
shown to target to specific DRMs of relatively high protein density, so-called heavy DRMs, 
supporting TCR signaling less efficiently than moderate expression levels of LAT targeted to 
the standard DRMs (Otahal et al., 2010). The heavy DRMs have also been incorporated into a 
more recent model of initial TCR triggering (Ballek et al., 2012). In this study, a small 
fraction of the kinase active Lck (pTyr394) in non-activated T cells is postulated to localize in 
heavy DRMs together with the phosphatase CD45 and the TCR/CD3 complex. Spatial 
restriction to heavy DRMs render these participants inaccessible to other possible substrates, 
and in addition to maintaining the phosphorylation status of Lck, CD45 keeps the net rate of 
tyrosine phosphorylation low on ITAMs on CD3 chains. Redistribution to standard DRMs 
upon T cell activation juxtapositions the complex to the vicinity of the LAT adaptor protein 
and allows amplification of the activation signal (Ballek et al., 2012). Thus, a structural, but 
also functionally distinction can be made between light and heavy DRMs in the context of 
their roles in the T cell activation process.  
Sensitivity to cholesterol chelation with reagents such as ȕ-methyl-cyclodextrin is 
widely used as a criterion for membrane raft localization of proteins as cholesterol depletion 
causes loss of raft domains and dysregulated signaling (Kabouridis et al., 2000). However, as 
plasma membranes can contain up to 40 mol% cholesterol (Simons and Gerl, 2010), 
cholesterol depletion may perturb several other cellular functions, for example by slowing the 
diffusion of both raft and non-raft proteins at the cell surface, altering the permeability and 
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fluidity of the cell membrane (Kenworthy et al., 2004; Sun et al., 2007) or by releasing 
calcium stores non-specifically (Pizzo et al., 2002). Interpretation of results from cholesterol-
depletion experiments should therefore be performed with caution. Lastly, it should be noted 
that phase separation in plasma membrane vesicles isolated from mammalian cells with 
detergent-free membrane disintegration under physiological pH and temperature has been 
observed and provide evidence of the existence of functionally relevant raft domains in 
biological membranes (Baumgart et al., 2007; Ayuyan and Cohen, 2008; Lingwood et al., 
2008). 
 
4.1.1 Studying the human primary T cell DRM proteome 
New raft associated proteins have been identified de novo by hypothesis-driven conventional 
biochemical approaches, e.g. PAG (Brdicka et al., 2000), however, if the sequence 
information is available in sequence databases, screening the DRM proteome provides a much 
more efficient and relatively unbiased method to identify new candidates in T cell signaling. 
On the other hand, comprehensive proteomic characterization of the components participating 
in membrane raft assembly and signaling has been challenged by their scarcity, strong 
hydrophobicity and dynamic nature. Attempts to delineate the complexity of TCR-mediated 
rearrangement of the cell membrane through mass spectrometry have therefore relied on the 
analysis of Jurkat T cells. Jurkat T cells are transformed T cell lines defect in the expression 
of the phosphatase and tensin homologue (PTEN), leading to constitutive activation of the 
PI3K signaling pathway and high basal PIP3 levels (Abraham and Weiss, 2004), features that 
could preclude generalization of those studies to normal T cells. In Paper I we therefore 
attempted to identify proteins exclusively associated with DRMs in the resting or activated 
state in human primary T cells. The use of quantitative MS using a variety of isotopic or 
isobaric labeling techniques followed by liquid chromatography (LC)-MS/MS has allowed 
increased detection sensitivity and a more comprehensive profile of the membrane raft 
proteome, but such an approach has been experimentally challenging to adopt to human 
primary T cells. To generate qualitative mass spectrometric data we made use of Triton X-100 
isolated DRMs and our study identified a total of 425 proteins, approximately 45% of the total 
number of proteins identified in T cells from human peripheral blood (Haudek et al., 2009). A 
fairly large proportion of the proteins identified were known membrane proteins or signaling 
proteins such as Lck, Fyn, ZAP-70, Csk, LAT, LIME, CD3 subunits, CD4 and CD8. Many 
cytosolic signaling proteins (e.g. PKCș and Itk) or transmembrane proteins (e.g. CD2 and 
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CD28) that are known to assemble into membrane rafts were not detected by this approach. 
Reasons for not detecting certain proteins could be the lengthy purification protocol necessary 
for separation of DRMs from soluble material, which is not adequate to maintain stable 
associations of proteins with membrane rafts in vitro, and that some peptides might be lost 
during liquid chromatography or ionization for mass spectrometry.  
The qualitative protein composition of DRMs was shown to be surprisingly stable 
upon TCR/CD28 triggering, only 16 and 19 proteins were observed exclusively in the resting 
or activated state, respectively (Paper I). In a comparable study on a human B cell line, 
binding of BCR with anti-IgM antibodies was reported to change the localization of only four 
proteins, the content of BCR itself and two myosin motor proteins increased with stimulation, 
whereas ezrin decreased (Gupta et al., 2006). In our study, components of the ARP2/3 
complex were observed to be selectively identified in DRMs from activated cells, 
emphasizing that membrane raft dynamics upon TCR triggering depends on cytoskeletal 
rearrangements. Other components of the actin cytoskeleton identified include flotillins, the 
ERM proteins ezrin and moesin and filamentous proteins such as tubulin, spectrins, talin and 
vimentin. Cytoskeletal proteins appear to be selectively concentrated in DRMs and constitute 
most of the proteins that have been identified in DRMs from both T and B cells by previously 
published mass-spectrometry based proteomics methods as well (von Haller et al., 2001; Bini 
et al., 2003; Gupta et al., 2006). 
Analysis of biochemical fractions depends on the quality of the initial preparation of 
the specific fraction, and the raft proteome and potential contaminants will undoubtedly vary, 
both with the biological system and the mass spectrometric approach. Several proteomic 
analyses have identified a large number of mitochondrial proteins in DRMs, including ATP 
synthase subunits, prohibitin and voltage-dependent anion-selective channel protein (VDAC) 
(Bini et al., 2003; Bae et al., 2004). Based on these findings it was proposed that mitochondria 
contain rafts (Bini et al., 2003) or that mitochondrial translocation to the immunological 
synapse controls the calcium-dependent activation of T cells (Quintana et al., 2007). However, 
it seems most likely that contamination of the membrane with mitochondrial membranes 
accounts for the presence of many of these proteins in raft proteomes (Zheng et al., 2009), 
although the existence of raft-like domains in mitochondria cannot be excluded. Synthesis of 
both membrane raft lipids and proteins starts in the ER and is completed in the Golgi before 
transport to the plasma membrane, and indeed, several proteins associated with these 
compartments are among the proteins identified in our study. Membrane rafts can be 
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assembled at the earliest point in the Golgi, but identification of these proteins does not 
necessarily demonstrate that rafts exist in those compartments, only that these proteins are in a 
detergent-resistant state while residing there. Lastly, contaminations coming from highly 
abundant proteins in the cell, such as ribosomal and nuclear proteins seem inevitable in mass 
spectrometric studies of DRMs. 
 
4.1.2 Future directions and unresolved questions concerning membrane rafts 
Spatiotemporal signal control in T cells is closely linked to the dynamic plasma membrane 
structure. Novel, dynamic super-resolution microscopy techniques have in recent years 
allowed for more definite descriptions of these nanometer structures in living cells (Eggeling 
et al., 2009; Orsini et al., 2012). Further application and development of these techniques will 
hopefully contribute to the understanding of membrane protein and lipid clustering in T cell 
signaling. Proteomic analyses have confirmed the partitioning of many proteins into DRMs 
previously demonstrated by other methods, but so far, the bioinformatics data handling has 
been in focus. Future membrane raft proteomics should therefore focus more on deciphering 
the functionality of proteins selectively recruited to signaling domains in the membrane upon 
stimulation and how, if at all, they contribute to either membrane raft function or T cell 
signaling. Accumulated insight into the biological relevance of these proteins will open the 
possibility of biological response interventions. Many terms and model predictions have been 
published to describe the compositional heterogeneity and lateral organization of proteins and 
lipids in the plasma membrane engaged in spatiotemporal control of T cell signaling, but 
mechanisms regulating compartmentalization of signaling molecules, their transient 
interactions, the number of proteins that associate with a given raft and how proteins diffuse 
within and between raft and non-raft domains have been more scarcely covered.  
Another unresolved matter is what percentage of the cell surface is actually covered by 
the raft domains. Most of the apical surface of polarized cells appears to be composed of the 
raft domains, but in other cell types, estimates vary from 10-50% (Pierce, 2002; Shaw, 2006). 
A protein is often regarded as a raft protein even if only 10-30% of this protein is found in the 
DRM fraction (Zeyda and Stulnig, 2006), and dependent on the fraction of membrane rafts 
within the cell membrane, a considerable proportion of membrane raft proteins could 
therefore reside in the bulk membrane. Lastly, the functional organization at the outer leaflet 
of the plasma membrane is likely to be reflected in an organization at the inner leaflet (Simons 
and Gerl, 2010), but we still do not know much about membrane assemblies on the cytosolic 
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side of the membrane. Nevertheless, despite disputes and unresolved problems, the lipid raft 
hypothesis and biochemical studies have been instrumental in developing the conceptual 
framework of lateral membrane organization. 
 
4.2 The role of the distal pole complex in T cell signaling 
The distal pole complex (DPC) was initially discovered based on the location of CD43 and 
ERM proteins to a region distal to the immunological synapse (IS) during the T cell response 
(Allenspach et al., 2001; Delon et al., 2001). Other proteins described to interfere with 
proximal T cell signaling also localize to the DPC, and the composition of the DPC indicates 
that it may serve as a sink for negative regulators of activation events occurring at the IS 
(Cullinan et al., 2002). In line with this prediction, we confirm the translocation of EBP50 and 
PAG to the DPC of human primary T cells, as well as reporting the translocation of PKA type 
I and Csk to the DPC upon sustained activation of T cells (Paper II). The removal of these 
negative regulators from the IS may be necessary to allow T cell activation to proceed. 
However, since some proteins that display patterns of localization corresponding to the DPC, 
such as PKCȗ and CD43, are not exclusively negatively regulatory molecules it has been 
proposed that the DPC also serves as a distinct signaling unit. In support of this, PKCȗ has 
been implicated in NF-țB and JAK/signal transducer and activator of transcription (STAT) 
activation (Moscat et al., 2006), whereas CD43 crosslinking can provide CD28-independent 
co-stimulation of T cells in mouse models (Sperling et al., 1995) and lead to MAP kinase and 
NFAT activation (del Rio et al., 2004). Rho-GDI can inhibit Rho-GTPase activation, and its 
sequestration at the DPC could therefore facilitate activation of Rho-GTPase at the IS (Huang 
and Burkhardt, 2007). The phosphatase PDE4B2, which downregulates cAMP production, 
was also shown to move distally upon T cell activation and to have an enhancing effect on 
TCR-mediated T cell activation at the IS (Arp et al., 2003). 
In addition to facilitating T cell activation, the DPC shares many proteins associated 
with the uropod of migrating T cells, e.g. CD43 and ezrin (Sanchez-Madrid and del Pozo, 
1999), and the DPC might therefore function to establish overall T cell polarity. Indeed, the 
DPC also contains proteins associated with cell polarity in other cell types such as epithelial 
cells and neurons (Burkhardt et al., 2008). Also localized at the DPC is Scribble. T cells with 
reduced Scribble expression levels loose polarization and fail to form a uropod and to 
segregate IS and DPC proteins in response to TCR signals (Ludford-Menting et al., 2005).  
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In conclusion, compared to the IS, relatively little is known about DPC functionality. 
Based on proteins that have been identified at the DPC, various implications in T cell 
activation have been proposed, none of which are mutually exclusive. Resolution of the 
functional roles of DPC requires more detailed analysis of individual DPC proteins, consistent 
with the approach in Paper II. How the DPC is organized is also unresolved. In Paper II we 
observed that Rp-8-Br-cAMPS inhibited sequestration of both PKA type I and other DPC 
components, and suggest that PKA type I activity may be involved in controlling the 
composition of the DPC. Further work will be needed to map out possible PKA substrates 
responsible for this effect. 
 
4.3 Co-stimulatory capabilities of CD2 versus CD28 
The repertoire of co-stimulatory receptors expressed on T cells is highly versatile and these 
receptors have a pivotal role in determining the functional outcome of TCR signaling. 
Whereas the function of individual co-stimulatory molecules has been more extensively 
studied, there is still a need for a more comprehensive approach to how distinct co-stimulatory 
signaling pathways integrate and crosstalk. In addition, subset-specific signaling analyses are 
warranted to link signaling activity to functional properties of individual subsets of T cells. 
Adoption of the phospho-specific flow cytometry technique in our laboratory has enabled 
detailed intracellular signaling studies at the single cell level of rare subsets. By exploiting the 
advantages of the phospho-flow technique we performed a study focusing on how co-
stimulation through CD2 versus CD28 contributes to signal intensity and how this leads to 
differential effects on T cell effector functions in functionally defined subsets (Paper III).  
The adhesive and cytoskeletal properties of both CD2 and CD28 have previously been 
shown to promote and stabilize T cell interactions with APCs, thereby initiating a higher and 
more stable increase in downstream tyrosine phosphorylation (Viola et al., 1999; Nunes et al., 
2008). In Paper III we reveal that CD2 co-stimulation induces more profound phosphorylation 
of the TCR-proximal signaling proteins, whereas CD28 co-stimulation results in more 
strongly activated distal signaling molecules, including NF-țB, activating transcription factor 
(ATF)-2, STAT3/5, p53 and c-Jun. A shared link for CD2 and CD28 in their initial signaling 
processes is the requirement for Lck and Fyn activation to couple to downstream signal 
transduction pathways. Proline-rich sequences of the cytoplasmic domains of CD2 and CD28 
have both been shown to be involved in the interaction with the SH3 domains of Lck and Fyn 
(Raab et al., 1995; Bell et al., 1996; Lin et al., 1998; Holdorf et al., 1999). In our phospho-
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specific flow cytometric studies we observed augmented phosphorylation of CD3ȗ and ZAP-
70, both Lck-mediated processes, in response to CD2 and CD28 co-stimulation (Paper III). 
Accordingly, signals mediated by CD2 and CD28 seem to integrate with those induced by the 
TCR already at a membrane-proximal level, but with different signal intensity. An ongoing 
project in our laboratory follow up on the findings in Paper III by a detailed analysis of the 
immediate sequence of events after CD2 or CD28 co-stimulation (Skånland et al., 
unpublished data). Further work is still needed to establish the entire range of functions 
controlled by the array of signaling mediators specifically coupled to CD2 or CD28. In 
addition, the stoichiometry of interactions with proximal CD2 and CD28 signaling molecules 
remains to be mapped out as it most likely results in a unique outcome or skewing of 
signaling pathways. 
The transcription factors of the NF-țB family are critical regulators of genes involved 
in T cell immune responses. Stimulation of T cells with a TCR signal alone is insufficient to 
activate the NF-țB pathway (Takeda et al., 2008) and compared to CD2 co-stimulation, CD28 
co-stimulation seems to be a unique requirement for full phosphorylation of NF-țB (pSer536) 
(Kalland et al., 2011, Paper III). The signaling intermediates that transduce the co-stimulatory 
signals from the CD28 receptor leading to release of NF-țB dimers and their translocation 
into the nucleus are many, but PKCș seems to be a central regulatory node. A complex of 
three proteins, CARMA-1, Bcl110 and MALT downstream of PKCș is involved in activation 
of NF-țB (Ruland et al., 2001; Wang et al., 2004). Analysis using CD28 deficient T cells has 
revealed that CD28 is required for the localization of PKCș to the cSMAC region of the IS, 
and failure to localize PKCș correctly results in poor activation of NF-țB (Huang et al., 2002; 
Yokosuka et al., 2008). Furthermore, PKCș phosphorylation of CARMA-1 enhances 
CARMA-1 activation (Takeda et al., 2008). Several experiments suggest a model in which 
CD28 ligation in the presence of TCR signaling activates the CARMA-1, Bcl110 and MALT 
signalosome through PI3K and Akt in cooperation with PKCș (Kane et al., 2001, Sanchez-
Lockhardt et al., 2004, Yokosuka et al., 2008). Despite extensive data, the relevance of PI3K-
signaling in NF-țB activation remains controversial. The YMNM motif of CD28 may also 
activate NF-țB by recruiting Grb2/Vav1 complexes, independently of PI3K activation 
(Marinari et al., 2002; Takeda et al., 2008; Thaker et al., 2015). CD28 co-stimulation is able to 
compensate for the lack of PI3K activity under conditions in which TCR/CD3-dependent 
proliferation is impaired (Okkenhaug et al., 2002; Deane et al., 2007). Furthermore, CD28 
mutants that interfere with the capacity of CD28 to recruit PI3K retain co-stimulatory capacity 
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in both Jurkat T cells and in primary murine T cells (Crooks et al., 1995; Okkenhaug et al., 
2001; Burr et al., 2001). Of note, initial in vitro studies of CD28 signaling results should be 
interpreted with caution as the Jurkat T cell line, as mentioned, lacks the PTEN phosphatase 
that functions to inactivate the products of PI3K. In addition, parts of the contradictory results 
could be explained by the ability of TCR ligation itself to generate phosphoinositides (Ward et 
al., 1992) or by the ability of CD28, independently of its PI3K recruitment motif, to enhance 
PIP3 production at the T cell synapse (Garcon et al., 2008), and thereby increase the efficiency 
of conjugate formation at the T cell-APC interface. In agreement of a PI3K-dependent 
pathway of NF-țB activation we observed that the PI3K inhibitor wortmannin partially 
inhibited CD28-induced NF-țB activation and that CD28 co-stimulation potently induced 
phosphorylation of Akt. On the other hand, calcium influx has shown essential in PI3K-
independent pathways of NF-țB activation and inhibitors of calcium release also perturbed 
TCR/CD28 co-stimulated NF-țB activation. From our phospho-flow studies, we can therefore 
conclude that there are several possible pathways between CD28 and NF-țB, both PI3K-
dependent and PI3K-independent.
A key aspect of the CD2 co-stimulatory signal compared to CD28 described in Paper 
III is strong Erk activation. MAP kinase p38 showed enhanced and prolonged phosphorylation 
signals upon CD28 co-stimulation, whereas Erk1/2 showed enhanced phosphorylation upon 
CD2 co-stimulation, confirmed both by phospho-flow and phospho-kinase array data. 
However, NF-țB activation does not appear to be regulated by the Mek/Erk pathway in T 
cells co-stimulated by anti-CD2 or anti-CD28, as we did not observe any significant effect of 
Mek/Erk inhibition on CD2 or CD28-induced NF-țB activation (Paper III).  
T cells from mice that lack the expression of CD2 show defects in proliferation and 
cytokine production (Killeen et al., 1992). In a similar manner, CD28 deficient mice show 
reduced T cell responses to antigen, defective germinal center formation and T cell 
differentiation (Shahinian et al., 1993; Green et al., 1994). Despite being immune 
compromised, T cells from CD2 or CD28 knockout mice are still capable of mounting 
significant responses to mitogenic stimuli, suggesting modest effects on T cell activation. 
Thus, residual T cell function exists in the absence of either of the co-stimulatory receptors 
and such results have been explained by adaptation or functional redundancy among other co-
stimulatory receptors in the T cell. However, CD2/CD28 double-deficient T cells have a 
profound defect in activation and proliferation (Green et al., 2000), suggesting the necessity of 
expression of at least one of the co-stimulatory receptors CD2 or CD28 for proper T cell 
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function. A central issue raised by these observations is how CD2 compensates for its lack of 
ability to properly activate NF-țB, assuming that the idea of redundancy is correct. The 
discrepancy of downstream CD2 and CD28 co-stimulatory induced signaling therefore 
warranted further functional studies. In Paper III we found CD2 co-stimulation to only trigger 
proliferation in a fraction of the T cells, whereas CD28 co-stimulation more potently induced 
cell proliferation. Furthermore, CD2 co-stimulation induced production of IL-4 and IL-10 
more profoundly, a cytokine pattern described as typical for TH2 cells, as well as granzyme B 
in CD8+ T cells. In contrast, CD28 co-stimulation enhanced the production of IL-2, but not 
IL-4 and IL-10. 
Even though the importance of CD28 in T cell function is well established, the 
molecular mechanisms whereby CD28 mediates its effects are not fully elucidated. Current 
evidence suggests that CD28 provides both quantitative and qualitative contributions to T cell 
activation. The demonstration that high doses and continuous delivery of antigen might 
compensate for lack of CD28 co-stimulation in vivo (Kundig et al., 1996) is consistent with a 
quantitative notion of co-stimulation. In a qualitative model, high TCR occupancy alone will 
never reach the threshold required for a biological response to occur, indicating a unique role 
for CD28. In line with this, a recent publication on murine T cells demonstrates that CD28, in 
a Lck-dependent manner, triggers a unique signaling pathway not shared with TCR signals. 
This pathway involves recruitment and binding of PKCș to the cytoplasmic tail of CD28 at 
the IS (Kong et al., 2011). Support for CD28 as an independent signaling unit has, however, 
mainly been provided from experiments overexpressing Vav1 and SLP-76 (Kaga et al., 1998; 
Raab et al., 2001) or by using superagonistic antibodies that bypass the requirement for TCR 
signals (Beyersdorf et al., 2005). Microarray analysis of T cells stimulated only through CD28 
supported TCR-independent triggering of distinct NF-țB subunits (Tuosto et al., 2000; Diehn 
et al., 2002; Marinari et al., 2004), but the effect on gene transcription appeared to be 
relatively short lived and reports seem to rather support CD28 as an amplifier of weak TCR 
signals and a modifier of gene regulation induced by TCR stimulation. Others have suggested 
that CD28 co-stimulation affects genes through splicing rather than by modulation of 
transcription (Butte et al., 2012).  
To conclude this section, accumulating research indicates that CD2 and CD28 share 
structural as well as functional features. However, even though the two co-receptors are 
largely able to compensate for each other, CD2 and CD28 most likely play distinct roles. CD2 
does not seem to fully match the capacity of CD28 to promote  proliferation, but both co-
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stimulatory receptors operate as amplifiers of TCR signaling and are separately, as well as in 
the absence of the other, still able to reduce the activation thresholds to a sufficient level for a 
productive proximal T cell signaling response to occur.  
 
4.3.1 CD28 and CD2 co-stimulation in therapy  
The crucial role of co-stimulation in determining the outcome of T cell activation is of great 
therapeutic interest. For example, augmentation of co-stimulation represents an attractive 
immunotherapeutic approach to combat cancers that escaped from the immune system. Many 
tumors lack the expression of ligands for positive co-stimulatory molecules, in particular B7, 
but clinical benefit of including B7 during the priming phase in various vaccine strategies has 
however been limited despite induction of tumor antigen-specific T cell responses (reviewed 
in Driessens et al., 2009). Genome wide association scans and phenotypical characterization 
of T cells from patients have identified associations of expression levels of co-stimulatory 
molecules with human autoimmune diseases (Schmidt et al., 1996; Garcia de et al., 2004), 
implicating a potential for CD2 and CD28 as autoimmune modulators. A critical challenge in 
intervention of the “second signal” is to find the optimal balance between targeting activation 
and effector functions of T cells without causing a generalized immunosuppression with 
comprised immunity against infection or malignancy. As an almost fatal example, 
administration of an anti-CD28 monoclonal antibody in a first-in-human trial resulted in acute 
induction of pro-inflammatory cytokines, later termed a cytokine storm, and associated multi-
organ failure (Suntharalingam et al., 2006). This led to the suspension of further development 
of this drug and of other antibodies directly targeting CD28. Currently, the only therapy to 
target the CD28 pathway is CTLA-4-Ig fusion proteins, which indirectly block CD28 
signaling and have proven efficacy in arthritis patients and in multi-drug regimens for the 
prophylaxis of organ rejection in kidney transplant recipients (Felix et al., 2010; Rostaing et 
al., 2013). 
The CD2-specific fusion protein LFA-3 (CD58)-Ig is approved for the use in moderate 
to severe chronic plaque psoriasis (Krueger et al., 2008). When used in a combined co-
stimulation blockade regimen, LFA-3-Ig has also shown to prolong renal allograft survival 
and delay the onset of alloantibody formation in non-human primates (Weaver et al., 2009). 
Moreover, the effect seemed related to the depletion of CD28- effector memory (CCR7-
CD45RA-) T cells. Interestingly, human T cells, particularly CD8+ T cells, are distinctly high 
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CD2 and low CD28 expressors (Lo et al., 2011) and cells that are least likely to respond to 
CD28-B7 blockade could therefore be most likely to be eliminated by LFA-3-Ig. 
 
4.4 Signaling responses in naïve versus effector/memory T cells 
Contrasting naïve T cells, antigen-experienced T cells have less stringent activation 
requirements and exhibit rapid effector responses upon antigen encounter (Cho et al., 1999; 
Veiga-Fernandes et al., 2000). The intrinsic cell signaling mechanisms accounting for the 
distinct properties of naïve and memory T cells remain unclear and were partly addressed at 
the single cell level in phospho-specific flow cytometric setups in Paper III and IV.  
Initially, memory recall responses of T cells were thought to be relatively independent 
of co-stimulatory signals (Croft et al., 1994; Flynn and Mullbacher, 1996), whereas 
succeeding in vivo experiments indicate that both CD4+ and CD8+ memory T cells require 
CD28 co-stimulation for maximal expansion and pathogen clearance (Ndejembi et al., 2006; 
Borowski et al., 2007; Fuse et al., 2008). Upon CD2/CD28 co-stimulation of T cells for short 
time kinetics, we found naïve T cells to exhibit stronger phosphorylation levels for proximal 
TCR signaling molecules (e.g. CD3ȗ, ZAP-70, SLP-76 and LAT) compared with 
effector/memory T cells. These signaling attributes were identified in both CD4+ and CD8+ T 
cells, although signals induced in CD8+ T cells overall were reduced compared to those in 
CD4+ T cells. The reduced immediate TCR-coupled phosphorylation in effector/memory T 
cells might seem as a paradox considering the rapid functional responses of these cells. Indeed, 
contradictory results have been published on this matter (Farber et al., 1997; Hall et al., 1999; 
Hussain et al., 2002; Kersh et al., 2003; Chandok et al., 2007). A research report accentuates 
the more distal MAPK kinases to account for the reduced response time of human memory 
cells. Two minutes of anti-CD3/CD28 stimulation of human T cells induced elevated Erk and 
p38 phosphorylation patterns in the naïve and antigen-experienced human T cells, 
respectively (Adachi and Davis, 2011). In line with this, our group has previously reported a 
slightly lower responsiveness of p38 phosphorylation in naïve cells compared to 
effector/memory cells, but reduced ability of effector/memory cells to become Erk 
phosphorylated upon TCR co-stimulation (Kalland et al., 2011). Thus, Erk might be a central 
regulator of the immediate signaling responses that functionally distinguish naïve from 
effector/memory cells. This warrants further signaling studies.  
When we compared all signaling responses in our phospho-flow analysis to 
unstimulated naïve T cells, downstream mediators like Erk, NF-țB, S6 ribosomal protein, 
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PKA substrates and STAT5 displayed constitutive phosphorylation in the effector/memory T 
cell subset, whereas all subsets exhibited equal basal phosphorylation levels of the CD3ȗ 
chain, ZAP-70, LAT and SLP-76 (Oberprieler et al., 2010; Kalland et al., 2011, Paper III, 
Paper IV). The pre-activated state of the more distal signaling molecules could contribute to 
setting the threshold for activation in the resting state of the effector/memory subset. Specific 
organization of the cell membrane upon encounter with APC could be another way in which 
signaling molecules could be poised for efficient biochemical responses. Indeed, the 
immunological synapse seems to form more rapidly and is maintained longer in memory cells 
(Watson and Lee, 2004). In addition, memory T cells redistribute their TCRs into higher order 
oligomers that may increase antigen sensitivity at the T cell-APC interface (Kumar et al., 
2011). Differential expression levels of central downstream signaling mediators could also 
offer a potential explanation for the convergence of TCR-induced signals between the naïve 
and effector/memory compartment. In line with this, increased levels of SLP-76 and reduced 
levels of Fyn, LAT and Syk, leading to a lower functional threshold, were found to regulate 
the functional heterogeneity among human memory CD4+ T cells (Hussain et al., 2002; 
Brembilla et al., 2008). Similarly, high expression levels of ZAP-70 in murine memory T cells 
were coupled to rapid effector functions (Chandok et al., 2007). 
When comparing findings in the studies included in this Thesis with other 
investigations of TCR signaling, it is evident that the characteristics ascribed to naïve and 
effector/memory T cells may have been influenced by the experimental systems used to test 
them, including disparity between the cell surface markers used to distinguish the populations 
(e.g. in our studies the effector and memory population are conflated), the purity of 
populations tested and varying stimulation conditions (e.g. suboptimal concentrations, 
antibodies versus peptides and APCs, and whether or not co-stimulations are present). 
Furthermore, studies on human memory T cells are detained with difficulties and most of the 
current knowledge is therefore based on results from mouse models. Lastly, most studies are 
based on peripheral blood although the vast majority of memory T cells reside in tissue sites 
such as lymphoid tissues, skin, lungs and intestines (Sathaliyawala et al., 2013). 
 
4.5 The impact of T cells in colorectal cancer 
Developing colorectal malignancies are normally eliminated by an intact immune system that 
protects the host against tumor development through mechanisms of immune surveillance, a 
notion supported by the higher incidence of CRC in immunosuppressed individuals (Johnson 


49 

et al., 2007; Wasserberg et al., 2007). Tumor infiltration of highly heterogeneous immune 
cells is a common feature of human CRC and tumor-immune interactions at local tumor sites 
represent complex networks of signaling between tumor cells, the lymphocytic infiltrate and 
the surrounding inflammatory and endothelial cells. In recent years, data collected from large 
cohorts have demonstrated that the type, density and location of the infiltrating immune cells 
of the primary tumors, known as the immune contexture, have a prognostic value superior to 
conventional staging systems evaluating the anatomical extent of the CRC (Galon et al., 2006). 
A coordinated TH1 polarization with cytotoxic and memory T cells in the center and the 
invasive margin of the colorectal tumor seem to be major factors influencing local tumor 
spreading, disease-free survival and overall survival, whereas low density of T cells is 
associated with a poor prognosis (Pages et al., 2005; Galon et al., 2006). The impact of 
immune cells other than TH1 and cytotoxic lymphocytes within the tumor microenvironment 
has often yielded contradictory results (Bindea et al., 2013). T cells with specificity for tumor-
associated antigens have been reported in the tumor tissue of patients with CRC (Koch et al., 
2006) and most recently, the in situ activity of tumor-specific CD8+ T cells has been 
suggested to be a more suitable factor for prognosis prediction in patients with CRC than the 
quantification of effector/memory CD8+ T cell infiltrates (Bork et al., 2015). 
  Despite provoking a lymphocytic infiltrate, some colorectal tumors grow relentlessly, 
suggesting that the tumors have developed a number of different strategies to escape immune 
surveillance and obstruct the lymphocytes from mediating specific anti-tumor responses. In 
support of this notion, loss in the expression levels of human leucocyte antigen (HLA), tumor 
antigens and Fas ligand that can induce apoptosis in activated T cell expression is commonly 
found in colorectal tumors (Cabrera et al., 1998; Ogawa et al., 2004). In addition, the 
generation of regulatory T cells that are able to downregulate the anti-tumor activity of 
effector T cells and the increased secretion of immunosuppressive cytokines such as IL-10, 
TGFȕ or PGE2 by the tumors or cells within the tumor microenvironment, also helps to create 
an immunosuppressive milieu that blunts antitumor effector responses (O'Hara et al., 1998; 
Shim et al., 1999; Yaqub et al., 2008). Furthermore, abnormalities of signal transduction 
pathways downstream of the TCR have been described in tumor infiltrating lymphocytes 
(TILs) obtained from CRC patients. More precisely, T cells from CRC patients with lymph 
node involvement and distant metastasis were shown to have atypical TCRs with loss of key 
signaling molecules such as CD3ȗ and Lck (Mizoguchi et al., 1992; Nakagomi et al., 1993; 
Matsuda et al., 1995). Reduced responses through CD3ȗ could result in defective T cell 
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activation after recognition of tumor antigens and thereby explain why T cells fail to generate 
tumor-specific specificity. In Paper IV we evaluated the phosphorylation status of an extended 
panel of proteins involved in proximal signaling cascades in peripheral T cells obtained from 
CRC patients after triggering T cell-, prostaglandin- and IL-2 receptors. We observed that T 
cells from CRC patients with elevated levels of PGE2 displayed aberrant T cell signaling 
responses when compared to T cells from CRC patients with lower levels of PGE2 and T cells 
from healthy blood donors. Revealing discrepancies in T cell signaling pathways are desirable 
as these may present potential targets for therapeutic intervention which could prevent tumors 
from subverting the immune system. Blockade of CTLA-4 and PD-1 with monoclonal 
antibodies has recently shown promising results in advanced melanomas (Larkin et al., 2015), 
but so far CRC seems to be insensitive to these immune checkpoint inhibitors. In fact, 
although some early-stage clinical trials have provided hope of immunotherapy as a realistic 
option also for CRC, most attempts made so far to cure CRC with immunotherapy have failed. 
Colorectal cancer cells express numerous tumor antigens such as CEA, mucin-1, EGFR, p53 
or mutated K-Ras that could be potential targets for antigen-defined vaccination (reviewed in 
Koido et al., 2013), but the high degree of heterogeneity in mutations, both between and 
within individual tumors poses a formidable challenge to scientists attempting to devise 
broadly applicable T cell therapies against CRC.  
 
4.5.1 Prostaglandin E2 as a potential target for colorectal cancer prevention and treatment
Increasing evidence points to an important role for PGE2 in promoting CRC. Gene mutations 
in CRC (Wood et al., 2007) may affect the production and degradation of PGE2, as well as 
PGE2-dependent signaling pathways in target cells. Expression patterns of the COX-2 
enzymes are considered the major determinant of PGE2 levels and are found to be unregulated 
in both pre-malignant and malignant colorectal tissue (see section 1.6.2). Initial observations 
of reduced incidence of CRC in regular users of non-steroid anti-inflammatory drugs 
(NSAIDs) (Gridley et al., 1993), which inhibits the action of COX enzymes, generated 
interest in the use of these drugs for chemoprevention and treatment of CRC. These results 
were reinforced by further longitudinal studies confirming that use of acetylsalicylic acid 
(ASA) had a beneficial effect in reducing sporadic adenomatous polyps, distant metastasis, 
CRC incidence and mortality (Imperiale, 2003; Baron et al., 2003; Rothwell et al., 2010; 
Rothwell et al., 2012). The irreversible inhibition of the COX enzymes by use of ASA causes 
lack of the COX-1-derived PGE2 protective effect of gastroduodenal epithelial integrity, and 
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increased risk of gastrointestinal ulceration and hemorrhage might negate the 
chemopreventive benefits (Imperiale, 2003). Co-prescription of gastro-protectants may reduce 
these side effects, but severely impacts on the cost-effectiveness of the use of ASA. The anti-
neoplastic effects of ASA arise from its ability to inhibit the activity of the COX-2 isoform, 
but while having a reduced impact on the gastric mucosa, the prolonged us of high dose COX-
2 selective inhibitors is associated with a risk of cardiovascular side effects (Bresalier et al., 
2005). To deliver safe and effective chemopreventive agents, a strong rationale also exists for 
exploring pathways downstream of COX-2. The impact of PGE2 effects reflects the balance 
between the activity of the COX- and PGE synthase (PGES)-driven synthesis, 15-
hydroxyprostaglandin dehydrogenase (15-PGDH)-mediated degradation and the differential 
expression patterns of the four prostaglandin receptors (EP1-4) during colorectal 
tumorigenesis. Selective EP1-4 receptor antagonism and selective inhibitors of PGE synthases 
have attracted considerable interest as strategies for preventing CRC. On the contrary, 
enzymes catalyzing degradation of prostaglandins are less evaluated in relationship to tumor 
progression, although loss of 15-PGDH has been reported to increase endogenous PGE2 levels 
and promote tumor growth in colorectal tumors (Backlund et al., 2005; Myung et al., 2006). 
Induced expression of microsomal PGES-1 has been observed in pathologies also 
overexpressing COX-2 and adds to the PGE2 hyperresponses (Yoshimatsu et al., 2001), and 
the effect and safety of selective inhibitors of microsomal PGES-1 are currently being 
explored (Jin et al., 2015). Colorectal tumors and their neighbor cells have augmented 
expression of EP2 (Sonoshita et al., 2001) and EP4 (Chell et al., 2006) receptors that stimulate 
cAMP production. In contrast, expression of the EP3 receptor, which is coupled to inhibition 
of cAMP generation, is often reduced in target cells (Shoji et al., 2004). However, moving 
downstream in the PGE2 pathway to target just one prostanoid receptor to devise more 
targeted therapeutic approaches might just dilute the efficacy, as opposed to the robust 
inhibition of all downstream prostaglandins by COX-inhibitors since there is considerable 
amount of redundancy in the system. In addition to looking at downstream molecular targets, 
examination of strategies to target chemopreventive therapies to the colonic mucosa with 
drugs either released or activated by colonic flora also represent attractive means of limiting 
systemic toxicity. 
The inhibition of immune cell responses by PGE2 derived from tumor stroma may 
have effects beyond the local site of the colorectal tumor, as investigated in Paper IV. This 
signaling study of circulating T cells from CRC patients is confirmatory of the inhibitory role 
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of PGE2 in proximal T cell signaling. Our laboratory has unraveled a molecular mechanism of 
the cAMP-mediated immunoregulation in T cells through the cAMP-PKA type I-Csk pathway. 
By acting on this pathway, PGE2 downregulates the proximal step of TCR activation, which 
involves phosphorylation of the CD3ȗ chains. Peripheral T cells obtained from CRC patients 
with elevated plasma levels of PGE2 displayed reduced phosphorylation of CD3ȗ after 
TCR/CD28 co-stimulation compared to T cells from patients with lower levels of circulating 
PGE2 and T cells from healthy blood donors. Furthermore, since the phosphorylation of CD3ȗ 
were responsive also to the addition of exogenous PGE2, independent of the endogenous 
levels of PGE2, the T cells already exposed to chronic elevated levels of PGE2 did not seem to 
be exhausted with respect to PGE2 responsiveness. Targeting the cAMP-PKA type I-Csk 
pathway could therefore be exploited in attempts to increase T cell anti-tumor responses in 
CRC. Studies from our group have previously reported elevated circulating levels of PGE2 in 
a majority of patients with both primary and metastatic CRC (Yaqub et al., 2008; Brudvik et 
al., 2012). Prostaglandin E2 was furthermore found to contribute to an immunosuppressive 
microenvironment in CRC and suppress T cell anti-tumor immune responses through PGE2-
cAMP dependent responses. Specifically, T cells obtained from blood samples of CRC 
patients displayed inhibited anti-tumor (i.e. anti-CEA) immune responses that could be 
reversed by addition of the non-selective COX-inhibitor indomethacin, as well as Rp-8-Br-
cAMPS, a cell-permeable PKA type I antagonist. Disruption of the cAMP-PKA type I-Csk 
pathway by molecular or genetic means has furthermore been shown to prevent PGE2-
mediated inhibition of T cell function (Carlson et al., 2006; Ruppelt et al., 2007). In mice, 
disruption of this pathway leads to enhanced T cell responsiveness, as evidenced by increased 
signaling, increased IL-2 secretion and reduced sensitivity to PGE2-mediated inhibition of T 
cell function (Mosenden et al., 2011). These mice also have improved resistance to murine 
AIDS, an immunodeficiency disease induced by the murine leukemia virus where the cAMP-
PKA pathway is hyperactivated. Interestingly, targeting COX-2 to reduce PGE2 production 
has been shown to lower cAMP levels and increase T cell function also in patients with 
human immunodeficiency virus (HIV) (Johansson et al., 2004; Kvale et al., 2006). 
 
4.6 Investigation of phosphorylation cascades  
Rapid and reversible phosphorylation of proteins has a central role in highly dynamic signal 
transduction pathways that read and respond to alterations in the cellular microenvironment. A 
physiological role for protein phosphorylation was first identified while investigating the 
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regulation of glycogen metabolism (Fischer and Krebs, 1955; Sutherland, 1972) and since 
then many aspects of cellular function have been shown to be controlled by this mechanism. 
The utility of protein phosphorylation as a predominant form of covalent modification of 
proteins in vivo is exemplified by the finding that around 30% of intracellular proteins are 
phospho-proteins (Hunter, 1987). In eukaryotes, protein phosphorylation involves the kinase-
transfer of the terminal phosphate group of ATP to the hydroxyl group of the residues serine, 
threonine or tyrosine of the target protein which subsequently can be removed by 
phosphatases (Deribe et al., 2010). Phospho-amino acids in proteins act as new chemical 
entities that do not resemble any natural amino acid and thereby provide a means of 
diversifying the chemical nature of protein surfaces (Hunter, 2012). The introduction of a 
phosphate group predominantly adds a í2 charge at physiological pH which is a major 
biophysical perturbation leading to alterations in protein conformation, subcellular 
localization, enzymatic activity and/or protein-protein interactions (Narayanan and Jacobson, 
2009). The unique size and charge properties of covalently attached phosphate allow specific 
and inducible recognition of phospho-proteins by phospho-specific-binding domains in other 
proteins, thus promoting inducible protein-protein associations. Domains that function as 
docking sites for phosphorylated tyrosine (e.g. SH2 and phospho-tyrosine-binding domain 
(PTB)) and serine (e.g. forkhead-associated domain) residues seem to have coevolved with 
phosphorylation (Deribe et al., 2010). Lastly, phosphorylations have also been shown to 
create a phospho-degron, leading to ubiquitin-dependent protein degradation (Hunter, 2012). 
Traditionally, protein phosphorylation has been studied by biochemical approaches 
such as in vivo labeling with radioisotopes, phospho-peptide mapping, kinase purification and 
phospho-amino acid analysis (Johnson and Hunter, 2005) and entire signaling pathways have 
been examined protein by protein. However, although some proteins fluctuate regularly in 
their phosphorylation status during the cell cycle, other proteins fluctuate in response to 
different stimuli and conditions, and only a small fraction of the available intracellular pool of 
a protein might be phosphorylated at any given time. Studying temporal phosphorylation 
dynamics therefore requires high sensitivity, specificity and analysis of multiple time points. 
Technological advances have allowed unbiased and dynamic measurements of 
phosphorylation events in a high-throughput manner. Nevertheless, limitations remain that 
have important implications for the design of mapping experiments and the subsequent 
interpretation of results in a functional setting. Some of the methods utilized in this Thesis for 
detecting phosphorylation status of proteins will be briefly compared below.  
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Immunoblotting (e.g western blotting) has been extensively used to study TCR 
signaling. Enzymatic amplification allows the detection of low abundance phospho-proteins 
with sufficient signal-to-noise ratios without concerns of autofluorescence and antigen 
accessibility. Other advantages are low costs and visualization of antibody selectivity based 
on molecular weight. To preserve phosphorylation, it is essential that buffers for extraction 
contain high concentrations of phosphatase inhibitors. Immunoblotting is time consuming for 
large sample sets, even though array methods with more high-throughput modes have been 
developed. For example, in Paper III we used a phospho-kinase antibody array to measure the 
phosphorylation of 43 kinases and two related total proteins using chemiluminescence 
detection. However, the method is still not amendable to large screening efforts. In addition, 
measurements are averaged readouts of cell populations and might require cell sorting or other 
cell purification assays prior to analysis. This is both time consuming and put cells through 
conditions that can lead to inadvertent changes in signaling status of proteins (Brumbaugh et 
al., 2011; Germain et al., 2011). The combined use of phospho-specific antibodies and 
antibodies for cell-surface antigens in a flow cytometric setup provide a tool of understanding 
the signal transduction dynamics at the single-cell level in heterogeneous populations with 
minimal handling and few purification steps (Krutzik and Nolan, 2003; Krutzik et al., 2004). 
Response to stimuli could be diverse even in synchronized cells of the same origin, and 
measurements at the individual cell level therefore provide crucial information. The additional 
introduction of fluorescent cell barcoding (FCB) reduces antibody consumption, improves the 
number of possible simultaneous analysis parameters and eliminates pipetting and staining 
variability between samples (Krutzik and Nolan, 2006). However, the phospho-flow protocol 
needs to be tuned with regard to stimulation, fixation, barcoding, permeabilization and 
staining conditions. Fixation techniques must be rapid and efficient at “freezing” signaling in 
time to prevent dephosphorylation. Furthermore, permeabilization steps must allow for 
complete antibody access to their cognate epitopes for binding and the protocol must provide 
a balance between maintenance of surface and intracellular epitopes. Experimental evidence 
suggests that a combination of formaldehyde and methanol provides a broadly applicable 
method (Krutzik and Nolan, 2003). Of note, when stored at -80 °C in methanol, phospho-
specific signals may be preserved for up to two years (Irish et al., 2010). Neither 
immunoblotting nor phospho-specific flow cytometry maintain the subcellular localization of 
phosphorylated proteins, this is better achieved with microscope techniques or cellular 
fractionation followed by western blotting. Confocal microscopy was used in Paper II to 
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locate fluorescently stained molecules within cells to study the translocation of central T cell 
signaling molecules to the distal pole complex. Although photobleaching and phototoxicity 
caused by high-energy excitation photons from the lasers are restricted to small areas, the 
acquisition of the confocal microscope is relatively slow and the penetration depth is limited. 
  
4.6.1 Antibody specificity 
Experimental setups to study phosphorylation events are highly dependent on the quality and 
availability of the phospho-specific antibodies. More than 100 000 different phosphorylation 
sites have so far been reported in literature-curated databases (Dephoure et al., 2013). Many of 
the reported sites are currently without known physiological relevance. However, once a site 
has been identified, it may be possible to generate phospho-specific antibodies that recognize 
the phospho-amino acid within specific short linear motifs in its surrounding context. 
Typically, the desired phosphorylated amino acid is placed in the middle of a 10-14 amino 
acids long peptide to allow enough exposure of the phosphorylation (Brumbaugh et al., 2011). 
In some cases, phospho-epitope analysis of a particular protein will not be possible because 
the phospho-epitopes are buried by protein-protein interactions or lie within the active sites 
that are bound to the substrate (Ubersax and Ferrell, Jr., 2007). In addition, after fixing cells 
with crosslinking reagents such as formaldehyde, epitopes may be buried within protein 
interfaces and obstruct the accessibility of the antibody. Hence, experimental setups might 
suffer from limited availability of specific phospho-epitope antibodies. In our laboratory we 
have carefully tested and titrated a panel of up to 40 phospho-specific antibodies utilized in 
TCR signaling studies, and similar data have been compiled and published by several other 
groups. Thus, signaling patterns may be compared. A standard calibration setup for signaling 
studies in T cells in our laboratory is to test each antibody for their concentration-response in 
T cells treated with well-established stimuli upstream or downstream of the target protein and 
phosphatase inhibitors. Examples include a pSer/pThr kinase inhibitor (Calyculin A), a pTyr 
inhibitor (sodium orthovanadate), crosslinking of anti-CD3 and anti-CD28 antibodies, an 
activator of MAPK (anisomycin) and the combined use of a PKC activator (PMA, phorbol 12-
myristate 13-acetate) together with an intracellular calcium inducer (ionomycin). Results from 
these phospho-flow calibration experiments are then compared with western blot analysis of 
the same sample, and in some cases we have experienced that the staining quality varies due 
to low affinity or high background in the context of fixed and permeabilized cells. Antibodies 
could also be tested in settings where the target protein has been specifically inhibited, e.g. in 
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cell lines known to not express the phospho-protein under investigation, by using chemical 
inhibitors or by applying small interfering RNA (siRNA) to knock down the protein of 
interest and see if this is reflected in a removal or reduction of the phospho-antibody signal. 
 
4.6.2 Extension of the phospho-flow technique and clinical applications 
Single-cell approaches provide a means to characterize complex phenotypes, isolate rare 
populations, track subcellular features and generate signaling signatures that can be associated 
with clinical features of each patient’s cancer disease (Irish and Doxie, 2014). There has been 
a drive to expand the number of simultaneous per-cell measurements that can be made, but the 
number of detectors in the fluorescence-activated cell sorting (FACS) analyzer and spectral 
overlap between fluorescent dyes limit the capacity of flow cytometry. The dimensionality 
could, however, be increased by coupling conventional flow cytometry with mass 
spectrometry detection through the use of antibodies tagged with stable isotopes instead of 
fluorescent labels. This extension of flow cytometry is named mass cytometry (CyTOF) 
(Bandura et al., 2009) and has already been demonstrated to simultaneously measure 34 
distinct cellular parameters in human bone marrow samples which provided an in-depth 
analysis of the relationships between immunophenotype, cell signaling and drug action 
(Bendall et al., 2011). In addition, the method is expected to be broadened further to allow for 
concomitant analysis of up to 100 parameters per cell. The promise of these techniques for 
personalized medicine is significant, but they also create the challenge of integrating results 
from multiple high-dimensional, single-cell techniques and the need for development of 
complex computational modeling of biological networks in pathogenic and healthy cells. 
           Not surprisingly, the breakdown in phosphorylation-based signal transduction may be 
the cause or consequence of many diseases. The expansion of techniques for studying global 
phosphorylation networks therefore has potential applications in multiple clinical settings. 
Phospho-specific flow cytometry has proven valuable in characterization of immune system 
development and signaling, drug screening, personalized treatment in cancer and disease 
phenotyping. Some specific examples include monitoring of changes in phospho-epitopes 
following mTOR-inhibition in adherent cells from glioblastoma multiforme cells (Cornez et 
al., 2013), profiling of disease specific signaling networks in acute myeloid leukemia 
(Krutzik et al., 2004) and identification of a negative prognostic cell subset with impaired 
BCR signaling in human lymphoma patients (Irish et al., 2010). In Paper IV, we performed a 
feasibility study on screening of blood samples from CRC patients to identify peripheral T 
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cell signaling aberrations linked to the levels of circulating PGE2. Although limited by its 
small sample size, specific signaling perturbations in T cell activation were localized to 
samples from patients with elevated serum levels of PGE2 and confirmed the potential of 
phospho-specific flow cytometry as a valuable tool for revealing specific signaling signatures 
in immunological disorders. We are presently trying to apply these signaling techniques in 
early detection and analysis of solid tumor cell signaling, tumor immunity and aggressive 
disease transformation.  
            In collaboration with the group of Dr. Klaus Okkenhaug at the Babraham Institute we 
also contributed with phospho-flow analysis in a drug responsiveness study using the small- 
molecule inhibitor IC87114 to inhibit the major PI3K isoform in T cells, p110į (see Figure 
10, adapted from Soond et al., 2010). The group had previously demonstrated critical and 
non-redundant roles for PI3K p110į during the activation and differentiation of naïve T cells 
(Okkenhaug et al., 2002; Okkenhaug et al., 2006), but it was not obvious whether p110į 
would also boost activation of effector/memory T cells. Along with other readouts, 
monitoring signaling responses in a phospho-flow setup contributed to demonstrate that 
 
 
 
Figure 10. Phospho-specific flow cytometric analysis of drug responsiveness shows that p110į regulates 
TCR signaling in human primary T cells. T cells from healthy human donors were pre-treated with DMSO 
alone (control), IC87114 (p110į inhibitor) or LY294002 (PI3K inhibitor) and stimulated with anti-CD3/CD28 
for different time points. The pooled barcoded aliquots were stained for surface markers and phospho-proteins 
and analyzed by flow cytometry. Populations were gated into naïve (CD45RO-) and effector/memory (CD45RO+) 
CD4+ and CD8 + T cells. Heatmap shows how we observed the anti-CD3/CD28 stimulated phosphorylation 
dynamics of Akt, Gsk3ȕ, Erk and S6 ribosomal proteins in DMSO and inhibitor-treated samples as fold change 
on an archsinh median scale. Data presented is representative of three independent experiments with different 
donors. Adapted from Soond et al., 2010. 
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previously activated effector/memory T cells are at least as sensitive to p110į inhibition as 
naïve T cells and that isoform-selective p110į inhibitors have the potential to be considered 
for therapeutic use in T cell-mediated autoimmune and inflammatory diseases where 
reactivation of memory T cells are important in disease maintenance. 
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5 Conclusions 

1. A comprehensive list of the primary human T cell DRM proteome was generated. 
 
2. Sets of proteins exclusively observed in DRMs from resting or stimulated T cells were 
identified. 
 
3. PKA type I was shown to translocate to the DPC upon sustained activation of primary 
human T cells. 
 
4. Co-stimulation through the CD2 and CD28 co-receptors induced distinct signaling 
responses and functional outcomes in T cells. 
 
5. Human peripheral T cells from CRC patients with elevated levels of PGE2 displayed 
aberrant proximal T cell signaling responses.  


60 

6 References 
 
Aandahl EM, Aukrust P, Skalhegg BS, Muller F, Froland SS, Hansson V and Tasken K (1998). Protein kinase A 
type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J. 12;855:862. 
Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, Tasken K and Nixon DF (2002). Inhibition of antigen-
specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol. 169;802:808. 
Abraham RT and Weiss A (2004). Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat 
Rev Immunol. 4;301:308. 
Adachi K and Davis MM (2011). T-cell receptor ligation induces distinct signaling pathways in naive vs. 
antigen-experienced T cells. Proc Natl Acad Sci U S A. 108;1549:1554. 
Ahmadi M, Emery DC and Morgan DJ (2008). Prevention of both direct and cross-priming of antitumor CD8+ 
T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 68;7520:7529. 
Akbar AN, Terry L, Timms A, Beverley PC and Janossy G (1988). Loss of CD45R and gain of UCHL1 
reactivity is a feature of primed T cells. J Immunol. 140;2171:2178. 
Alexander DD, Weed DL, Cushing CA and Lowe KA (2011). Meta-analysis of prospective studies of red meat 
consumption and colorectal cancer. Eur J Cancer Prev. 20;293:307. 
Allenspach EJ, Cullinan P, Tong J, Tang Q, Tesciuba AG, Cannon JL, Takahashi SM, Morgan R, Burkhardt JK 
and Sperling AI (2001). ERM-dependent movement of CD43 defines a novel protein complex distal to the 
immunological synapse. Immunity. 15;739:750. 
Anastassiou ED, Paliogianni F, Balow JP, Yamada H and Boumpas DT (1992). Prostaglandin E2 and other 
cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J Immunol. 
148;2845:2852. 
Andersen NN and Jess T (2013). Has the risk of colorectal cancer in inflammatory bowel disease decreased? 
World J Gastroenterol. 19;7561:7568. 
Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA (1998). Kirsten ras mutations in patients 
with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 90;675:684. 
Annibaldi A, Sajeva A, Muscolini M, Ciccosanti F, Corazzari M, Piacentini M and Tuosto L (2008). CD28 
ligation in the absence of TCR promotes RelA/NF-kappaB recruitment and trans-activation of the HIV-1 LTR. 
Eur J Immunol. 38;1446:1451. 
Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina 
CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, 
McMichael AJ and Rowland-Jones SL (2002). Memory CD8+ T cells vary in differentiation phenotype in 
different persistent virus infections. Nat Med. 8;379:385. 
Arcaro A, Gregoire C, Boucheron N, Stotz S, Palmer E, Malissen B and Luescher IF (2000). Essential role of 
CD8 palmitoylation in CD8 coreceptor function. J Immunol. 165;2068:2076. 
Arp J, Kirchhof MG, Baroja ML, Nazarian SH, Chau TA, Strathdee CA, Ball EH and Madrenas J (2003). 
Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during 
immunological synapse formation. Mol Cell Biol. 23;8042:8057. 
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW 
and Cuzick J (2010). Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a 
multicentre randomised controlled trial. Lancet. 375;1624:1633. 
Aukrust P, Aandahl EM, Skalhegg BS, Nordoy I, Hansson V, Tasken K, Froland SS and Muller F (1999). 
Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable 
immunodeficiency. J Immunol. 162;1178:1185. 


61 

Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E and Norat T (2011). Dietary fibre, whole 
grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. 
BMJ. 343;d6617. 
Ayuyan AG and Cohen FS (2008). Raft composition at physiological temperature and pH in the absence of 
detergents. Biophys J. 94;2654:2666. 
Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL and Somoza C (1993). B70 antigen is a second 
ligand for CTLA-4 and CD28. Nature. 366;76:79. 
Babiychuk EB and Draeger A (2006). Biochemical characterization of detergent-resistant membranes: a 
systematic approach. Biochem J. 397;407:416. 
Bachmann MF, Barner M and Kopf M (1999). CD2 sets quantitative thresholds in T cell activation. J Exp Med. 
190;1383:1392. 
Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S and DuBois RN 
(2005). 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 
280;3217:3223. 
Bae TJ, Kim MS, Kim JW, Kim BW, Choo HJ, Lee JW, Kim KB, Lee CS, Kim JH, Chang SY, Kang CY, Lee 
SW and Ko YG (2004). Lipid raft proteome reveals ATP synthase complex in the cell surface. Proteomics. 
4;3536:3548. 
Ballek O, Brouckova A, Manning J and Filipp D (2012). A specific type of membrane microdomains is involved 
in the maintenance and translocation of kinase active Lck to lipid rafts. Immunol Lett. 142;64:74. 
Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, Pavlov S, Vorobiev S, Dick JE and 
Tanner SD (2009). Mass cytometry: technique for real time single cell multitarget immunoassay based on 
inductively coupled plasma time-of-flight mass spectrometry. Anal Chem. 81;6813:6822. 
Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S and 
Dubinett SM (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human 
CD4+ T cells. J Immunol. 175;1483:1490. 
Barclay AN and McCall MN (1992). CD45; from alloantigen to mapping of restricted epitopes using 
recombinant soluble CD45 isoforms. Biochem Soc Trans. 20;161:164. 
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, 
Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, 
Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F and van Stolk RU (2003). A randomized trial of aspirin to 
prevent colorectal adenomas. N Engl J Med. 348;891:899. 
Baumgart T, Hammond AT, Sengupta P, Hess ST, Holowka DA, Baird BA and Webb WW (2007). Large-scale 
fluid/fluid phase separation of proteins and lipids in giant plasma membrane vesicles. Proc Natl Acad Sci U S A. 
104;3165:3170. 
Beals CR, Sheridan CM, Turck CW, Gardner P and Crabtree GR (1997). Nuclear export of NF-ATc enhanced by 
glycogen synthase kinase-3. Science. 275;1930:1934. 
Beier KC, Kallinich T and Hamelmann E (2007). Master switches of T-cell activation and differentiation. Eur 
Respir J. 29;804:812. 
Bell GM, Fargnoli J, Bolen JB, Kish L and Imboden JB (1996). The SH3 domain of p56lck binds to proline-rich 
sequences in the cytoplasmic domain of CD2. J Exp Med. 183;169:178. 
Bendall SC, Simonds EF, Qiu P, Amir E, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, 
Balderas RS, Plevritis SK, Sachs K, Pe'er D, Tanner SD and Nolan GP (2011). Single-cell mass cytometry of 
differential immune and drug responses across a human hematopoietic continuum. Science. 332;687:696. 
Bengtsson G, Carlsson G, Hafstrom L and Jonsson PE (1981). Natural history of patients with untreated liver 
metastases from colorectal cancer. Am J Surg. 141;586:589. 


62 

Berard M, Brandt K, Bulfone-Paus S and Tough DF (2003). IL-15 promotes the survival of naive and memory 
phenotype CD8+ T cells. J Immunol. 170;5018:5026. 
Bergman M, Mustelin T, Oetken C, Partanen J, Flint NA, Amrein KE, Autero M, Burn P and Alitalo K (1992). 
The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. 
EMBO J. 11;2919:2924. 
Betz M and Fox BS (1991). Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 
lymphokines. J Immunol. 146;108:113. 
Beyersdorf N, Hanke T, Kerkau T and Hunig T (2005). Superagonistic anti-CD28 antibodies: potent activators 
of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis. 64;iv91-iv95. 
Bi K, Tanaka Y, Coudronniere N, Sugie K, Hong S, van Stipdonk MJ and Altman A (2001). Antigen-induced 
translocation of PKC-theta to membrane rafts is required for T cell activation. Nat Immunol. 2;556:563. 
Billadeau DD, Nolz JC and Gomez TS (2007). Regulation of T-cell activation by the cytoskeleton. Nat Rev 
Immunol. 7;131:143. 
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine 
L, Berger A, Bruneval P, Fridman WH, Becker C, Pages F, Speicher MR, Trajanoski Z and Galon J (2013). 
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 
39;782:795. 
Bini L, Pacini S, Liberatori S, Valensin S, Pellegrini M, Raggiaschi R, Pallini V and Baldari CT (2003). 
Extensive temporally regulated reorganization of the lipid raft proteome following T-cell antigen receptor 
triggering. Biochem J. 369;301:309. 
Boerth NJ, Sadler JJ, Bauer DE, Clements JL, Gheith SM and Koretzky GA (2000). Recruitment of SLP-76 to 
the membrane and glycolipid-enriched membrane microdomains replaces the requirement for linker for 
activation of T cells in T cell receptor signaling. J Exp Med. 192;1047:1058. 
Bogin Y, Ainey C, Beach D and Yablonski D (2007). SLP-76 mediates and maintains activation of the Tec 
family kinase ITK via the T cell antigen receptor-induced association between SLP-76 and ITK. Proc Natl Acad 
Sci U S A. 104;6638:6643. 
Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T and Thompson CB (1995). CD28 
costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 3;87:98. 
Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, McKenzie BS, 
Kastelein RA, Cua DJ and de Waal MR (2009). Prostaglandin E2 regulates Th17 cell differentiation and function 
through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 206;535:548. 
Bork U, Rahbari NN, Scholch S, Reissfelder C, Kahlert C, Buchler MW, Weitz J and Koch M (2015). 
Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 
112;1306:1313. 
Borowski AB, Boesteanu AC, Mueller YM, Carafides C, Topham DJ, Altman JD, Jennings SR and Katsikis PD 
(2007). Memory CD8+ T cells require CD28 costimulation. J Immunol. 179;6494:6503. 
Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG and Nadler LM (1994). CD2 is involved in 
maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 180;1665:1673. 
Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, Scherer J, Shevchenko A, Hilgert I, Cerny 
J, Drbal K, Kuramitsu Y, Kornacker B, Horejsi V and Schraven B (2000). Phosphoprotein associated with 
glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor 
protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med. 
191;1591:1604. 
Brembilla NC, Weber J, Rimoldi D, Pradervand S, Schutz F, Pantaleo G, Ruegg C, Quadroni M, Harshman K 
and Doucey MA (2008). c-Cbl expression levels regulate the functional responses of human central and effector 
memory CD4 T cells. Blood. 112;652:660. 


63 

Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L and Haug U (2007). Risk of progression of 
advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. 
Gut. 56;1585:1589. 
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, 
Konstam MA and Baron JA (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma 
chemoprevention trial. N Engl J Med. 352;1092:1102. 
Bretscher P and Cohn M (1970). A theory of self-nonself discrimination. Science. 169;1042:1049. 
Brown DA and Rose JK (1992). Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains 
during transport to the apical cell surface. Cell. 68;533:544. 
Brown DA and London E (1998). Structure and origin of ordered lipid domains in biological membranes. J
Membr Biol. 164;103:114. 
Brownlie RJ and Zamoyska R (2013). T cell receptor signalling networks: branched, diversified and bounded. 
Nat Rev Immunol. 13;257:269. 
Brudvik KW, Henjum K, Aandahl EM, Bjornbeth BA and Tasken K (2012). Regulatory T-cell-mediated 
inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis 
from colorectal cancer. Cancer Immunol Immunother. 61;1045:1053. 
Brumbaugh K, Johnson W, Liao WC, Lin MS, Houchins JP, Cooper J, Stoesz S and Campos-Gonzalez R (2011). 
Overview of the generation, validation, and application of phosphosite-specific antibodies. Methods Mol Biol. 
717;3:43. 
Bubeck WJ, Fu C, Jackman JK, Flotow H, Wilkinson SE, Williams DH, Johnson R, Kong G, Chan AC and 
Findell PR (1996). Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell 
receptor function. J Biol Chem. 271;19641:19644. 
Bunnell SC, Diehn M, Yaffe MB, Findell PR, Cantley LC and Berg LJ (2000). Biochemical interactions 
integrating Itk with the T cell receptor-initiated signaling cascade. J Biol Chem. 275;2219:2230. 
Burack WR, Lee KH, Holdorf AD, Dustin ML and Shaw AS (2002). Cutting edge: quantitative imaging of raft 
accumulation in the immunological synapse. J Immunol. 169;2837:2841. 
Burkhardt JK, Carrizosa E, and Shaffer MH (2008). The actin cytoskeleton in T cell activation. Annu Rev 
Immunol. 26;233:259. 
Burr JS, Savage ND, Messah GE, Kimzey SL, Shaw AS, Arch RH and Green JM (2001). Cutting edge: distinct 
motifs within CD28 regulate T cell proliferation and induction of Bcl-XL. J Immunol. 166;5331:5335. 
Butte MJ, Lee SJ, Jesneck J, Keir ME, Haining WN and Sharpe AH (2012). CD28 costimulation regulates 
genome-wide effects on alternative splicing. PLoS One. 7;e40032. 
Cabrera T, Collado A, Fernandez MA, Ferron A, Sancho J, Ruiz-Cabello F and Garrido F (1998). High 
frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens. 52;114:123. 
Cai M, Zhao W, Shang X, Jiang J, Ji H, Tang Z and Wang H (2012). Direct evidence of lipid rafts by in situ 
atomic force microscopy. Small. 8;1243:1250. 
Campi G, Varma R and Dustin ML (2005). Actin and agonist MHC-peptide complex-dependent T cell receptor 
microclusters as scaffolds for signaling. J Exp Med. 202;1031:1036. 
Carlson CR, Lygren B, Berge T, Hoshi N, Wong W, Tasken K and Scott JD (2006). Delineation of type I protein 
kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem. 281;21535:21545. 
Carmo AM, Mason DW and Beyers AD (1993). Physical association of the cytoplasmic domain of CD2 with the 
tyrosine kinases p56lck and p59fyn. Eur J Immunol. 23;2196:2201. 
Centelles JJ (2012). General aspects of colorectal cancer. ISRN Oncol. 2012;139268. 


64 

Chandok MR, Okoye FI, Ndejembi MP and Farber DL (2007). A biochemical signature for rapid recall of 
memory CD4 T cells. J Immunol. 179;3689:3698. 
Chang HC, Moingeon P, Lopez P, Krasnow H, Stebbins C and Reinherz EL (1989). Dissection of the human 
CD2 intracellular domain. Identification of a segment required for signal transduction and interleukin 2 
production. J Exp Med. 169;2073:2083. 
Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, Williams AC and Paraskeva C 
(2006). Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage 
independence. Cancer Res. 66;3106:3113. 
Chemnitz JM, Driesen J, Classen S, Riley JL, Debey S, Beyer M, Popov A, Zander T and Schultze JL (2006). 
Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. 
Cancer Res. 66;1114:1122. 
Chen L and Flies DB (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev 
Immunol. 13;227:242. 
Cheng PC, Dykstra ML, Mitchell RN and Pierce SK (1999). A role for lipid rafts in B cell antigen receptor 
signaling and antigen targeting. J Exp Med. 190;1549:1560. 
Chichili GR and Rodgers W (2009). Cytoskeleton-membrane interactions in membrane raft structure. Cell Mol 
Life Sci. 66;2319:2328. 
Cho BK, Wang C, Sugawa S, Eisen HN and Chen J (1999). Functional differences between memory and naive 
CD8 T cells. Proc Natl Acad Sci U S A. 96;2976:2981. 
Choudhry MA, Ahmad S and Sayeed MM (1995). Role of Ca2+ in prostaglandin E2-induced T-lymphocyte 
proliferative suppression in sepsis. Infect Immun. 63;3101:3105. 
Choudhry MA, Uddin S and Sayeed MM (1998). Prostaglandin E2 modulation of p59fyn tyrosine kinase in T 
lymphocytes during sepsis. J Immunol. 160;929:935. 
Chow LM, Fournel M, Davidson D and Veillette A (1993). Negative regulation of T-cell receptor signalling by 
tyrosine protein kinase p50csk. Nature. 365;156:160. 
Constant SL and Bottomly K (1997). Induction of Th1 and Th2 CD4+ T cell responses: the alternative 
approaches. Annu Rev Immunol. 15;297:322. 
Corbin JD, Keely SL and Park CR (1975). The distribution and dissociation of cyclic adenosine 3':5'-
monophosphate-dependent protein kinases in adipose, cardiac, and other tissues. J Biol Chem. 250;218:225. 
Cornez I, Joel M, Tasken K, Langmoen IA, Glover JC and Berge T (2013). EGF signalling and rapamycin-
mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry. J
Neurooncol. 112;49:57. 
Croft M, Bradley LM and Swain SL (1994). Naive versus memory CD4 T cell response to antigen. Memory cells 
are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types 
including resting B cells. J Immunol. 152;2675:2685. 
Crooks ME, Littman DR, Carter RH, Fearon DT, Weiss A and Stein PH (1995). CD28-mediated costimulation in 
the absence of phosphatidylinositol 3-kinase association and activation. Mol Cell Biol. 15;6820:6828. 
Cullinan P, Sperling AI and Burkhardt JK (2002). The distal pole complex: a novel membrane domain distal to 
the immunological synapse. Immunol Rev. 189;111:122. 
Davidson D, Bakinowski M, Thomas ML, Horejsi V and Veillette A (2003). Phosphorylation-dependent 
regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol. 
23;2017:2028. 
Davies RJ, Miller R and Coleman N (2005). Colorectal cancer screening: prospects for molecular stool analysis. 
Nat Rev Cancer. 5;199:209. 


65 

Davis SJ and van der Merwe PA (1996). The structure and ligand interactions of CD2: implications for T-cell 
function. Immunol Today. 17;177:187. 
Davis SJ and van der Merwe PA (2006). The kinetic-segregation model: TCR triggering and beyond. Nat 
Immunol. 7;803:809. 
de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L and 
Pawlik TM (2009). Rates and patterns of recurrence following curative intent surgery for colorectal liver 
metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 250;440:448. 
Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE and Fruman 
DA (2007). T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. 
Blood. 109;2894:2902. 
Deans JP, Serra HM, Shaw J, Shen YJ, Torres RM and Pilarski LM (1992). Transient accumulation and 
subsequent rapid loss of messenger RNA encoding high molecular mass CD45 isoforms after T cell activation. J
Immunol. 148;1898:1905. 
Deindl S, Kadlecek TA, Brdicka T, Cao X, Weiss A and Kuriyan J (2007). Structural basis for the inhibition of 
tyrosine kinase activity of ZAP-70. Cell. 129;735:746. 
del RR, Rincon M, Layseca-Espinosa E, Fierro NA, Rosenstein Y and Pedraza-Alva G (2004). PKCtheta is 
required for the activation of human T lymphocytes induced by CD43 engagement. Biochem Biophys Res 
Commun. 325;133:143. 
Delon J, Kaibuchi K and Germain RN (2001). Exclusion of CD43 from the immunological synapse is mediated 
by phosphorylation-regulated relocation of the cytoskeletal adaptor moesin. Immunity. 15;691:701. 
Demeure CE, Yang LP, Desjardins C, Raynauld P and Delespesse G (1997). Prostaglandin E2 primes naive T 
cells for the production of anti-inflammatory cytokines. Eur J Immunol. 27;3526:3531. 
Dephoure N, Gould KL, Gygi SP and Kellogg DR (2013). Mapping and analysis of phosphorylation sites: a 
quick guide for cell biologists. Mol Biol Cell. 24;535:542. 
Deribe YL, Pawson T and Dikic I (2010). Post-translational modifications in signal integration. Nat Struct Mol 
Biol. 17;666:672. 
Dey I, Lejeune M and Chadee K (2006). Prostaglandin E2 receptor distribution and function in the 
gastrointestinal tract. Br J Pharmacol. 149;611:623. 
Diehn M, Alizadeh AA, Rando OJ, Liu CL, Stankunas K, Botstein D, Crabtree GR and Brown PO (2002). 
Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc 
Natl Acad Sci U S A. 99;11796:11801. 
Dodson LF, Boomer JS, Deppong CM, Shah DD, Sim J, Bricker TL, Russell JH and Green JM (2009). Targeted 
knock-in mice expressing mutations of CD28 reveal an essential pathway for costimulation. Mol Cell Biol. 
29;3710:3721. 
Dostmann WR and Taylor SS (1991). Identifying the molecular switches that determine whether (Rp)-cAMPS 
functions as an antagonist or an agonist in the activation of cAMP-dependent protein kinase I. Biochemistry 
(Mosc). 30;8710:8716. 
Dransfield DT, Bradford AJ, Smith J, Martin M, Roy C, Mangeat PH and Goldenring JR (1997). Ezrin is a cyclic 
AMP-dependent protein kinase anchoring protein. EMBO J. 16;35:43. 
Drevot P, Langlet C, Guo XJ, Bernard AM, Colard O, Chauvin JP, Lasserre R and He HT (2002). TCR signal 
initiation machinery is pre-assembled and activated in a subset of membrane rafts. EMBO J. 21;1899:1908. 
Driessens G, Kline J and Gajewski TF (2009). Costimulatory and coinhibitory receptors in anti-tumor immunity. 
Immunol Rev. 229;126:144. 


66 

Dustin ML, Golan DE, Zhu DM, Miller JM, Meier W, Davies EA and van der Merwe PA (1997). Low affinity 
interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve 
high physiological affinity. J Biol Chem. 272;30889:30898. 
Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, Widder P, Rosenberger F, van der Merwe PA, 
Allen PM and Shaw AS (1998). A novel adaptor protein orchestrates receptor patterning and cytoskeletal 
polarity in T-cell contacts. Cell. 94;667:677. 
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN (1994). Up-regulation of 
cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 
107;1183:1188. 
Eggeling C, Ringemann C, Medda R, Schwarzmann G, Sandhoff K, Polyakova S, Belov VN, Hein B, von MC, 
Schonle A and Hell SW (2009). Direct observation of the nanoscale dynamics of membrane lipids in a living cell. 
Nature. 457;1159:1162. 
Elder DJ, Baker JA, Banu NA, Moorghen M and Paraskeva C (2002). Human colorectal adenomas demonstrate 
a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol. 198;428:434. 
Ellis JH, Ashman C, Burden MN, Kilpatrick KE, Morse MA and Hamblin PA (2000). GRID: a novel Grb-2-
related adapter protein that interacts with the activated T cell costimulatory receptor CD28. J Immunol. 
164;5805:5814. 
Erdogan S and Houslay MD (1997). Challenge of human Jurkat T-cells with the adenylate cyclase activator 
forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and 
inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. 
Biochem J. 321 ( Pt 1);165:175. 
Farber DL, Acuto O and Bottomly K (1997). Differential T cell receptor-mediated signaling in naive and 
memory CD4 T cells. Eur J Immunol. 27;2094:2101. 
Farber DL, Yudanin NA and Restifo NP (2014). Human memory T cells: generation, compartmentalization and 
homeostasis. Nat Rev Immunol. 14;24:35. 
Faure S, Salazar-Fontana LI, Semichon M, Tybulewicz VL, Bismuth G, Trautmann A, Germain RN and Delon J 
(2004). ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation. Nat Immunol. 
5;272:279. 
Fearon ER (2011). Molecular genetics of colorectal cancer. Annu Rev Pathol. 6;479:507. 
Felix NJ, Suri A, Salter-Cid L, Nadler SG, Gujrathi S, Corbo M and Aranda R (2010). Targeting lymphocyte co-
stimulation: from bench to bedside. Autoimmunity. 43;514:525. 
Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, Tjonneland A, Overvad K, Jensen MK, Boutron-
Ruault MC, Clavel-Chapelon F, Morois S, Rohrmann S, Linseisen J, Boeing H, Bergmann M, Kontopoulou D, 
Trichopoulou A, Kassapa C, Masala G, Krogh V, Vineis P, Panico S, Tumino R, van Gils CH, Peeters P, Bueno-
de-Mesquita HB, Ocke MC, Skeie G, Lund E, Agudo A, Ardanaz E, Lopez DC, Sanchez MJ, Quiros JR, Amiano 
P, Berglund G, Manjer J, Palmqvist R, Van GB, Allen N, Key T, Bingham S, Mazuir M, Boffetta P, Kaaks R and 
Riboli E (2007). Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European 
prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 121;2065:2072. 
Fievet BT, Gautreau A, Roy C, Del ML, Mangeat P, Louvard D and Arpin M (2004). Phosphoinositide binding 
and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol. 164;653:659. 
Fischer EH and Krebs EG (1955). Conversion of phosphorylase b to phosphorylase a in muscle extracts. J Biol 
Chem. 216;121:132. 
Flynn K and Mullbacher A (1996). Memory alloreactive cytotoxic T cells do not require costimulation for 
activation in vitro. Immunol Cell Biol. 74;413:420. 


67 

Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J, Sacristan C, Victora GD, Zanin-
Zhorov A and Dustin ML (2010). Functional anatomy of T cell activation and synapse formation. Annu Rev 
Immunol. 28;79:105. 
Forstermann U and Neufang B (1983). Elimination from the circulation of cats of 6-keto-prostaglandin E1 
compared with prostaglandins E2 and I2. J Pharm Pharmacol. 35;724:728. 
Fragoso R, Ren D, Zhang X, Su MW, Burakoff SJ and Jin YJ (2003). Lipid raft distribution of CD4 depends on 
its palmitoylation and association with Lck, and evidence for CD4-induced lipid raft aggregation as an additional 
mechanism to enhance CD3 signaling. J Immunol. 170;913:921. 
Fraser JD, Irving BA, Crabtree GR and Weiss A (1991). Regulation of interleukin-2 gene enhancer activity by 
the T cell accessory molecule CD28. Science. 251;313:316. 
Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Jr., Lombard LA, Gray GS and Nadler LM 
(1993). Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 
262;909:911. 
Freiberg BA, Kupfer H, Maslanik W, Delli J, Kappler J, Zaller DM and Kupfer A (2002). Staging and resetting 
T cell activation in SMACs. Nat Immunol. 3;911:917. 
Friend LD, Shah DD, Deppong C, Lin J, Bricker TL, Juehne TI, Rose CM and Green JM (2006). A dose-
dependent requirement for the proline motif of CD28 in cellular and humoral immunity revealed by a targeted 
knockin mutant. J Exp Med. 203;2121:2133. 
Fujino H, West KA and Regan JW (2002). Phosphorylation of glycogen synthase kinase-3 and stimulation of T-
cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem. 
277;2614:2619. 
Fukai I, Hussey RE, Sunder-Plassmann R and Reinherz EL (2000). A critical role for p59(fyn) in CD2-based 
signal transduction. Eur J Immunol. 30;3507:3515. 
Fuld S, Borland G and Yarwood SJ (2005). Elevation of cyclic AMP in Jurkat T-cells provokes distinct 
transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP 
(EPAC) pathways. Exp Cell Res. 309;161:173. 
Fuse S, Zhang W, and Usherwood EJ (2008). Control of memory CD8+ T cell differentiation by CD80/CD86-
CD28 costimulation and restoration by IL-2 during the recall response. J Immunol. 180;1148:1157. 
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger 
A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F (2006). Type, 
density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 
313;1960:1964. 
Garcia de TJ, Manzano L, Leal JC, San AE, Sualdea V and Alvarez-Mon M (2004). Active Crohn's disease 
patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol. 
24;185:196. 
Garcon F, Patton DT, Emery JL, Hirsch E, Rottapel R, Sasaki T and Okkenhaug K (2008). CD28 provides T-cell 
costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with 
the p85/p110 heterodimer. Blood. 111;1464:1471. 
Germain RN, Meier-Schellersheim M, Nita-Lazar A, and Fraser ID (2011). Systems biology in immunology: a 
computational modeling perspective. Annu Rev Immunol. 29;527:585. 
Gold P and Freedman SO (1965). Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 
122;467:481. 
Gomez-Mouton C, Abad JL, Mira E, Lacalle RA, Gallardo E, Jimenez-Baranda S, Illa I, Bernad A, Manes S and 
Martinez A (2001). Segregation of leading-edge and uropod components into specific lipid rafts during T cell 
polarization. Proc Natl Acad Sci U S A. 98;9642:9647. 


68 

Goodwin JS, Bankhurst AD and Messner RP (1977). Suppression of human T-cell mitogenesis by prostaglandin. 
Existence of a prostaglandin-producing suppressor cell. J Exp Med. 146;1719:1734. 
Goswami D, Gowrishankar K, Bilgrami S, Ghosh S, Raghupathy R, Chadda R, Vishwakarma R, Rao M and 
Mayor S (2008). Nanoclusters of GPI-anchored proteins are formed by cortical actin-driven activity. Cell. 
135;1085:1097. 
Goto T, Herberman RB, Maluish A and Strong DM (1983). Cyclic AMP as a mediator of prostaglandin E-
induced suppression of human natural killer cell activity. J Immunol. 130;1350:1355. 
Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM and Dustin ML (1999). The immunological 
synapse: a molecular machine controlling T cell activation. Science. 285;221:227. 
Granelli-Piperno A and Nolan P (1991). Nuclear transcription factors that bind to elements of the IL-2 promoter. 
Induction requirements in primary human T cells. J Immunol. 147;2734:2739. 
Gray D and Matzinger P (1991). T cell memory is short-lived in the absence of antigen. J Exp Med. 174;969:974. 
Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA and Thompson CB (1994). Absence of 
B7-dependent responses in CD28-deficient mice. Immunity. 1;501:508. 
Green JM, Karpitskiy V, Kimzey SL and Shaw AS (2000). Coordinate regulation of T cell activation by CD2 
and CD28. J Immunol. 164;3591:3595. 
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF, Jr. 
(1993). Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 85;307:311. 
Gupta N, Wollscheid B, Watts JD, Scheer B, Aebersold R and DeFranco AL (2006). Quantitative proteomic 
analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. Nat 
Immunol. 7;625:633. 
Gureasko J, Galush WJ, Boykevisch S, Sondermann H, Bar-Sagi D, Groves JT and Kuriyan J (2008). 
Membrane-dependent signal integration by the Ras activator Son of sevenless. Nat Struct Mol Biol. 15;452:461. 
Hale AH, Evans DL and Daniel LW (1982). Effect of prostaglandins on elicitation of anti-viral-cytolytic activity. 
Immunol Lett. 4;171:174. 
Hall SR, Heffernan BM, Thompson NT and Rowan WC (1999). CD4+ CD45RA+ and CD4+ CD45RO+ T cells 
differ in their TCR-associated signaling responses. Eur J Immunol. 29;2098:2106. 
Hannan LM, Jacobs EJ and Thun MJ (2009). The association between cigarette smoking and risk of colorectal 
cancer in a large prospective cohort from the United States. Cancer Epidemiol Biomarkers Prev. 18;3362:3367. 
Hansen JA, Martin PJ and Nowinski RC (1980). Monoclonal antibodies identifying a novel T-cell antigen and Ia 
antigens of human lymphocytes. Immunogenetics. 10;247:260. 
Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD and Mangham CM 
(1996). Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 
348;1472:1477. 
Harder T, Scheiffele P, Verkade P and Simons K (1998). Lipid domain structure of the plasma membrane 
revealed by patching of membrane components. J Cell Biol. 141;929:942. 
Harizi H, Juzan M, Pitard V, Moreau JF and Gualde N (2002). Cyclooxygenase-2-issued prostaglandin e(2) 
enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol. 
168;2255:2263. 
Haudek VJ, Slany A, Gundacker NC, Wimmer H, Drach J and Gerner C (2009). Proteome maps of the main 
human peripheral blood constituents. J Proteome Res. 8;3834:3843. 


69 

Hawash IY, Hu XE, Adal A, Cassady JM, Geahlen RL and Harrison ML (2002). The oxygen-substituted 
palmitic acid analogue, 13-oxypalmitic acid, inhibits Lck localization to lipid rafts and T cell signaling. Biochim 
Biophys Acta. 1589;140:150. 
He HT and Marguet D (2008). T-cell antigen receptor triggering and lipid rafts: a matter of space and time scales. 
Talking Point on the involvement of lipid rafts in T-cell activation. EMBO Rep. 9;525:530. 
Heerklotz H (2002). Triton promotes domain formation in lipid raft mixtures. Biophys J. 83;2693:2701. 
Hendricks A, Leibold W, Kaever V and Schuberth HJ (2000). Prostaglandin E2 is variably induced by bacterial 
superantigens in bovine mononuclear cells and has a regulatory role for the T cell proliferative response. 
Immunobiology. 201;493:505. 
Holdorf AD, Green JM, Levin SD, Denny MF, Straus DB, Link V, Changelian PS, Allen PM and Shaw AS 
(1999). Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell 
costimulation. J Exp Med. 190;375:384. 
Holdorf AD, Lee KH, Burack WR, Allen PM and Shaw AS (2002). Regulation of Lck activity by CD4 and 
CD28 in the immunological synapse. Nat Immunol. 3;259:264. 
Hope HR and Pike LJ (1996). Phosphoinositides and phosphoinositide-utilizing enzymes in detergent-insoluble 
lipid domains. Mol Biol Cell. 7;843:851. 
Horejsi V (2003). The roles of membrane microdomains (rafts) in T cell activation. Immunol Rev. 191;148:164. 
Horejsi V and Hrdinka M (2014). Membrane microdomains in immunoreceptor signaling. FEBS Lett. 
588;2392:2397. 
Huang J, Lo PF, Zal T, Gascoigne NR, Smith BA, Levin SD and Grey HM (2002). CD28 plays a critical role in 
the segregation of PKC theta within the immunologic synapse. Proc Natl Acad Sci U S A. 99;9369:9373. 
Huang Y and Burkhardt JK (2007). T-cell-receptor-dependent actin regulatory mechanisms. J Cell Sci. 
120;723:730. 
Huang YH and Sauer K (2010). Lipid signaling in T-cell development and function. Cold Spring Harb Perspect 
Biol. 2;a002428: 
Hui E and Vale RD (2014). In vitro membrane reconstitution of the T-cell receptor proximal signaling network. 
Nat Struct Mol Biol. 21;133:142. 
Hunter T (1987). A thousand and one protein kinases. Cell. 50;823:829. 
Hunter T (2012). Why nature chose phosphate to modify proteins. Philos Trans R Soc Lond B Biol Sci. 
367;2513:2516. 
Huppa JB, Gleimer M, Sumen C and Davis MM (2003). Continuous T cell receptor signaling required for 
synapse maintenance and full effector potential. Nat Immunol. 4;749:755. 
Huse M, Klein LO, Girvin AT, Faraj JM, Li QJ, Kuhns MS and Davis MM (2007). Spatial and temporal 
dynamics of T cell receptor signaling with a photoactivatable agonist. Immunity. 27;76:88. 
Hussain SF, Anderson CF and Farber DL (2002). Differential SLP-76 expression and TCR-mediated signaling in 
effector and memory CD4 T cells. J Immunol. 168;1557:1565. 
Imperiale TF (2003). Aspirin and the prevention of colorectal cancer. N Engl J Med. 348;879:880. 
Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP and Levy R (2010). B-
cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor 
progression. Proc Natl Acad Sci U S A. 107;12747:12754. 
Irish JM and Doxie DB (2014). High-dimensional single-cell cancer biology. Curr Top Microbiol Immunol. 
377;1:21. 


70 

Irles C, Arias-Martinez J, Guzman-Barcenas J and Ortega A (2010). Plasma membrane subdomain partitioning 
of Lck in primary human T lymphocytes. Can J Physiol Pharmacol. 88;487:496. 
Irvine DJ, Purbhoo MA, Krogsgaard M and Davis MM (2002). Direct observation of ligand recognition by T 
cells. Nature. 419;845:849. 
Isa P, Realpe M, Romero P, Lopez S and Arias CF (2004). Rotavirus RRV associates with lipid membrane 
microdomains during cell entry. Virology. 322;370:381. 
Janes PW, Ley SC and Magee AI (1999). Aggregation of lipid rafts accompanies signaling via the T cell antigen 
receptor. J Cell Biol. 147;447:461. 
Jenkins MK, Chen CA, Jung G, Mueller DL and Schwartz RH (1990). Inhibition of antigen-specific proliferation 
of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol. 
144;16:22. 
Jin Y, Smith CL, Hu L, Campanale KM, Stoltz R, Huffman LG, Jr., McNearney TA, Yang XY, Ackermann BL, 
Dean R, Regev A and Landschulz W (2015). Pharmacodynamic Comparison of LY3023703, a Novel 
Microsomal Prostaglandin E Synthase 1 Inhibitor, with Celecoxib. Clin Pharmacol Ther. Accepted article. 
Johansson CC, Bryn T, Aandahl EM, Areklett MA, Aukrust P, Tasken K and Froland SS (2004). Treatment with 
type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected 
patients on highly active antiretroviral therapy. AIDS. 18;951:952. 
Johnson EE, Leverson GE, Pirsch JD and Heise CP (2007). A 30-year analysis of colorectal adenocarcinoma in 
transplant recipients and proposal for altered screening. J Gastrointest Surg. 11;272:279. 
Johnson SA and Hunter T (2005). Kinomics: methods for deciphering the kinome. Nat Methods. 2;17:25. 
Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR and Ohashi PS (2000). Protein kinase B 
regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med. 
191;1721:1734. 
Jury EC, Kabouridis PS, Flores-Borja F, Mageed RA and Isenberg DA (2004). Altered lipid raft-associated 
signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin 
Invest. 113;1176:1187. 
Kabouridis PS, Magee AI and Ley SC (1997). S-acylation of LCK protein tyrosine kinase is essential for its 
signalling function in T lymphocytes. EMBO J. 16;4983:4998. 
Kabouridis PS, Janzen J, Magee AL and Ley SC (2000). Cholesterol depletion disrupts lipid rafts and modulates 
the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol. 30;954:963. 
Kaga S, Ragg S, Rogers KA and Ochi A (1998). Stimulation of CD28 with B7-2 promotes focal adhesion-like 
cell contacts where Rho family small G proteins accumulate in T cells. J Immunol. 160;24:27. 
Kaizuka Y, Douglass AD, Vardhana S, Dustin ML and Vale RD (2009). The coreceptor CD2 uses plasma 
membrane microdomains to transduce signals in T cells. J Cell Biol. 185;521:534. 
Kalinski P (2012). Regulation of immune responses by prostaglandin E2. J Immunol. 188;21:28. 
Kalland ME, Oberprieler NG, Vang T, Tasken K and Torgersen KM (2011). T cell-signaling network analysis 
reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK 
pathway between resting and activated regulatory T cells. J Immunol. 187;5233:5245. 
Kammer GM, Laxminarayana D and Khan IU (2004). Mechanisms of deficient type I protein kinase A activity 
in lupus T lymphocytes. Int Rev Immunol. 23;225:244. 
Kane LP, Andres PG, Howland KC, Abbas AK and Weiss A (2001). Akt provides the CD28 costimulatory 
signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol. 2;37:44. 


71 

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro 
JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR (2008). K-ras mutations 
and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359;1757:1765. 
Kaupp UB and Seifert R (2002). Cyclic nucleotide-gated ion channels. Physiol Rev. 82;769:824. 
Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A and Okada M (2000). 
Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature. 
404;999:1003. 
Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE and Graybiel AM 
(1998). A family of cAMP-binding proteins that directly activate Rap1. Science. 282;2275:2279. 
Kenworthy AK, Nichols BJ, Remmert CL, Hendrix GM, Kumar M, Zimmerberg J and Lippincott-Schwartz J 
(2004). Dynamics of putative raft-associated proteins at the cell surface. J Cell Biol. 165;735:746. 
Kenworthy AK (2008). Have we become overly reliant on lipid rafts? Talking Point on the involvement of lipid 
rafts in T-cell activation. EMBO Rep. 9;531:535. 
Kersh EN, Kaech SM, Onami TM, Moran M, Wherry EJ, Miceli MC and Ahmed R (2003). TCR signal 
transduction in antigen-specific memory CD8 T cells. J Immunol. 170;5455:5463. 
Khayrullina T, Yen JH, Jing H and Ganea D (2008). In vitro differentiation of dendritic cells in the presence of 
prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol. 
181;721:735. 
Killeen N, Stuart SG and Littman DR (1992). Development and function of T cells in mice with a disrupted CD2 
gene. EMBO J. 11;4329:4336. 
King CL, Stupi RJ, Craighead N, June CH and Thyphronitis G (1995). CD28 activation promotes Th2 subset 
differentiation by human CD4+ cells. Eur J Immunol. 25;587:595. 
Kivens WJ, Hunt SW, III, Mobley JL, Zell T, Dell CL, Bierer BE and Shimizu Y (1998). Identification of a 
proline-rich sequence in the CD2 cytoplasmic domain critical for regulation of integrin-mediated adhesion and 
activation of phosphoinositide 3-kinase. Mol Cell Biol. 18;5291:5307. 
Klammt C and Lillemeier BF (2012). How membrane structures control T cell signaling. Front Immunol. 3;291: 
Klausner RD, O'Shea JJ, Luong H, Ross P, Bluestone JA and Samelson LE (1987). T cell receptor tyrosine 
phosphorylation. Variable coupling for different activating ligands. J Biol Chem. 262;12654:12659. 
Koch M, Beckhove P, Op den WJ, Autenrieth D, Wagner P, Nummer D, Specht S, Antolovic D, Galindo L, 
Schmitz-Winnenthal FH, Schirrmacher V, Buchler MW and Weitz J (2006). Tumor infiltrating T lymphocytes in 
colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg. 244;986:992. 
Koch U and Radtke F (2011). Mechanisms of T cell development and transformation. Annu Rev Cell Dev Biol. 
27;539:562. 
Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, 
Arihiro S, Arakawa H, Okamoto M, Gong J and Tajiri H (2013). Immunotherapy for colorectal cancer. World J 
Gastroenterol. 19;8531:8542. 
Kolenko V, Rayman P, Roy B, Cathcart MK, O'Shea J, Tubbs R, Rybicki L, Bukowski R and Finke J (1999). 
Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine 
monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood. 93;2308:2318. 
Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD and Bradley LM (2003). Interleukin 7 regulates the 
survival and generation of memory CD4 cells. J Exp Med. 198;1797:1806. 
Kong KF, Yokosuka T, Canonigo-Balancio AJ, Isakov N, Saito T and Altman A (2011). A motif in the V3 
domain of the kinase PKC-theta determines its localization in the immunological synapse and functions in T 
cells via association with CD28. Nat Immunol. 12;1105:1112. 


72 

Kopperud R, Christensen AE, Kjarland E, Viste K, Kleivdal H and Doskeland SO (2002). Formation of inactive 
cAMP-saturated holoenzyme of cAMP-dependent protein kinase under physiological conditions. J Biol Chem. 
277;13443:13448. 
Koretzky GA, Abtahian F and Silverman MA (2006). SLP76 and SLP65: complex regulation of signalling in 
lymphocytes and beyond. Nat Rev Immunol. 6;67:78. 
Kosugi A, Saitoh S, Noda S, Yasuda K, Hayashi F, Ogata M and Hamaoka T (1999). Translocation of tyrosine-
phosphorylated TCRzeta chain to glycolipid-enriched membrane domains upon T cell activation. Int Immunol. 
11;1395:1401. 
Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M and Legler DF (2009). Prostaglandin E(2) enhances 
T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. 
Blood. 113;2451:2460. 
Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N and Tsokos GC (2004). Alterations in 
lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J
Immunol. 172;7821:7831. 
Krueger GG, Gottlieb AB, Sterry W, Korman N and Van De Kerkhof P (2008). A multicenter, open-label study 
of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic 
plaque psoriasis. J Dermatolog Treat. 19;146:155. 
Krummel MF and Allison JP (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to 
stimulation. J Exp Med. 182;459:465. 
Krutzik PO and Nolan GP (2003). Intracellular phospho-protein staining techniques for flow cytometry: 
monitoring single cell signaling events. Cytometry A. 55;61:70. 
Krutzik PO, Irish JM, Nolan GP and Perez OD (2004). Analysis of protein phosphorylation and cellular 
signaling events by flow cytometry: techniques and clinical applications. Clin Immunol. 110;206:221. 
Krutzik PO and Nolan GP (2006). Fluorescent cell barcoding in flow cytometry allows high-throughput drug 
screening and signaling profiling. Nat Methods. 3;361:368. 
Kuhns MS and Davis MM (2012). TCR Signaling Emerges from the Sum of Many Parts. Front Immunol. 3;159: 
Kumar R, Ferez M, Swamy M, Arechaga I, Rejas MT, Valpuesta JM, Schamel WW, Alarcon B and van Santen 
HM (2011). Increased sensitivity of antigen-experienced T cells through the enrichment of oligomeric T cell 
receptor complexes. Immunity. 35;375:387. 
Kundig TM, Shahinian A, Kawai K, Mittrucker HW, Sebzda E, Bachmann MF, Mak TW and Ohashi PS (1996). 
Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity. 5;41:52. 
Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Froland SS and Tasken K (2006). 
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral 
treatment. AIDS. 20;813:820. 
Lafferty KJ and Cunningham AJ (1975). A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 
53;27:42. 
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, 
Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur 
GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, 
Rollin LM, Horak C, Hodi FS and Wolchok JD (2015). Combined Nivolumab and Ipilimumab or Monotherapy 
in Untreated Melanoma. N Engl J Med. 373;23:34. 
Lau LL, Jamieson BD, Somasundaram T and Ahmed R (1994). Cytotoxic T-cell memory without antigen. 
Nature. 369;648:652. 
Legler DF, Krause P, Scandella E, Singer E and Groettrup M (2006). Prostaglandin E2 is generally required for 
human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol. 176;966:973. 


73 

Lerner A, Jacobson B and Miller RA (1988). Cyclic AMP concentrations modulate both calcium flux and 
hydrolysis of phosphatidylinositol phosphates in mouse T lymphocytes. J Immunol. 140;936:940. 
Leslie M (2011). Mysteries of the cell. Do lipid rafts exist? Science. 334;1046:1047. 
Lesslauer W, Koning F, Ottenhoff T, Giphart M, Goulmy E and van Rood JJ (1986). T90/44 (9.3 antigen). A cell 
surface molecule with a function in human T cell activation. Eur J Immunol. 16;1289:1296. 
Levental I, Grzybek M and Simons K (2010). Greasing their way: lipid modifications determine protein 
association with membrane rafts. Biochemistry (Mosc). 49;6305:6316. 
Li J, Nishizawa K, An W, Hussey RE, Lialios FE, Salgia R, Sunder-Plassmann R and Reinherz EL (1998). A 
cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered 
adhesion. EMBO J. 17;7320:7336. 
Liang S, Ledbetter J and Goodwin JS (1989). Phosphatidyl inositol hydrolysis after CD3 binding in human 
peripheral blood T cells: inhibition by prostaglandin E2. Int J Immunopharmacol. 11;809:816. 
Liao XC and Littman DR (1995). Altered T cell receptor signaling and disrupted T cell development in mice 
lacking Itk. Immunity. 3;757:769. 
Lillemeier BF, Pfeiffer JR, Surviladze Z, Wilson BS and Davis MM (2006). Plasma membrane-associated 
proteins are clustered into islands attached to the cytoskeleton. Proc Natl Acad Sci U S A. 103;18992:18997. 
Lin H, Hutchcroft JE, Andoniou CE, Kamoun M, Band H and Bierer BE (1998). Association of p59(fyn) with 
the T lymphocyte costimulatory receptor CD2. Binding of the Fyn Src homology (SH) 3 domain is regulated by 
the Fyn SH2 domain. J Biol Chem. 273;19914:19921. 
Lin J, Weiss A and Finco TS (1999). Localization of LAT in glycolipid-enriched microdomains is required for T 
cell activation. J Biol Chem. 274;28861:28864. 
Lin JK, Lin CC, Yang SH, Wang HS, Jiang JK, Lan YT, Lin TC, Li AF, Chen WS and Chang SC (2011). Early 
postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of 
patients with curable colorectal cancer. Int J Colorectal Dis. 26;1135:1141. 
Lin SL, Chien CW, Han CL, Chen ES, Kao SH, Chen YJ and Liao F (2010). Temporal proteomics profiling of 
lipid rafts in CCR6-activated T cells reveals the integration of actin cytoskeleton dynamics. J Proteome Res. 
9;283:297. 
Lindholm E, Brevinge H and Haglind E (2008). Survival benefit in a randomized clinical trial of faecal occult 
blood screening for colorectal cancer. Br J Surg. 95;1029:1036. 
Lingwood D and Simons K (2007). Detergent resistance as a tool in membrane research. Nat Protoc. 
2;2159:2165. 
Lingwood D, Ries J, Schwille P and Simons K (2008). Plasma membranes are poised for activation of raft phase 
coalescence at physiological temperature. Proc Natl Acad Sci U S A. 105;10005:10010. 
Liu SK, Fang N, Koretzky GA and McGlade CJ (1999). The hematopoietic-specific adaptor protein gads 
functions in T-cell signaling via interactions with the SLP-76 and LAT adaptors. Curr Biol. 9;67:75. 
Lo DJ, Weaver TA, Stempora L, Mehta AK, Ford ML, Larsen CP and Kirk AD (2011). Selective targeting of 
human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant. 11;22:33. 
Ludford-Menting MJ, Oliaro J, Sacirbegovic F, Cheah ET, Pedersen N, Thomas SJ, Pasam A, Iazzolino R, Dow 
LE, Waterhouse NJ, Murphy A, Ellis S, Smyth MJ, Kershaw MH, Darcy PK, Humbert PO and Russell SM 
(2005). A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and 
immunological synapse formation. Immunity. 22;737:748. 
Lugnier C (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of 
specific therapeutic agents. Pharmacol Ther. 109;366:398. 


74 

Macdonald JL and Pike LJ (2005). A simplified method for the preparation of detergent-free lipid rafts. J Lipid 
Res. 46;1061:1067. 
Mahic M, Yaqub S, Johansson CC, Tasken K and Aandahl EM (2006). FOXP3+CD4+CD25+ adaptive 
regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent 
mechanism. J Immunol. 177;246:254. 
Manes S, del RG, Lacalle RA, Lucas P, Gomez-Mouton C, Sanchez-Palomino S, Delgado R, Alcami J, Mira E 
and Martinez A (2000). Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. 
EMBO Rep. 1;190:196. 
Marengere LE, Okkenhaug K, Clavreul A, Couez D, Gibson S, Mills GB, Mak TW and Rottapel R (1997). The 
SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory 
receptor CD28. J Immunol. 159;3220:3229. 
Marinari B, Costanzo A, Marzano V, Piccolella E and Tuosto L (2004). CD28 delivers a unique signal leading to 
the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters. Proc Natl 
Acad Sci U S A. 101;6098:6103. 
Martelli MP, Lin H, Zhang W, Samelson LE and Bierer BE (2000). Signaling via LAT (linker for T-cell 
activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 
stimulation. Blood. 96;2181:2190. 
Mary D, Aussel C, Ferrua B and Fehlmann M (1987). Regulation of interleukin 2 synthesis by cAMP in human 
T cells. J Immunol. 139;1179:1184. 
Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P and Kiessling R (1995). 
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut 
mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer. 61;765:772. 
Mayo SC, Heckman JE, Shore AD, Nathan H, Parikh AA, Bridges JF, Anders RA, Anaya DA, Becker NS and 
Pawlik TM (2011). Shifting trends in liver-directed management of patients with colorectal liver metastasis: a 
population-based analysis. Surgery. 150;204:216. 
Melkonian KA, Ostermeyer AG, Chen JZ, Roth MG and Brown DA (1999). Role of lipid modifications in 
targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are 
prenylated. J Biol Chem. 274;3910:3917. 
Michie CA, McLean A, Alcock C and Beverley PC (1992). Lifespan of human lymphocyte subsets defined by 
CD45 isoforms. Nature. 360;264:265. 
Miller MJ, Wei SH, Parker I, and Cahalan MD (2002). Two-photon imaging of lymphocyte motility and antigen 
response in intact lymph node. Science. 296;1869:1873. 
Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW and Ochoa AC (1992). Alterations in signal 
transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258;1795:1798. 
Monks CR, Freiberg BA, Kupfer H, Sciaky N and Kupfer A (1998). Three-dimensional segregation of 
supramolecular activation clusters in T cells. Nature. 395;82:86. 
Montixi C, Langlet C, Bernard AM, Thimonier J, Dubois C, Wurbel MA, Chauvin JP, Pierres M and He HT 
(1998). Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane 
domains. EMBO J. 17;5334:5348. 
Moscat J, Rennert P and Diaz-Meco MT (2006). PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 
signaling pathways. Cell Death Differ. 13;702:711. 
Mosenden R and Tasken K (2011). Cyclic AMP-mediated immune regulation--overview of mechanisms of 
action in T cells. Cell Signal. 23;1009:1016. 


75 

Mosenden R, Singh P, Cornez I, Heglind M, Ruppelt A, Moutschen M, Enerback S, Rahmouni S and Tasken K 
(2011). Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced 
immunodeficiency. J Immunol. 186;5119:5130. 
Mueller DL, Seiffert S, Fang W and Behrens TW (1996). Differential regulation of bcl-2 and bcl-x by CD3, 
CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells. 
J Immunol. 156;1764:1771. 
Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J and Ahmed R (1999). Persistence of memory 
CD8 T cells in MHC class I-deficient mice. Science. 286;1377:1381. 
Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, 
Pretlow TP, Newman RA, Willis J, Dawson D and Markowitz SD (2006). 15-Hydroxyprostaglandin 
dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 103;12098:12102. 
Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P 
and Kiessling R (1993). Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells 
and NK cells of patients with colorectal carcinoma. Cancer Res. 53;5610:5612. 
Nakamura T, Kamogawa Y, Bottomly K and Flavell RA (1997). Polarization of IL-4- and IFN-gamma-
producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol. 158;1085:1094. 
Narayanan A and Jacobson MP (2009). Computational studies of protein regulation by post-translational 
phosphorylation. Curr Opin Struct Biol. 19;156:163. 
National Cancer Institute (2014). SEER Stat Fact Sheets: Colon and Rectum Cancer. http://seer.cancer 
gov/statfacts/html/colorect.html. Accessed 20 September 2014. 
Ndejembi MP, Teijaro JR, Patke DS, Bingaman AW, Chandok MR, Azimzadeh A, Nadler SG and Farber DL 
(2006). Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol. 
177;7698:7706. 
Neisch AL and Fehon RG (2011). Ezrin, Radixin and Moesin: key regulators of membrane-cortex interactions 
and signaling. Curr Opin Cell Biol. 23;377:382. 
Nika K, Soldani C, Salek M, Paster W, Gray A, Etzensperger R, Fugger L, Polzella P, Cerundolo V, Dushek O, 
Hofer T, Viola A and Acuto O (2010). Constitutively active Lck kinase in T cells drives antigen receptor signal 
transduction. Immunity. 32;766:777. 
Ning Y, Wang L and Giovannucci EL (2010). A quantitative analysis of body mass index and colorectal cancer: 
findings from 56 observational studies. Obes Rev. 11;19:30. 
Nishizawa K, Freund C, Li J, Wagner G and Reinherz EL (1998). Identification of a proline-binding motif 
regulating CD2-triggered T lymphocyte activation. Proc Natl Acad Sci U S A. 95;14897:14902. 
Nunes RJ, Castro MA, Goncalves CM, Bamberger M, Pereira CF, Bismuth G and Carmo AM (2008). Protein 
interactions between CD2 and Lck are required for the lipid raft distribution of CD2. J Immunol. 180;988:997. 
O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, Lee PW and 
Monson JR (1998). Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced 
interleukin 10 production. Clin Cancer Res. 4;1943:1948. 
Oberprieler NG, Lemeer S, Kalland ME, Torgersen KM, Heck AJ and Tasken K (2010). High-resolution 
mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node 
in CD8+CD45RO+ T cells. Blood. 116;2253:2265. 
Oeckinghaus A and Ghosh S (2009). The NF-kappaB family of transcription factors and its regulation. Cold 
Spring Harb Perspect Biol. 1;a000034. 
Ogawa S, Nagao M, Kanehiro H, Hisanaga M, Ko S, Ikeda N and Nakajima Y (2004). The breakdown of 
apoptotic mechanism in the development and progression of colorectal carcinoma. Anticancer Res. 24;1569:1579. 


76 

Oh-hora M (2009). Calcium signaling in the development and function of T-lineage cells. Immunol Rev. 
231;210:224. 
Okkenhaug K and Rottapel R (1998). Grb2 forms an inducible protein complex with CD28 through a Src 
homology 3 domain-proline interaction. J Biol Chem. 273;21194:21202. 
Okkenhaug K, Wu L, Garza KM, La RJ, Khoo W, Odermatt B, Mak TW, Ohashi PS and Rottapel R (2001). A 
point mutation in CD28 distinguishes proliferative signals from survival signals. Nat Immunol. 2;325:332. 
Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, 
Waterfield MD, Smith AJ and Vanhaesebroeck B (2002). Impaired B and T cell antigen receptor signaling in 
p110delta PI 3-kinase mutant mice. Science. 297;1031:1034. 
Okkenhaug K, Patton DT, Bilancio A, Garcon F, Rowan WC and Vanhaesebroeck B (2006). The p110delta 
isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol. 
177;5122:5128. 
Orsini F, Cremona A, Arosio P, Corsetto PA, Montorfano G, Lascialfari A and Rizzo AM (2012). Atomic force 
microscopy imaging of lipid rafts of human breast cancer cells. Biochim Biophys Acta. 1818;2943:2949. 
Orstavik S, Funderud A, Hafte TT, Eikvar S, Jahnsen T and Skalhegg BS (2005). Identification and 
characterization of novel PKA holoenzymes in human T lymphocytes. FEBS J. 272;1559:1567. 
Otahal P, Angelisova P, Hrdinka M, Brdicka T, Novak P, Drbal K and Horejsi V (2010). A new type of 
membrane raft-like microdomains and their possible involvement in TCR signaling. J Immunol. 184;3689:3696. 
Pagan AJ, Pepper M, Chu HH, Green JM and Jenkins MK (2012). CD28 promotes CD4+ T cell clonal expansion 
during infection independently of its YMNM and PYAP motifs. J Immunol. 189;2909:2917. 
Pages F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J and Olive D (1994). Binding of 
phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature. 369;327:329. 
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, 
Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Galon J (2005). Effector 
memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 353;2654:2666. 
Park SG, Schulze-Luehrman J, Hayden MS, Hashimoto N, Ogawa W, Kasuga M and Ghosh S (2009). The 
kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate 
T cells. Nat Immunol. 10;158:166. 
Parry RV, Reif K, Smith G, Sansom DM, Hemmings BA and Ward SG (1997). Ligation of the T cell co-
stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. Eur J Immunol. 
27;2495:2501. 
Pathak P and London E (2011). Measurement of lipid nanodomain (raft) formation and size in 
sphingomyelin/POPC/cholesterol vesicles shows TX-100 and transmembrane helices increase domain size by 
coalescing preexisting nanodomains but do not induce domain formation. Biophys J. 101;2417:2425. 
Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naemura J and Linsley PS (1994). Complementarity 
determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-
1. J Exp Med. 180;2049:2058. 
Pearson MA, Reczek D, Bretscher A and Karplus PA (2000). Structure of the ERM protein moesin reveals the 
FERM domain fold masked by an extended actin binding tail domain. Cell. 101;259:270. 
Perkins GL, Slater ED, Sanders GK, and Prichard JG (2003). Serum tumor markers. Am Fam Physician. 
68;1075:1082. 
Pierce SK (2002). Lipid rafts and B-cell activation. Nat Rev Immunol. 2;96:105. 
Pike LJ (2006). Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid 
Res. 47;1597:1598. 


77 

Pizzo P, Giurisato E, Tassi M, Benedetti A, Pozzan T and Viola A (2002). Lipid rafts and T cell receptor 
signaling: a critical re-evaluation. Eur J Immunol. 32;3082:3091. 
Pizzo P, Giurisato E, Bigsten A, Tassi M, Tavano R, Shaw A and Viola A (2004). Physiological T cell activation 
starts and propagates in lipid rafts. Immunol Lett. 91;3:9. 
Potter RL and Taylor SS (1979). Relationships between structural domains and function in the regulatory subunit 
of cAMP-dependent protein kinases I and II from porcine skeletal muscle. J Biol Chem. 254;2413:2418. 
Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, 
Cunningham D and Shapiro JD (2013). Current opinion on optimal treatment for colorectal cancer. Expert Rev 
Anticancer Ther. 13;597:611. 
Quill H and Schwartz RH (1987). Stimulation of normal inducer T cell clones with antigen presented by purified 
Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative 
nonresponsiveness. J Immunol. 138;3704:3712. 
Quintana A, Schwindling C, Wenning AS, Becherer U, Rettig J, Schwarz EC and Hoth M (2007). T cell 
activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A. 
104;14418:14423. 
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, 
Hou TZ, Futter CE, Anderson G, Walker LS and Sansom DM (2011). Trans-endocytosis of CD80 and CD86: a 
molecular basis for the cell-extrinsic function of CTLA-4. Science. 332;600:603. 
Raab M, Cai YC, Bunnell SC, Heyeck SD, Berg LJ and Rudd CE (1995). p56Lck and p59Fyn regulate CD28 
binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific 
protein-tyrosine kinase ITK: implications for T-cell costimulation. Proc Natl Acad Sci U S A. 92;8891:8895. 
Raab M, Pfister S and Rudd CE (2001). CD28 signaling via VAV/SLP-76 adaptors: regulation of cytokine 
transcription independent of TCR ligation. Immunity. 15;921:933. 
Reczek D, Berryman M and Bretscher A (1997). Identification of EBP50: A PDZ-containing phosphoprotein 
that associates with members of the ezrin-radixin-moesin family. J Cell Biol. 139;169:179. 
Rigas B, Goldman IS, and Levine L (1993). Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 
122;518:523. 
Rincon M, Tugores A, Lopez-Rivas A, Silva A, Alonso M, De Landazuri MO and Lopez-Botet M (1988). 
Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in 
human T cells. Eur J Immunol. 18;1791:1796. 
Robert V, Triffaux E, Savignac M and Pelletier L (2011). Calcium signalling in T-lymphocytes. Biochimie. 
93;2087:2094. 
Rodgers W and Rose JK (1996). Exclusion of CD45 inhibits activity of p56lck associated with glycolipid-
enriched membrane domains. J Cell Biol. 135;1515:1523. 
Rodgers W and Zavzavadjian J (2001). Glycolipid-enriched membrane domains are assembled into membrane 
patches by associating with the actin cytoskeleton. Exp Cell Res. 267;173:183. 
Rostaing L, Vincenti F, Grinyo J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, 
Mondragon-Ramirez GA, Kothari J, Pupim L and Larsen CP (2013). Long-term belatacept exposure maintains 
efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 
13;2875:2883. 
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP and Meade TW (2010). Long-term effect 
of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 
376;1741:1750. 
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW and Mehta Z (2012). Effect of daily aspirin on risk of 
cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 379;1591:1601. 


78 

Rudd CE, Taylor A and Schneider H (2009). CD28 and CTLA-4 coreceptor expression and signal transduction. 
Immunol Rev. 229;12:26. 
Ruland J, Duncan GS, Elia A, del BB, I, Nguyen L, Plyte S, Millar DG, Bouchard D, Wakeham A, Ohashi PS 
and Mak TW (2001). Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and 
neural tube closure. Cell. 104;33:42. 
Rulifson IC, Sperling AI, Fields PE, Fitch FW and Bluestone JA (1997). CD28 costimulation promotes the 
production of Th2 cytokines. J Immunol. 158;658:665. 
Ruppelt A, Mosenden R, Gronholm M, Aandahl EM, Tobin D, Carlson CR, Abrahamsen H, Herberg FW, 
Carpen O and Tasken K (2007). Inhibition of T cell activation by cyclic adenosine 5'-monophosphate requires 
lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol. 179;5159:5168. 
Sadra A, Cinek T and Imboden JB (2004). Translocation of CD28 to lipid rafts and costimulation of IL-2. Proc 
Natl Acad Sci U S A. 101;11422:11427. 
Salek-Ardakani S and Croft M (2006). Regulation of CD4 T cell memory by OX40 (CD134). Vaccine. 
24;872:883. 
Sallusto F, Lenig D, Forster R, Lipp M and Lanzavecchia A (1999). Two subsets of memory T lymphocytes with 
distinct homing potentials and effector functions. Nature. 401;708:712.
Sanchez-Lockhart M, Marin E, Graf B, Abe R, Harada Y, Sedwick CE and Miller J (2004). Cutting edge: CD28-
mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different 
signaling pathways. J Immunol. 173;7120:7124. 
Sanchez-Madrid F and del Pozo MA (1999). Leukocyte polarization in cell migration and immune interactions. 
EMBO J. 18;501:511. 
Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, Thome JJ, Bickham KL, Lerner H, Goldstein M, 
Sykes M, Kato T and Farber DL (2013). Distribution and compartmentalization of human circulating and tissue-
resident memory T cell subsets. Immunity. 38;187:197. 
Schaeffer EM, Debnath J, Yap G, McVicar D, Liao XC, Littman DR, Sher A, Varmus HE, Lenardo MJ and 
Schwartzberg PL (1999). Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. 
Science. 284;638:641. 
Schmidt D, Goronzy JJ and Weyand CM (1996). CD4+ CD7-CD28- T cells are expanded in rheumatoid arthritis 
and are characterized by autoreactivity. J Clin Invest. 97;2027:2037. 
Schmoll HJ and Stein A (2014). Colorectal cancer in 2013: Towards improved drugs, combinations and patient 
selection. Nat Rev Clin Oncol. 11;79:80. 
Schneider H, Cai YC, Prasad KV, Shoelson SE and Rudd CE (1995). T cell antigen CD28 binds to the GRB-
2/SOS complex, regulators of p21ras. Eur J Immunol. 25;1044:1050. 
Schneider H and Rudd CE (2008). CD28 and Grb-2, relative to Gads or Grap, preferentially co-operate with 
Vav1 in the activation of NFAT/AP-1 transcription. Biochem Biophys Res Commun. 369;616:621. 
Schuck S, Honsho M, Ekroos K, Shevchenko A and Simons K (2003). Resistance of cell membranes to different 
detergents. Proc Natl Acad Sci U S A. 100;5795:5800. 
Schumacher TN, Gerlach C and van Heijst JW (2010). Mapping the life histories of T cells. Nat Rev Immunol. 
10;621:631. 
Schweitzer AN, Borriello F, Wong RC, Abbas AK and Sharpe AH (1997). Role of costimulators in T cell 
differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J Immunol. 
158;2713:2722. 
Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S and Springer TA (1987). The T lymphocyte 
glycoprotein CD2 binds the cell surface ligand LFA-3. Nature. 326;400:403. 


79 

Shaffer MH, Dupree RS, Zhu P, Saotome I, Schmidt RF, McClatchey AI, Freedman BD and Burkhardt JK 
(2009). Ezrin and moesin function together to promote T cell activation. J Immunol. 182;1021:1032. 
Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB 
and Mak TW (1993). Differential T cell costimulatory requirements in CD28-deficient mice. Science. 
261;609:612. 
Shapiro VS, Truitt KE, Imboden JB and Weiss A (1997). CD28 mediates transcriptional upregulation of the 
interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. 
Mol Cell Biol. 17;4051:4058. 
Sharma P, Varma R, Sarasij RC, Ira, Gousset K, Krishnamoorthy G, Rao M and Mayor S (2004). Nanoscale 
organization of multiple GPI-anchored proteins in living cell membranes. Cell. 116;577:589. 
Sharpe HJ, Stevens TJ and Munro S (2010). A comprehensive comparison of transmembrane domains reveals 
organelle-specific properties. Cell. 142;158:169. 
Shaw AS (2006). Lipid rafts: now you see them, now you don't. Nat Immunol. 7;1139:1142. 
Shcherbina A, Bretscher A, Kenney DM and Remold-O'Donnell E (1999). Moesin, the major ERM protein of 
lymphocytes and platelets, differs from ezrin in its insensitivity to calpain. FEBS Lett. 443;31:36. 
Sheets ED, Holowka D and Baird B (1999). Critical role for cholesterol in Lyn-mediated tyrosine 
phosphorylation of FcepsilonRI and their association with detergent-resistant membranes. J Cell Biol. 
145;877:887. 
Shim EK, Moon CS, Lee GY, Ha YJ, Chae SK and Lee JR (2004). Association of the Src homology 2 domain-
containing leukocyte phosphoprotein of 76 kD (SLP-76) with the p85 subunit of phosphoinositide 3-kinase. 
FEBS Lett. 575;35:40. 
Shim KS, Kim KH, Han WS and Park EB (1999). Elevated serum levels of transforming growth factor-beta1 in 
patients with colorectal carcinoma: its association with tumor progression and its significant decrease after 
curative surgical resection. Cancer. 85;554:561. 
Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya 
S, Sugimura T and Wakabayashi K (2004). Downregulation of prostaglandin E receptor subtype EP3 during 
colon cancer development. Gut. 53;1151:1158. 
Siliciano RF, Pratt JC, Schmidt RE, Ritz J and Reinherz EL (1985). Activation of cytolytic T lymphocyte and 
natural killer cell function through the T11 sheep erythrocyte binding protein. Nature. 317;428:430. 
Simkin NJ, Jelinek DF and Lipsky PE (1987). Inhibition of human B cell responsiveness by prostaglandin E2. J
Immunol. 138;1074:1081. 
Simons K and Ikonen E (1997). Functional rafts in cell membranes. Nature. 387;569:572. 
Simons K and Gerl MJ (2010). Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol. 
11;688:699. 
Simons PC, Pietromonaco SF, Reczek D, Bretscher A and Elias L (1998). C-terminal threonine phosphorylation 
activates ERM proteins to link the cell's cortical lipid bilayer to the cytoskeleton. Biochem Biophys Res Commun. 
253;561:565. 
Singer A, Adoro S and Park JH (2008). Lineage fate and intense debate: myths, models and mechanisms of CD4- 
versus CD8-lineage choice. Nat Rev Immunol. 8;788:801. 
Singer SJ and Nicolson GL (1972). The fluid mosaic model of the structure of cell membranes. Science. 
175;720:731. 
Skålhegg BS, Landmark BF, Doskeland SO, Hansson V, Lea T and Jahnsen T (1992). Cyclic AMP-dependent 
protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication 
in human T lymphocytes. J Biol Chem. 267;15707:15714. 


80 

Skålhegg BS and Taskén K (2000). Specificity in the cAMP/PKA signaling pathway. Differential 
expression,regulation, and subcellular localization of subunits of PKA. Front Biosci. 5;D678:D693. 
Smith-Garvin JE, Koretzky GA and Jordan MS (2009). T cell activation. Annu Rev Immunol. 27;591:619. 
Smyth EM, Grosser T, Wang M, Yu Y and FitzGerald GA (2009). Prostanoids in health and disease. J Lipid Res. 
50 Suppl;S423:S428. 
Snijdewint FG, Kalinski P, Wierenga EA, Bos JD and Kapsenberg ML (1993). Prostaglandin E2 differentially 
modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol. 150;5321:5329. 
Soderling TR, Corbin JD and Park CR (1973). Regulation of adenosine 3',5'-monophosphate-dependent protein 
kinase. II. Hormonal regulation of the adipose tissue enzyme. J Biol Chem. 248;1822:1829. 
Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M and Taketo MM (2001). 
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat 
Med. 7;1048:1051. 
Soond DR, Bjorgo E, Moltu K, Dale VQ, Patton DT, Torgersen KM, Galleway F, Twomey B, Clark J, Gaston JS, 
Tasken K, Bunyard P and Okkenhaug K (2010). PI3K p110delta regulates T-cell cytokine production during 
primary and secondary immune responses in mice and humans. Blood. 115;2203:2213. 
Specht C, Bexten S, Kolsch E and Pauels HG (2001). Prostaglandins, but not tumor-derived IL-10, shut down 
concomitant tumor-specific CTL responses during murine plasmacytoma progression. Int J Cancer. 91;705:712. 
Sperling AI, Green JM, Mosley RL, Smith PL, DiPaolo RJ, Klein JR, Bluestone JA and Thompson CB (1995). 
CD43 is a murine T cell costimulatory receptor that functions independently of CD28. J Exp Med. 182;139:146. 
Sperling AI, Sedy JR, Manjunath N, Kupfer A, Ardman B and Burkhardt JK (1998). TCR signaling induces 
selective exclusion of CD43 from the T cell-antigen-presenting cell contact site. J Immunol. 161;6459:6462. 
Staubach S and Hanisch FG (2011). Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. 
Expert Rev Proteomics. 8;263:277. 
Stinchcombe JC, Majorovits E, Bossi G, Fuller S and Griffiths GM (2006). Centrosome polarization delivers 
secretory granules to the immunological synapse. Nature. 443;462:465. 
Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, 
Lee JC and Dubinett SM (2000). Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering 
the balance of IL-10 and IL-12 synthesis. J Immunol. 164;361:370. 
Sun M, Northup N, Marga F, Huber T, Byfield FJ, Levitan I and Forgacs G (2007). The effect of cellular 
cholesterol on membrane-cytoskeleton adhesion. J Cell Sci. 120;2223:2231. 
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD and Panoskaltsis N (2006). 
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 
355;1018:1028. 
Sutherland EW (1972). Studies on the mechanism of hormone action. Science. 177;401:408. 
Takeda K, Harada Y, Watanabe R, Inutake Y, Ogawa S, Onuki K, Kagaya S, Tanabe K, Kishimoto H and Abe R 
(2008). CD28 stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-Grb2/Gads axis. Int 
Immunol. 20;1507:1515. 
Takeuchi S, Takayama Y, Ogawa A, Tamura K and Okada M (2000). Transmembrane phosphoprotein Cbp 
positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J Biol Chem. 275;29183:29186. 
Tavano R, Contento RL, Baranda SJ, Soligo M, Tuosto L, Manes S, and Viola A (2006). CD28 interaction with 
filamin-A controls lipid raft accumulation at the T-cell immunological synapse. Nat Cell Biol. 8;1270:1276. 
Thaker YR, Schneider H and Rudd CE (2015). TCR and CD28 activate the transcription factor NF-kappaB in T-
cells via distinct adaptor signaling complexes. Immunol Lett. 163;113:119. 


81 

The Cancer Genome Atlas Network (2012). Comprehensive molecular characterization of human colon and 
rectal cancer. Nature. 487;330:337. 
Thomson DM, Krupey J, Freedman SO and Gold P (1969). The radioimmunoassay of circulating 
carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A. 64;161:167. 
Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO and Lothe RA (2005). Genetic and 
epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by 
microsatellite instability. Neoplasia. 7;99:108. 
Tong J, Allenspach EJ, Takahashi SM, Mody PD, Park C, Burkhardt JK and Sperling AI (2004). CD43 
regulation of T cell activation is not through steric inhibition of T cell-APC interactions but through an 
intracellular mechanism. J Exp Med. 199;1277:1283. 
Trub T, Frantz JD, Miyazaki M, Band H and Shoelson SE (1997). The role of a lymphoid-restricted, Grb2-like 
SH3-SH2-SH3 protein in T cell receptor signaling. J Biol Chem. 272;894:902. 
Tsujii M, Kawano S and DuBois RN (1997). Cyclooxygenase-2 expression in human colon cancer cells 
increases metastatic potential. Proc Natl Acad Sci U S A. 94;3336:3340. 
Tu X, Huang A, Bae D, Slaughter N, Whitelegge J, Crother T, Bickel PE and Nel A (2004). Proteome analysis of 
lipid rafts in Jurkat cells characterizes a raft subset that is involved in NF-kappaB activation. J Proteome Res. 
3;445:454. 
Tuosto L, Michel F and Acuto O (1996). p95vav associates with tyrosine-phosphorylated SLP-76 in antigen-
stimulated T cells. J Exp Med. 184;1161:1166. 
Tuosto L, Costanzo A, Guido F, Marinari B, Vossio S, Moretti F, Levrero M and Piccolella E (2000). Mitogen-
activated kinase kinase kinase 1 regulates T cell receptor- and CD28-mediated signaling events which lead to 
NF-kappaB activation. Eur J Immunol. 30;2445:2454. 
Turunen O, Wahlstrom T and Vaheri A (1994). Ezrin has a COOH-terminal actin-binding site that is conserved 
in the ezrin protein family. J Cell Biol. 126;1445:1453. 
Ubersax JA and Ferrell JE, Jr. (2007). Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell 
Biol. 8;530:541. 
Valitutti S, Dessing M and Lanzavecchia A (1993). Role of cAMP in regulating cytotoxic T lymphocyte 
adhesion and motility. Eur J Immunol. 23;790:795. 
van den Eynde M and Hendlisz A (2009). Treatment of colorectal liver metastases: a review. Rev Recent Clin 
Trials. 4;56:62. 
van der Merwe PA and Davis SJ (2003). Molecular interactions mediating T cell antigen recognition. Annu Rev 
Immunol. 21;659:684. 
van der Merwe PA and Dushek O (2011). Mechanisms for T cell receptor triggering. Nat Rev Immunol. 11;47:55. 
van MG and Simons K (1988). Lipid polarity and sorting in epithelial cells. J Cell Biochem. 36;51:58. 
Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS, Hansson V, Mustelin T and Tasken K 
(2001). Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling 
through the T cell receptor. J Exp Med. 193;497:507. 
Vang T, Abrahamsen H, Myklebust S, Horejsi V and Tasken K (2003). Combined spatial and enzymatic 
regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem. 
278;17597:17600. 
Vanhaesebroeck B and Alessi DR (2000). The PI3K-PDK1 connection: more than just a road to PKB. Biochem J. 
346;561:576. 


82 

Veiga-Fernandes H, Walter U, Bourgeois C, McLean A and Rocha B (2000). Response of naive and memory 
CD8+ T cells to antigen stimulation in vivo. Nat Immunol. 1;47:53. 
Veillette A, Bookman MA, Horak EM and Bolen JB (1988). The CD4 and CD8 T cell surface antigens are 
associated with the internal membrane tyrosine-protein kinase p56lck. Cell. 55;301:308. 
Veillette A and Fournel M (1990). The CD4 associated tyrosine protein kinase p56lck is positively regulated 
through its site of autophosphorylation. Oncogene. 5;1455:1462. 
Veit M and Thaa B (2011). Protein association with membrane rafts. eLS John Wiley & Sons. 1:9. 
Viola A, Schroeder S, Sakakibara Y and Lanzavecchia A (1999). T lymphocyte costimulation mediated by 
reorganization of membrane microdomains. Science. 283;680:682. 
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM 
and Bos JL (1988). Genetic alterations during colorectal-tumor development. N Engl J Med. 319;525:532. 
von Haller PD, Donohoe S, Goodlett DR, Aebersold R and Watts JD (2001). Mass spectrometric characterization 
of proteins extracted from Jurkat T cell detergent-resistant membrane domains. Proteomics. 1;1010:1021. 
von Haller PD, Yi E, Donohoe S, Vaughn K, Keller A, Nesvizhskii AI, Eng J, Li XJ, Goodlett DR, Aebersold R 
and Watts JD (2003). The application of new software tools to quantitative protein profiling via isotope-coded 
affinity tag (ICAT) and tandem mass spectrometry: II. Evaluation of tandem mass spectrometry methodologies 
for large-scale protein analysis, and the application of statistical tools for data analysis and interpretation. Mol 
Cell Proteomics. 2;428:442. 
Walker C, Kristensen F, Bettens F and deWeck AL (1983). Lymphokine regulation of activated (G1) 
lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol. 130;1770:1773. 
Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D (2009). Genetic prognostic and 
predictive markers in colorectal cancer. Nat Rev Cancer. 9;489:499. 
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB and Bluestone JA 
(1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1;405:413. 
Wang D, Matsumoto R, You Y, Che T, Lin XY, Gaffen SL and Lin X (2004). CD3/CD28 costimulation-induced 
NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to 
the immunological synapse through CARMA1. Mol Cell Biol. 24;164:171. 
Wang D and DuBois RN (2010). Eicosanoids and cancer. Nat Rev Cancer. 10;181:193. 
Wang JH, Smolyar A, Tan K, Liu JH, Kim M, Sun ZY, Wagner G and Reinherz EL (1999). Structure of a 
heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell. 97;791:803. 
Ward SG, Ley SC, MacPhee C and Cantrell DA (1992). Regulation of D-3 phosphoinositides during T cell 
activation via the T cell antigen receptor/CD3 complex and CD2 antigens. Eur J Immunol. 22;45:49. 
Wasserberg N, Nunoo-Mensah JW, Gonzalez-Ruiz C, Beart RW, Jr. and Kaiser AM (2007). Colorectal cancer in 
HIV-infected patients: a case control study. Int J Colorectal Dis. 22;1217:1221. 
Watson AR and Lee WT (2004). Differences in signaling molecule organization between naive and memory 
CD4+ T lymphocytes. J Immunol. 173;33:41. 
Weaver TA, Charafeddine AH, Agarwal A, Turner AP, Russell M, Leopardi FV, Kampen RL, Stempora L, Song 
M, Larsen CP and Kirk AD (2009). Alefacept promotes co-stimulation blockade based allograft survival in 
nonhuman primates. Nat Med. 15;746:749. 
WHO (2012). GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 14 NOvember 2013. 
Willoughby D and Cooper DM (2007). Organization and Ca2+ regulation of adenylyl cyclases in cAMP 
microdomains. Physiol Rev. 87;965:1010. 


83 

Wills MR, Carmichael AJ, Weekes MP, Mynard K, Okecha G, Hicks R and Sissons JG (1999). Human virus-
specific CD8+ CTL clones revert from CD45ROhigh to CD45RAhigh in vivo: CD45RAhighCD8+ T cells 
comprise both naive and memory cells. J Immunol. 162;7080:7087. 
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, 
Panish JF and The National Polyp Study Workgroup (1993). Prevention of colorectal cancer by colonoscopic 
polypectomy. N Engl J Med. 329;1977:1981. 
Wing JB and Sakaguchi S (2011). TCR diversity and Treg cells, sometimes more is more. Eur J Immunol. 
41;3097:3100. 
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, 
Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, 
Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant 
PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, 
Parmigiani G, Kinzler KW, Velculescu VE and Vogelstein B (2007). The genomic landscapes of human breast 
and colorectal cancers. Science. 318;1108:1113. 
Wu CY, Wang K, McDyer JF and Seder RA (1998). Prostaglandin E2 and dexamethasone inhibit IL-12 receptor 
expression and IL-12 responsiveness. J Immunol. 161;2723:2730. 
Wulfing C, Bauch A, Crabtree GR and Davis MM (2000). The vav exchange factor is an essential regulator in 
actin-dependent receptor translocation to the lymphocyte-antigen-presenting cell interface. Proc Natl Acad Sci U 
S A. 97;10150:10155. 
Wunderlich L, Farago A, Downward J and Buday L (1999). Association of Nck with tyrosine-phosphorylated 
SLP-76 in activated T lymphocytes. Eur J Immunol. 29;1068:1075. 
Xavier R, Brennan T, Li Q, McCormack C and Seed B (1998). Membrane compartmentation is required for 
efficient T cell activation. Immunity. 8;723:732. 
Yablonski D, Kuhne MR, Kadlecek T and Weiss A (1998). Uncoupling of nonreceptor tyrosine kinases from 
PLC-gamma1 in an SLP-76-deficient T cell. Science. 281;413:416. 
Yamaguchi H and Hendrickson WA (1996). Structural basis for activation of human lymphocyte kinase Lck 
upon tyrosine phosphorylation. Nature. 384;484:489. 
Yang H and Reinherz EL (2001). Dynamic recruitment of human CD2 into lipid rafts. Linkage to T cell signal 
transduction. J Biol Chem. 276;18775:18785. 
Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, Robinson CR and Giardiello 
FM (1998). Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous 
polyposis. Cancer Res. 58;1750:1753. 
Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjornbeth BA and Tasken K (2008). Regulatory T 
cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer 
Immunol Immunother. 57;813:821. 
Yasuda K, Nagafuku M, Shima T, Okada M, Yagi T, Yamada T, Minaki Y, Kato A, Tani-Ichi S, Hamaoka T and 
Kosugi A (2002). Cutting edge: Fyn is essential for tyrosine phosphorylation of Csk-binding 
protein/phosphoprotein associated with glycolipid-enriched microdomains in lipid rafts in resting T cells. J
Immunol. 169;2813:2817. 
Yokosuka T, Sakata-Sogawa K, Kobayashi W, Hiroshima M, Hashimoto-Tane A, Tokunaga M, Dustin ML and 
Saito T (2005). Newly generated T cell receptor microclusters initiate and sustain T cell activation by 
recruitment of Zap70 and SLP-76. Nat Immunol. 6;1253:1262. 
Yokosuka T, Kobayashi W, Sakata-Sogawa K, Takamatsu M, Hashimoto-Tane A, Dustin ML, Tokunaga M and 
Saito T (2008). Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein 
kinase C theta translocation. Immunity. 29;589:601. 


84 

Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S and Tsukita S (1998). Ezrin/radixin/moesin 
(ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of 
CD44, CD43, and ICAM-2. J Cell Biol. 140;885:895. 
Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K and Dannenberg 
AJ (2001). Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. 
Clin Cancer Res. 7;3971:3976. 
Zech T, Ejsing CS, Gaus K, de WB, Shevchenko A, Simons K and Harder T (2009). Accumulation of raft lipids 
in T-cell plasma membrane domains engaged in TCR signalling. EMBO J. 28;466:476. 
Zeyda M, Staffler G, Horejsi V, Waldhausl W and Stulnig TM (2002). LAT displacement from lipid rafts as a 
molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids. J Biol Chem. 
277;28418:28423. 
Zeyda M and Stulnig TM (2006). Lipid Rafts & Co.: an integrated model of membrane organization in T cell 
activation. Prog Lipid Res. 45;187:202. 
Zhang N and Bevan MJ (2011). CD8(+) T cells: foot soldiers of the immune system. Immunity. 35;161:168. 
Zhang W, Trible RP and Samelson LE (1998a). LAT palmitoylation: its essential role in membrane microdomain 
targeting and tyrosine phosphorylation during T cell activation. Immunity. 9;239:246. 
Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP and Samelson LE (1998b). LAT: the ZAP-70 tyrosine kinase 
substrate that links T cell receptor to cellular activation. Cell. 92;83:92. 
Zhang W, Trible RP, Zhu M, Liu SK, McGlade CJ and Samelson LE (2000). Association of Grb2, Gads, and 
phospholipase C-gamma 1 with phosphorylated LAT tyrosine residues. Effect of LAT tyrosine mutations on T 
cell angigen receptor-mediated signaling. J Biol Chem. 275;23355:23361. 
Zheng YZ, Berg KB and Foster LJ (2009). Mitochondria do not contain lipid rafts, and lipid rafts do not contain 
mitochondrial proteins. J Lipid Res. 50;988:998. 
Zhu J, Yamane H and Paul WE (2010). Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 
28;445:489. 
Zhu M, Shen S, Liu Y, Granillo O and Zhang W (2005). Cutting Edge: Localization of linker for activation of T 
cells to lipid rafts is not essential in T cell activation and development. J Immunol. 174;31:35. 
